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This dissertation explores the complex nature of the influenza virus quasispecies. 
Influenza populations exist as a mixture of mostly replication-deficient biologically-active 
particles. These particles are measured and quantified based upon the phenotype they 
manifest upon entry into the host. Three subpopulations are characterized: infectious, 
interferon-inducing, and interferon induction-suppressing particles. 
It has been observed that only 5 out of every 100 particles of influenza are 
infectious. A novel biological assay was developed and, for the first time, directly 
demonstrated that infectious particles are the progenitors of all other virus particles. 
From the disparity observed to exist between the numbers of physical and infectious 
particles, a mathematical approach is presented which quantifies the frequency of 
expression of individual gene segments. 
Interferon-inducing particles are demonstrated to be resistant to physical and 
chemical inactivation when measured in avian cells –the best evidence to date that the 
interferon-inducing moiety is preformed within the virion. In contrast, interferon-inducing 
particles are inactivated at a rate consistent with inactivation of the NS gene in 
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mammalian cells, suggesting that primary transcription is necessary for interferon-
induction in these cells. 
Interferon induction-suppressing particles inhibit interferon production in cells 
otherwise programed to induce. This activity is nonspecific, blocking interferon-induction 
by viruses belonging to multiple families, and is dependent upon expression of the NS1 
protein. A mathematical model, based on a random (Poisson) distribution of virus 
particles amongst the cell monolayer, is presented that predicts the fraction of cells that 
will induce interferon, dependent upon the ratio of interferon-inducing and interferon 
induction-suppressing particles present in the virus stock. A novel method for 
quantifying interferon-inducing particles in preparations with high interferon induction-
suppressing particle content is described. A highly potent interferon induction-
suppression activity was also found to be associated with exposure to 
lipopolysaccharide. 
The functional heterogeneity demonstrated by a single strain of influenza was 
quantified, utilizing interferon-induction and interferon induction-suppression as 
phenotypic markers of the quasispecies. The activities of 117 plaque-derived isolates 
were measured, and variability in these phenotypes was observed over a 1000-fold 
range. The genetic basis of this phenotypic variance was investigated through 
sequencing the NS genes of several isolates demonstrating extreme phenotypes.   
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CHAPTER 1 
 
 
 
 
 
LITERATURE REVIEW 
  
 2 
 
Part I: Overview of Influenza Virus 
1.1 Taxonomy and nomenclature of influenza virus 
The Orthomyxoviridae family of viruses are segmented, negative-sense, single-
stranded RNA viruses. The family is comprised of a total of five genera, including 
Influenzavirus A, Influenzavirus B, Influenzavirus C, Thogotovirus, and Isavirus. The 
three types of influenza viruses are differentiated based upon differences in the 
antigenic characteristics of their nucleocapsid (NP) and matrix (M1) proteins 
[32,134,176]. These two proteins are used for typing as they are internal to the virion 
and are thus antigenically stable due to the absence of immunogenic pressures [32]. 
Genetic differences also exist between the types of influenza virus: type-A and type-B 
influenza viruses are comprised of a total of eight gene segments, whereas type-C 
influenza viruses possess only seven. Type-A and type-B influenza viruses have two 
separate genes which express the two surface glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA). These proteins are involved in viral attachment and elution, 
respectively. In type-C influenza virus, these two genes are effectively combined as 
both of these activities are manifest through a single surface protein. 
Type-A influenza viruses are further subtypes based on the antigenicity of the HA 
and NA surface proteins. To date, 16 HA and 9 NA subtypes have been demonstrated 
[36,171]. Subtypes of HA and NA as expressed by type-B and type-C influenza viruses 
have not been described [171]. 
The current system of nomenclature for influenza viruses was set by the World 
Health Organization in 1980 [176]. The full nomenclature should include the following 
 3 
 
components: the type of virus (A, B, or C); the host from which the virus was isolated, 
although if the host is human this designation need not be specified; the geographic site 
of isolation; the strain number; the year of isolation; and the HA and NA subtypes, which 
should appear in parentheses. An example of correct nomenclature for a type-A 
influenza virus isolated from a human host is as follows: A/Puerto Rico/8/34 (H1N1). 
Note that the host (human) is not specified and that the date is presented as two digits. 
If the virus strain is isolated in the year 2000 or after, the full 4 digit date should be used 
[177].  
 
1.2 Host range restriction and determinants of pathogenicity 
In terms of host range, type-A influenza viruses are known to infect humans, 
birds, swine, horses, dogs, cats, whales, and seals [171]. Type-B influenza viruses 
primarily circulate in humans but also have been isolated from seals. Finally, type-C 
influenza viruses have been known to infect humans, swine, and dogs. Although type-A 
influenza viruses tend to present asymptomatically in wild birds [65,118,164,164,165], 
they can cause significant morbidity and/or mortality in domestic birds and mammals, 
including humans. Type-B influenza viruses tend to produce only mild illness, with more 
serious cases requiring hospitalization occurring with four-fold less frequency than in the 
case of influenza A infections [171]. Influenza C viruses are typically associated with 
mild upper respiratory tract illness [98]. 
The host range of influenza viruses is largely based on the hemagglutinin protein, 
whose sialic acid-binding activity is the major determinant factor governing viral 
attachment and infectivity. Influenza viruses bind primarily to the N-acetylneuraminic 
 4 
 
acid form of sialic acid (Neu5Ac), which has an acetyl-group bound to the nitrogen 
attached at the 5-carbon position. Neu5Ac is the primary form of sialic acid found in 
adult humans and most other vertebrates, but other forms of sialic acid can be 
recognized if the hemagglutinin of the virus is properly adapted [151]. The sialic acid 
must be the terminal sugar residue of the oligosaccharide, and must also be directly 
linked to a galactose sugar molecule. The stereochemistry of the sialic acid-galactose 
linkage is another host range determinant: human influenza viruses bind preferentially 
to NeuAc(α2,6)-Gal, whereas avian influenza viruses bind preferentially to NeuAc(α2,3)-
Gal [52,60,128,151].  
These ligand preferences are related to the types of sialic acid receptors 
expressed on those cells within the host where the virus typically replicates. In humans, 
the upper respiratory epithelial cells express NeuAc(α2,6)-Gal and thus are susceptible 
to infection by human influenza viruses. Conversely, NeuAc(α2,3)-Gal receptors are 
expressed by the epithelial cells lining the intestinal tract of wild birds, being the primary 
site of avian influenza virus replication. Swine are recognized as a mixing vessel for 
influenza viruses –when infected by multiple strains of influenza simultaneously, swine 
cells may produce novel strains through the process of gene reassortment. This can 
occur because the epithelial cells lining the trachea of swine express both NeuAc(α2,3)-
Gal and NeuAc(α2,6)-Gal, allowing individual cells to be coinfected by both human and 
avian influenza viruses. Additionally, since both types of receptors are present in swine, 
ongoing replication can facilitate avian influenza viruses adaptation, switching from 
preferentially binding the avian-type receptor (NeuAc(α2,3)-Gal) to binding the human-
type receptor (NeuAc(α2,6)-Gal) [59,60]. 
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The second viral surface glycoprotein, neuraminidase, cleaves off sialic acid 
residues to help facilitate the release of progeny during a productive infection. Similar to 
the activity of hemagglutinin, avian influenza neuraminidase preferentially recognizes 
and cleaves NeuAc(α2,3)-Gal, whereas human influenza neuraminidase cleaves 
NeuAc(α2,6)-Gal. This limitation effects the efficient spread of the virus, thereby 
contributing to host range restriction [8]. It has been demonstrated that, over time, type-
A influenza neuraminidase subtype N2 has adapted and gained the ability to cleave 
both types of alpha-linkages [8,67,68]. The presence of valine at position 275 increased 
specificity for NeuAc(α2,6)-Gal, thereby adapting a traditionally avian influenza isolate 
for human hosts [67]. Later studies have shown that recognition of the correct alpha-
linkage (substrate-specificity) must also be accompanied by sufficient rates of activity. 
The increased specific activity of the human-adapted N2 have been shown to depend 
on the following six amino acid residues: Arg331, Asn339, Ser367, Leu370, Ser400, 
and Glu431 [68].  
Beyond the activities of the viral surface glycoproteins, host range is also 
influenced by the replication efficiency of the virus as dictated by the genotype of the 
viral genes encoding for the viral proteins internal to the virion. Replication efficiency 
and host range restriction has been noted to depend upon the expression of specific 
amino acid residues of the PB2 subunit of the viral polymerase complex [3,101,150]. 
The PB2 subunit is responsible for binding to, and snatching, host cell message caps, 
providing the primer sequence necessary for viral transcription to occur. In studies of 
pathogenesis in mice, H5N1 isolates from avian species expressed a glutamic acid at 
position 627, whereas isolates from human species expressed a lysine residue at this 
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position [50]. It was found that the presence of Lys627 correlated with high 
pathogenicity in mice [50]. 
Finally, the activity of the nonstructural protein NS1 also influences host range by 
suppressing the interferon-inducing branch of the innate immune system. In competent 
host cells, recognition of viral moieties results in the induction of interferon and the 
establishment of an antiviral state in surrounding cells. Additionally, interferon-
stimulated genes are activated, producing a number of proteins with antiviral properties 
including protein kinase R, Mx proteins, RNase L, and 2’-5’ oligoadenylate synthetase. 
As will be discussed in detail later in this thesis, NS1 is expressed early in the 
replication cycle of influenza virus and through a variety of mechanisms suppresses 
IFN-induction [80,81,87]. By blocking the interferon-induction response, NS1 facilitates 
efficient viral replication and spread throughout the host. Additionally, truncations to the 
C-terminal effector domain of NS1 interfere with the temporal regulation of viral-
mediated apoptosis, resulting in increased rates of cell death [111,174]. 
 
1.3 Type-A influenza virus structure and lifecycle 
Type-A influenza virus (IAV) are typically spherical in shape, measuring 80-120 
nm in diameter, but rod-like, filamentous particles have also been observed [119]. The 
viral capsid consists of a layer of matrix 1 (M1) protein, which is enveloped by a host-
derived lipid membrane containing the viral hemagglutinin (HA), neuraminidase (NA) 
and matrix 2 (M2) proteins [119]. The core of the virion consists of eight unique gene 
segments (vRNA), each of which is bound by multiple nucleoproteins (NP) and a 
heterotrimeric, viral RNA-dependent RNA polymerase complex made up of 3 
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polymerase subunits. Combined, the vRNA, NP and viral polymerase complex are 
referred to as the viral ribonucleoprotein complex (vRNP). Each of the eight gene 
segments is independently transcribed [1], and collectively encode for a total of 11 
proteins. Additionally, the nonstructural protein 2 (NS2) is found packaged within the 
virion, but the nonstructural protein 1 (NS1) and PB2-F2 proteins are not.  
Infection begins with attachment of the virion to a host cell, mediated through the 
ligand-binding activity of HA. HA exists on the surface of the virion as homotrimeric 
spikes and recognizes cell surface glycoproteins containing oligosaccharide sequences 
terminating with sialic acid. NA is the second major protein on the surface of the virion 
and is responsible for cleaving these sialic acid residues. The hydrolytic activity of NA is 
important for release of virus from the host cell, a necessary step for the release of 
progeny virus by budding from the cell surface after a successful infection leading to 
viral replication. The balance between these two competing activities is important for the 
efficient establishment of infection [68]. 
After attachment, the virus is engulfed by the cell primarily through clathrin-
mediated endocytosis [93,119], although entry through caveolae-dependent and other 
independent pathways also have been reported [117,129]. Low pH in the endosome 
triggers a structural change in HA, bringing the virus envelope into close proximity with 
the membrane of the endosome and facilitating fusion [146]. Fusion can only occur if 
the HA has been activated, that is cleaved by the appropriate cellular enzymes thereby 
allowing for the exposure of the fusion peptide sequence upon acidification. 
Concurrently, the ion channel function of the M2 protein allows for an influx of H+ into 
the virion which begins the process of uncoating [93,173]. High [H+] destabilizes M1 
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protein interactions and allows for the release of vRNP into the cytosol [119]. The 
nucleoprotein component of the vRNP contains a nuclear localization sequence which 
interacts with the host cell protein karyopherin α, which transports the viral gene 
segments into the nucleus where viral transcription and gene replication occurs [119]. 
The viral polymerase complex is made up of three subunits: polymerase basic 
protein 1(PB1), polymerase basic protein 2 (PB2), and polymerase acidic protein (PA). 
Initiation of viral transcription requires that PB2 binds a 5’ 7-methyl-guanosine cap from 
host pre-messenger RNA [73], which is excised by the endonuclease function of PA [27] 
and acts as a primer for viral transcription –so called “cap-snatching” activity [71,119]. 
RNA chain elongation is carried out by PB1. Viral mRNA terminates in a 3’-poly(A) tail, 
the result of stuttering by PB1 on a poly(U) sequence near the 5’-end of the vRNA 
template. This poly(A) motif is important for nuclear export of viral message, a 
prerequisite for translation [122]. As the infection progresses, nascent NP accumulates 
in the cell and nucleus causing the viral RNA polymerase to switch from the production 
of message to the replication of vRNA. This process is primer-independent and results 
in the production of a positive-sense cRNA template from which nascent negative-sense 
vRNA is derived. 
Temporal regulation of protein expression has been observed, with NP and 
nonstructural protein 1 (NS1) being produced first [119]. NP accumulates in the nucleus 
and binds to newly replicated vRNA while NS1 suppresses the host immune response 
and thus facilitates productive infection. Nascent viral polymerase subunits PB1, PB2 
and PA are imported to the nucleus, although this process is not yet well understood 
[119]. The complete heterotrimeric viral polymerase complex engages in the 
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amplification of viral transcription and replication [119]. A single viral polymerase 
complex will also associate with the NP-coated vRNA, producing nascent vRNP 
complex. As infection progresses, the viral surface proteins HA, NA, and M2 are 
expressed on the cell’s plasma membrane. M1 is produced en masse at late time points 
and associates with vRNP in the nucleus. 
The M1-coated vRNP complex interacts with the viral protein NS2, which in turn 
associates with the host cell factor Crm1 and allows for nuclear export of the nascent 
vRNP –a necessary step for the eventual packaging of viral progeny. The vRNP is 
exported from the nucleus, and the M1 protein directs the complex to accumulate at the 
lipid bilayer where M1 associates with the cytosolic tails of the viral surface proteins 
(HA, NA, and M2).  
Although the mechanism of gene selection during viral packaging appears to be 
regulated [37], it is postulated that aberrant assembly may occur under natural 
propagation conditions [138]. Regardless of the mechanism, a virus particle must be 
packaged with at least one copy of each of the eight unique gene segments to be 
potentially infectious. Sufficient quantities of M1 at the lipid bilayer initiate the budding 
process, which proceeds until the inner core of vRNPs are enclosed by an M1 shell. At 
this point the outward curvature of the cell membrane reaches a point where the 
membrane fuses at the base of the budding virus, completing the formation of the virus 
particle. NA activity cleaves sialic acid residues so that progeny can efficiently elute 
from the infected cell. When this neuraminidase activity is blocked by specific inhibitors 
(i.e. antiviral drugs like oseltamivir, zanamivir), the virus remains trapped at the cell 
surface [119]. 
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1.4 Genetic variation of influenza virus populations 
The viral RNA-dependent RNA-polymerase complex of IAV is error-prone and 
lacks a proof-reading mechanism. Mutations are estimated to accumulate at a rate of 
one per genome copied [113,119,120]. Host selection pressure in the form of 
neutralizing antibodies favors antigenic drift and so stable mutations tend to accumulate 
in the HA and NA genes [34,171]. The different types of influenza virus (A, B, or C) 
display significant differences in the rates in which mutations appear, and these rates 
are also dependent upon the host in which the virus replicates. Influenza B and C 
viruses accumulate few to no changes in humans, suggesting that an evolutionary 
equilibrium has been established [171]. Type-A influenza viruses accumulate mutations 
in mammalian hosts, but are much more stable in aquatic birds, the natural reservoir of 
these viruses[40,165]. 
IAV may also undergo rapid evolutionary changes via gene reassortment. When 
multiple IAV strains simultaneously infect a cell, cognate gene segments may be 
swapped between strains as progeny virus is packaged [171]. This can result in 
antigenic shift; sudden, drastic changes in a virus’s antigenicity and/or pathogenicity. 
The importance of reassortment is best illustrated by the 2009 H1N1 “Swine flu” 
pandemic, in which a novel IAV strain containing genes originating from human-, avian-, 
and swine-adapted strains emerged and caused the first influenza pandemic since 1968 
(16, 20). It is suspected that all of the major influenza pandemics of the 20 th century 
(1918 H1N1 “Spanish” flu; 1957 H2N2 “Asian” flu; 1968 H3N2 “Hong Kong” flu) were 
 11 
 
the result of genetic reassortment incorporating the hemagglutinin gene from an IAV 
strain of animal origin into a preexisting, low-pathogenic, human-adapted strain [66]. 
 
Part II – Significance of Influenza Virus 
1.5 Morbidity and mortality 
Due to the facile with which type-A influenza viruses (IAV) mutate and evolve, 
influenza viruses remain a major contributor to morbidity and mortality in both human 
and poultry populations [95]. Although IAV infections present asymptomatically in wild 
birds, mild to severe respiratory tract illness results when land poultry and human 
populations are infected. Worldwide, seasonal influenza epidemics amongst humans 
are responsible for up to 50 million cases of illness [171] and between 250,000 and 
500,000 deaths [170]. About 36,000 deaths occur in the United States each year [47]. 
The possibility for the emergence of a novel pandemic strain of IAV with 
potentially devastating public health implications remains a constant threat [166]. These 
pandemic strains are characterized by high levels of morbidity and mortality, largely due 
to the lack of preexisting immunity amongst the human population. The first major flu 
pandemic of the 20th century, caused by an H1N1 IAV virus, occurred in 1918 and is 
known as the “Spanish flu”. It is estimated that a total of 500 million people worldwide 
were made ill. It is estimated that 20-50 million cases resulted in death [62], effectively 
killing 3-5% of the world’s population at that time. 
Additional, lesser pandemics have occurred since the 1918 Spanish flu. In 1957, 
an H2N2 pandemic virus strain arose in the southern Chinese province of Guizhou, 
sickening 250,000 people in the course of a single week [66]. The 1957 “Asian flu” was 
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characterized by high infection rates in persons age 5-19 [39] and would go on to cause 
69,800 deaths in the United States [23,171]. The virus was especially virulent at the 
time because it expressed HA and NA subtypes of avian origin that were different from 
those expressed by the H1N1 viruses that had previously circulated amongst the human 
population. Similarly, in 1968, an influenza A H3N2 pandemic virus was insolated in 
Hong Kong. This virus expressed an avian hemagglutinin protein, H3, that shared <30% 
sequence homology with the H2 virus that circulated previously [135]. More recently, in 
2009, a pandemic was caused by the emergence of a novel H1N1 virus expressing 
gene segments from a mixture of swine, avian and human influenza viruses [116]. In all 
of the pandemics outlined above, genetic reassortment was responsible for generating 
novel, antigenically-distinct versions of IAV to which there was little to no preexisting 
immunity. 
 
1.6 Economic impact 
It is estimated that 50,000 to 100,000 Americans are hospitalized each season 
due to influenza-related infections [171]. Based on epidemiological data and the US 
population in 2003, it is estimated that influenza viruses result in the loss of 600,000 life-
years-worth of productivity in the United States each year. Additionally, annual influenza 
infections result in the accumulation of 3.1 million hospitalization days and 31.4 million 
outpatient visits amongst Americans. These reports estimate that annual seasonal 
influenza epidemics cost $10.4 billion per year in medical expenses related to 
hospitalization, testing, and treatment [95]. An additional $16.4 billion is attributed to lost 
wages due to illness by influenza on an annual basis [95].  
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Given that IAV epidemics of highly pathogenic viruses may also spread amongst 
avian population, the financial cost to agriculture and the poultry industry can also be 
substantial. Although most IAV infections amongst domestic land poultry cause mild 
respiratory disease, outbreaks of highly pathogenic viruses of the H5 and H7 subtypes 
occur with some frequency [152]. Some 28 outbreaks of highly pathogenic IAV have 
been recorded amongst poultry since 1955, with 11 of those outbreaks being classified 
as causing significant economic loss as defined by the culling of 1 million or more birds 
[171]. One example is that of an outbreak of H7N2 influenza virus in Virginia in 2002. 
This outbreak affected 197 farms, resulted in $130 million in lost sales, and required an 
additional $82 million in federal funds to cover the costs of flock eradication [2,152]. 
Approximately 8.4% of the 56 million birds at risk of infection in the surrounding areas 
had to be destroyed to control the outbreak [142]. 
 
1.7 Prophylactic control of influenza virus by vaccination 
Due to high mutation rates [113,120], many seasonal IAV strains have acquired 
resistances to antiviral treatments and other forms of chemoprophylaxis [48]. To date, 
vaccination continues to be the most effective means of preventing and containing 
outbreaks of pandemic and seasonal strains [48]. There are two different types of 
vaccines that have been approved for use by the United States Food and Drug 
Administration: i) trivalent inactivated influenza virus vaccines, and ii) live-attenuated 
influenza virus vaccines (LAIV). Use of cold-adapted LAIV is becoming more prevalent 
due to the ease with which LAIV may be administered to patients and its ability to 
induce both cellular and humoral immune responses [12,41,99,106]. 
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Part III – Emergent Biological Activity of Influenza Virus 
1.8 Influenza virus populations exist as a quasispecies 
As mentioned in section 1.4, IAV constantly accumulates point mutations during 
replication due to the error-prone nature of the viral RNA-dependent RNA-polymerase 
complex, contributing to the process of antigenic drift. Studies of the NS gene 
sequences from plaque isolates of A/WSN/33 (H1N1) have estimated that the frequency 
at which point mutation accumulate is equal to 7.3×10-5 mutations per nucleotide per 
infectious cycle [33]. Combined with the total number of nucleotides in the influenza 
virus genome (≈13,588 nts), this equates to one point change per genome replicated: 
extrapolating, this indicates that every single virus particle in an influenza virus 
population is closely related yet genetically distinct from every other particle in the 
population. IAV populations therefore exist as a quasispecies, that is, as a closely 
related mutant spectra or cloud [30,124,132]. 
Note that the accumulation of point changes in these earlier studies could only be 
detected if the mutation was present in the majority of particles in the population. The 
Sanger sequencing method used provides a consensus sequence which is only 
representative of the average of all of the genetic sequences within the population. As 
such, these studies likely underrepresent the true mutation rate of IAV. Indeed, more 
recent reports utilizing de novo sequencing methods (pyrosequencing) have allowed for 
the independent detection of nucleotide polymorphisms in all eight gene segments, and 
the mutation rates observed range from 10- to 100-fold higher than those estimated 
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previously [7]. The PB2 polymerase subunit gene of the 2009 pandemic H1N1 strain, for 
example, is estimated to accumulate point mutations at a frequency of 359×10-5 
mutations per nucleotide. Taking into account the number of nucleotides making up the 
coding region of the PB2 protein (2277nts), every virus particle has approximately 8 
point mutations within the PB2 coding region alone [7].  
This same study evaluated the occurrence of non-synonymous mutations in 
which the point mutation resulted in an alteration of the amino acid residue. A range of 
non-synonymous:synonymous ratios, measured independently for every gene segment, 
was reported as follows: PB2 = 0.35; PB1 = 0.35; PA = 0.38; HA = 0.41; NP = 0.37; NA 
= 0.36; M1 = 0.35; M2 = 0.62; NS1 = 0.58; and NEP = 1.00 [7]. Note that these rates 
were generated based on the 2009 pandemic H1N1 strain isolated from patients during 
the course of the pandemic. For the NEP protein of this virus, every mutation resulted in 
a non-synonymous substitution. This evidence suggests that some positive selection 
force was being leveraged against this gene segment during the stage of the pandemic 
during which the virus was isolated, a finding collaborated in another report during this 
timeframe of the pandemic [155]. Returning to the PB2 example given above, if every 
particle has 8 point mutations within this gene and non-synonymous mutations occur at 
a frequency of 0.35, then, for the PB2 coding region alone, every virus particle has at 
least 2 amino acid residues which vary from the consensus sequence. This evaluation 
is intended to underscore the genetic plasticity of IAV and begs the question, what is the 
consequence? 
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1.9 Replication-deficient biologically-active particles 
Infectious particles are the most often studied subpopulation due to their role in 
viral replication and pathogenesis, but make up only a small subsection of the entire 
virus population, approximately 5 in 100 physical particles [85,111].  Very few IAV 
particles display the genetic and functional integrity necessary to establish a productive 
infection, representing one possible consequence of the genetic plasticity demonstrated 
by the virus. Although the vast majority of IAV particles do not result in a productive 
infection, they may still engage in an abortive, single-cycle infection in which some 
portion of the viral genes are expressed and some influence is manifest against the host 
cell. 
Recent studies, including those reported later in this thesis, have shown that 
stocks of influenza A virus (IAV) are composed of a complex mixture of these 
biologically-active particle (BAP) subpopulations. BAP subpopulations are measured by 
the phenotypes they produce, altering either normal cellular functions or virus-related 
metabolic processes in a quantifiable manner. Given that only 5 in 100 physical 
particles are infectious, the remainder are inherently noninfectious, meaning that 
infection by these particles does not produce progeny. Hence, these subpopulations 
whose biological activities are not dependent upon infectivity are termed replication-
deficient BAP (rdBAP) [85].  
Subpopulations of BAP had escaped detection and quantification until biological 
assays that detected and measured the expression of the relevant phenotypes were 
applied to IAV [81,85,87,111]. In addition to the infectious particles of IAV, scored as 
plaque-forming particles (PFP), several other particle types have been described. 
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Hemagglutinating particles (HAP) are considered the equivalent of physical particles, 
and all other subpopulations are subsumed within this population. The types of rdBAP 
reported thus far are: defective-interfering particles (DIP) [78,85]; noninfectious cell-
killing (apoptosis-inducing) particles (niCKP) [111]; interferon (IFN)-inducing particles 
(IFP) [87] and IFN induction-suppressing particles (ISP) [78,87,91].  While some types 
of BAP may exist as discrete subpopulations (e.g. DIP as compared to PFP), there may 
be some overlap between other types. Significantly, for influenza virus, many of the 
assays used to quantify these particle subpopulations were first developed in the Virus 
and Interferon Laboratory at the University of Connecticut in Storrs. 
It should be clarified that although both the sialic-acid binding activity and the 
activation of the fusion peptide of HAP [54] are required for attachment and entry into 
the host cell, these activities are not sufficient for classification as a BAP. HAP 
themselves do not cause any observable change in the biological activity of the cell 
unless the particle also expresses one of the other phenotypes mentioned above. 
However, note that HAP do represent the major source of the surface antigens to which 
neutralizing antibody is directed against following activation of the adaptive immune 
system.  
      
1.10 Emergent biological activity 
As noted, in order for a particle to be infectious, all eight of the unique viral gene 
segments must be functionally expressed within the host cell. There are several 
assumed caveats that must be fulfilled: i) the viral gene segments must be properly 
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delivered to the cell; ii) one copy of each of the eight unique viral gene segments must 
be trafficked to the nucleus such that transcription and replication may occur; iii) the 
genetic integrity of each viral gene must be competent such that the resulting protein is 
functional; iv) the viral proteins must be properly adapted to function with the specific 
host.  
The qualities of genetic integrity and functional protein expression are most 
stringent for infectious particles; all eight of the unique viral gene segments must be 
expressed within the host in concert so as to produce progeny. There exists a large 
opportunity for errors in this process, as illustrated by the observation that so few 
physical IAV particles (≤5%) register as infectious. This is no doubt the result of the 
compounding error inherent in a biological system which depends upon the independent 
transcription/replication of eight physically separate gene segments. Infectivity may 
therefore be considered an emergent biological property that depends upon the 
successful completion of each of those prerequisites outlined above. 
As will be discussed in subsequent chapters of this thesis, some of the biological 
activities associated with rdBAP are the result of the partial expression of the viral 
genome within the host. When a virus particle fails to fully express and does not 
produce a productive infection, alternate biological activities emerge that are dependent 
upon those genes and gene products which are successfully expressed within the host. 
For example, the activity of the defective-interfering particle (DIP) subpopulation 
requires the expression of a defective-interfering RNA [29,35,108]. The interferon 
induction-suppressing particle (ISP) subpopulation is a second example, as ISP activity 
has been shown to be dependent upon the expression of the NS gene segment 
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(Chapter 4). Other rdBAP phenotypes are the result of cellular machinery interacting 
with viral moieties. In these cases, it is the recognition of some viral component by the 
proper host cell receptor which results in the emergence of a specific biological activity. 
The interferon-inducing particle (IFP) subpopulation is an example of an rdBAP whose 
phenotype is manifest through recognition of viral moieties by the appropriate host cell 
receptors (Chapter 3). 
Further, one must be cognizant of the large numbers of gene segments that may 
accumulate in infected cells as the multiplicity of infection increases. Given an average 
IAV population, at a multiplicity of 2 infectious particles, there may be as many as 200 
physical particles entering the cell. With each particle carrying 8 viral gene segments, 
this is 1,600 or more segments in total being deposited within the cell, each capable of 
being transcribed independently. It is not surprising that the efficiency of expressing 
specific phenotypes decreases markedly with multiplicity of infection [85,87,111] as the 
carefully orchestrated events in replication face so many copies of genes being 
expressed during replication, assembly, and packaging. 
 
Part IV – Rationale and goals 
1.11 The significance of replication-deficient biologically-active particles 
The composition of BAP subpopulations can vary significantly between 
passages, and even amongst individual preparations of the same IAV strain. This has 
been observed in laboratory settings [84,85,109,111] and in nature [10,20]. In April 
1983, a low-pathogenic strain of IAV, A/Chicken/Pennsylvania/83, emerged in chicken 
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populations in Pennsylvania. Six months later, the strain returned but was highly virulent 
and caused a large number of deaths in poultry stocks. Bean et al. characterized both 
the low- and high-pathogenic strains and, despite not finding any significant genetic 
differences that would account for the enhanced virulence, they observed that the 
earlier strain tended to produce large numbers of DIPs, whereas the more virulent strain 
did not [10,20]. This is a clear example where subtle variations in genetic composition 
changed the virus’s propensity to produce certain types of BAPs, and resulted in 
significant changes in the biological behavior of the virus. Other types of BAPs, now 
detectable and quantifiable by in vitro biological assays, may have similar effects on the 
biological outcome of virus infection. 
 
1.12 Potential to influence vaccine design 
The vaccine production process, and influenza research in general, can be 
complicated by the fact that IAV preparations are not uniform in regards to particle 
composition and function. At present, candidate LAIV are screened by using avian 
(chickens) or mammalian (mouse, ferret, pig, or monkey) species, to determine their 
effectiveness and their potential for use in humans. This is time-consuming, expensive, 
and requires the use of avian or mammalian species.  
Recent studies have identified two criteria that tend to predict effective vaccines: 
(i) viruses that replicate well; and (ii) those that are good inducers of IFN, based largely 
on the production of truncated NS1 proteins from deletion mutants in the NS gene 
[84,125]. The second criteria may be assessed using in vitro biological assays that 
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measure the appropriate rdBAP subpopulations. Indicative of the innovation behind this 
approach to improved LAIVs is the report that in vitro analyses of virus particle 
subpopulations in candidate LAIVs [161] made it possible to distinguish effective (vac) 
from ineffective (vac) [84]. Further, studies have demonstrated that the species of the 
host cell can have marked effects on the expression of these phenotypes and the 
effectiveness of the vaccine [109]. A full understanding of the potential effectiveness of 
candidate LAIVs, and the methods that would allow researchers to enhance that 
potential, requires a complete analysis of the rdBAP subpopulations that are associated 
with effective vs. ineffective LAIVs.   
      
1.13 Goals 
This thesis and the research presented herein are designed to facilitate a better 
understanding of the nature of IAV, and the prerequisites or mechanisms by which 
various emergent biological activities manifest are explored. First, the patterns of 
expression of the IAV infectious particle subpopulation are characterized under 
conditions of high multiplicity. This section addresses certain behavioral expectations 
given recent studies demonstrating that the majority of influenza virus particles are 
packaged with one copy of each of the eight gene segments yet fail to score as 
infectious (Chapter 2). Second, those rdBAP subpopulations that are most involved in 
the regulation of IFN, namely, IFP and ISP, are characterized in greater detail. These 
studies focus in greater detail on the interaction of IFP and ISP and the regulation of 
IFN induction because of its important role in virus-cell interaction in general, and the 
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extent to which IFP activity may be predictive of LAIV efficacy [83]. A mathematical 
model is presented which describes those particle and host cell interactions which 
dictate the magnitude of IFN-induction induced by IAV infection (Chapters 3 to 5). 
Finally, the quasispecies nature of IAV is systematically explored using IFN-induction 
activity as a phenotypic marker of genetic and functional heterogeneity amongst plaque 
isolates from a single IAV strain. This last study demonstrates the full range of 
functional variance that may be observed within a single IAV population (Chapter 6).  
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CHAPTER 2 
 
 
 
 
 
CHARACTERIZATION OF INFECTIOUS PARTICLES OF IAV 
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2.1 Abstract 
Type-A influenza virus preparations exist as a mixture of particles in which only a 
small fraction of physical particles are infectious. This is observed despite recent reports 
that the vast majority of virus particles are packaged with one copy of each of the eight 
unique viral gene segments required for infectivity. All eight gene segments must be 
successfully and functionally expressed in a host cell in order to establish a productive 
infection. Therefore, the failure of the majority of physical particles to score as infectious 
represents some quantifiable inefficiency of the gene expression process and is 
mathematically described. Further, the segmented and independently-transcribed 
nature of the genome suggests this deficiency could be overcome through increased 
multiplicity of infection: this would increase the copy number of each gene delivered to 
the cell and should theoretically allow for genetic complementation to occur and a 
productive infection established as a result. A novel assay demonstrates that 
multiplicity-dependent complementation does not significantly contribute to the infectivity 
of influenza A virus in Vero, a mammalian cell line. Utilizing UV-irradiation, progeny 
production is shown to be dependent upon the infectious particle content of influenza A 
virus stocks. This result directly demonstrates that productive infectious events occur 
due to infection by individual infectious particles: these are the progenitors of all other 
particle-types. 
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2.2 Introduction 
Type-A influenza viruses (IAV) are composed of a complex mixture of 
biologically-active particle subpopulations which express a variety of measurable 
phenotypes [80,81,84,85,109,111]. Infectious particles, commonly measured as plaque-
forming particles (PFP), are those particles which establish a productive infection in the 
host and result in the formation of viral progeny. In order for infection by IAV to result in 
a productive infection, each of the eight unique viral gene segments must be 
functionally expressed within the host cell.  
Recent studies utilizing IAV stocks produced via reverse genetics techniques 
have shown that influenza packaging is an ordered process, and that the vast majority 
of particles from such populations receive exactly one copy of each of the eight gene 
segments [21,114]. Combined with observations from electron microscopy studies 
where virus particles with exactly eight gene segments dominate [115], it is assumed 
that virtually all IAV particles, particularly those of viruses created de novo via reverse 
genetics and tested within their first few passages, physically contain all eight of those 
genes necessary to establish a productive infection.  
Despite these observations, a comparison of the PFP titer to the total number of 
physical particles, measured as hemagglutinating particles (HAP), reveals that within 
the typical IAV preparation only a small fraction of the total number of physical virus 
particles register as infectious [26,31,84,85]. The vast majority of IAV particles, although 
biologically-active in other ways, are classified as noninfectious in that the virus enters 
the cell but progeny are not produced. Based on the results of the studies highlighted 
above, it can no longer be assumed that the large discrepancy between physical and 
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infectious particles is the result of errant or inefficient packaging. Despite the vast 
majority of particles possessing those genes necessary to initiate a productive infection, 
the large numbers of detectable noninfectious particles must result as a byproduct of 
the majority of IAV particles failing to express one or more essential viral protein, as was 
recently reported in a study examining viral protein expression [15]. 
The possibility is raised by Brooke and his colleagues [15] that a productive 
infection within the host may be established should the missing protein be 
supplemented via co-infection of the host with a second noninfectious particle. They 
question whether the traditional methods of assessing infectivity may underrepresent 
the true infectious potential of a given virus stock. Consider that under the conditions of 
the plaque assay, which is typically performed at high dilution, even the multiplicity of 
physical virus particles, which is itself much greater than the multiplicity of infectious 
particles, is exceedingly low (mHAP = 5 × 10-4 and mPFP = 2 × 10-5, given a virus 
preparation consisting of 5 × 108 PFP/ml and 1.15 × 1010 HAP/ml, properly diluted to 
produce < 200 plaques, and a cell monolayer consisting of 107 cells). It is therefore 
assumed that any single plaque which develops over the course of the assay may be 
traced back to the infection of one cell by only a single virus particle. As such, the 
standard plaque assay does not account for the contributions of multiplicity 
complementation, if such activity is occurring. On this basis, the research presented in 
this chapter investigates the potential contribution of complementation to the overall 
infectivity of IAV through the use of a novel dose-response assay which measures the 
production of nascent HAP.  
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2.3 Materials and Methods 
2.3.1 Cells and media 
 Vero cell monolayers are maintained in MEM medium plus 5% fetal bovine 
serum and are grown at 37.5°C plus 6.5% CO2. Primary chicken embryo kidney cells 
(CEK) were obtained as suspensions from Charles River SPAFAS, Inc. (North Franklin, 
CT) and are grown in NCI medium plus 6% calf serum (AS = attachment solution). CEK 
are incubated at 38.5°C in an air-CO2 mixture to maintain a pH  7.1 
 
2.3.2 Viruses 
Seed stocks of A/TK/OR/71-NS1 (1-230) (H7N3) = [TK/OR-NS1] and its variant 
A/TK/OR/71-delNS1 (1-124) (H7N3) = [TK/OR-delNS1] were generated via reverse 
genetics and kindly provided by Chang-Won Lee (Ohio State University, Wooster, OH). 
A/PR/8/34 (H1N1) = [PR/8] was generated de novo through reverse genetics and was 
obtained from R.G. Webster (St. Jude Children’s Research Hospital, Memphis, TN).  
 
2.3.3 Infectious (Plaque-forming) particle assay 
Infectious particles of the above virus stocks were initially quantified by plaque 
assay in either CEK or GMK-Vero cell monolayers. CEK cell suspensions were provided 
by Charles River SPAFAS, Inc. (Storrs and Willimantic, CT) and were seeded at a 
density of 18×106 CEK/50mm plate. GMK-Vero cells were plated at a density of 1×107 
cells/50mm plate. Viral attachment, the first step of the plaque assay, was performed 
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24hr after seeding in a total attachment volume of 300µl. Attachment was allowed to 
proceed at 37.5°C for 1hour, after which the supernatant was aspirated. 
CEK cell monolayers were then overlaid with Nutrient Colorado Inositol (NCI) 
medium containing 0.6% agarose. GMK-Vero cell monolayers were overlaid with 
minimum essential medium (MEM), also containing 0.6% agarose. Trypsin (Sigma 
T14263) at a final concentration of 2 µg/ml was added to the overlay used for GMK-
Vero cells in order to activate the hemagglutinin fusogenic peptide of progeny, 
facilitating plaque formation by enabling multiple rounds of replication/propagation 
[4,97,175]. GMK-Vero cell plaque assays also received a second trypsin-containing 
agarose overlay 24 hours post-initial overlay in order to counter the anti-trypsin inhibitor 
produced by these cells [64]. Plaques are counted after 2 to 3 days of incubation at 
37.5°C plus 6.5% CO2. Both cell types are ideal for use in plaque assays as CEK 
intrinsically produce low yields of IFN, and GMK-Vero cells lack the molecular 
components necessary for the IFN-induction branch of the innate immune system. 
When GMK-Vero cells are used just at the point of monolayer confluence (≈1×107 
cells/50mm plate), the resulting plaque titers are similar to those obtained using CEK. 
 
2.3.4 Complementation-dependent infectious particle assay 
A novel assay was developed in which a series of cell monolayers are infected 
by increasing doses of a virus preparation. The total number of physical progeny 
resulting from that infection is collected and then quantified via hemagglutination assay 
[26,31]. GMK-Vero cells, a mammalian cell line, was specifically selected for use as 
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these cells lack an interferon-inducible system [28], negating the possibility of IFN-
related feedback and the corresponding repression of virus progeny production. Further, 
IAV progeny released from Vero cells do not possess an activated (cleaved) fusogenic 
peptide, and without the addition of trypsin to the medium [64] only a single-round of 
replication based solely on the input virus is ensured.  
Initially, monolayers of GMK-Vero cells were infected by a constant dose of IAV 
(rgA/TK/OR/71-NS1 (1-230)) and monitored for the release of progeny, measured as 
HAP, over time. Attachment was allowed to proceed for 1 hour at 37.5C + 6% CO2, after 
which the attachment medium was aspirated and replaced with 2mL of MEM and the 
cells returned to the incubator. At 12, 24, 48, and 72 hours post-attachment the 
supernatants were collected and frozen at -80°C. After all of the samples were 
collected, the samples were thawed and then assayed for their content of 
hemagglutinating-positive particles via a standard hemagglutination assay, described 
below. It was determined that maximal amounts of progeny were recoverable at 48 
hours post-infection (data not shown), and thus all subsequent assays were harvested 
at 48 hours so as to recover peak yields of virus progeny. 
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2.3.5 Hemagglutinating particle assay 
The general hemagglutinating particle assay has been described previously 
[26,31]. The number of progeny generated during the course of the infectious particle 
assay was assessed via a 2-dimensional hemagglutination assay. Briefly, 4 rows of a 
96-well tray were used to quantify each sample. In the first column, dilutions of virus into 
PBS-6 (PBS adjusted to pH 6) were made as follows: 1/2; 1/2.5; 1/3; 1/3.5. These 
mixtures were then diluted two-fold down the length of the titer tray. This protocol allows 
for greater resolution when determining the hemagglutination end point than could be 
achieved using only a single dilution of virus. A total of 2.3 × 106 chicken red blood cells 
(RBCs) were added to each well in a volume of 100 µl and then placed at 4°C for 4 
hours. The highest dilution of virus which provided complete hemagglutination was 
considered to contain 1 hemagglutinating unit (HAU), and the HAU titer (HAU/100µl) 
was assessed to be the reciprocal of that dilution. HAU titers were converted into 
hemagglutinating particles (HAP) using a conversion factor based on the number of red 
blood cells in each well (2.3 x 106) and the assumption that one virus particle per red 
blood cell is necessary to maintain the hemagglutination lattice; [HAU/ml × (2.3×106 
HAP/HAU) = HAP/ml]. 
 
2.3.6 UV-irradiation and influenza virus inactivation 
     Short wavelength ultraviolet (254 nm) radiation was delivered to virus aliquots prior 
to attachment and was performed using a calibrated UV light source. The protocol by 
which UV-irradiation was performed has been described [87,88]. Lethal UV hits prevent 
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full transcription of the viral RNA and occur as the result of dimer formation at adjacent 
uridine residues in the vRNA gene segments. Lethal UV hits are distributed throughout 
the genome according to a random (Poisson) distribution. Inactivation of influenza virus 
infectivity has been observed experimentally and has been reported previously as 1 
lethal hit (D37) = 82.8 ergs/mm2 [87]. 
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2.4 Results 
2.4.1 Complementation-dependent infectious particles are not detected in GMK-
Vero cells 
Stocks of TK/OR-NS1, TK/OR-delNS1, and PR/8 were used to independently 
infect three different series of GMK-Vero monolayers with increasing multiplicities of 
infectious particles. After 48 hours the supernatants were harvested and assessed for 
their content of hemagglutinating-positive progeny. As shown in Figure 2.1, all three 
viruses show similar trends. Hemagglutinating-positive progeny (circles) are produced 
at a rate equal to that predicted by the PFP titer of each respective virus preparation 
(dashed lines).  
The dashed lines in Figure 2.1 are theoretical and represent the fraction of cells 
receiving one or more PFP according to a Poisson distribution of PFP amongst the cell 
monolayer, the assumed minimum condition which leads to the establishment of a 
productive infection. The expected fraction of hemagglutinating–positive progeny 
produced varies for each virus preparation based on the infectious particle content of 
each stock. The equation which describes the theoretical curves appears below: 
𝑃(𝑃𝐹𝑃) = 1 − (
𝑒−𝑚(𝑃𝐹𝑃)𝑚(𝑃𝐹𝑃)
𝑟(𝑃𝐹𝑃)
𝑟(𝑃𝐹𝑃)!
) 
Where m(PFP) is the multiplicity of PFP; r(PFP) is the exact number of PFP that attaches to 
a given cell; e is the base of the natural logarithm and; ! = factorial. When r(PFP) is set 
equal to zero the equation describes the probability that a productive infection will occur 
(P(PFP)) based on the cell being infected by one or more PFP at a given multiplicity of 
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PFP (m(PFP)). The theoretical curves are produced by varying the value of m(PFP) over a 
wide range. 
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Fig 2.1 IAV produce progeny at a rate consistent with infectious particle titers. 
The data points represent the number of hemagglutinating-positive progeny recovered 
from monolayers of GMK-Vero cells 48 hours post-infection as a fraction of the peak 
yield recovered. The dashed lines are theoretical and are based on a Poisson 
distribution of infectious particles amongst the Vero cell monolayer. These theoretical 
lines represent the fraction of cells receiving one or more PFP and are based on the 
number of cells in the monolayer (4.5 × 106 cells/50mm dish) and the PFP titer of the 
virus preparations, as follows: TK/OR-NS1, 3.75 × 107 PFP/ml; TK/OR-delNS1, 4.9 × 
107 PFP/ml; PR/8, 120 × 107 PFP/ml.  
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2.4.2 UV-irradiated virus produces progeny at a rate consistent with infectious 
particle titers in GMK-Vero cells 
     Aliquots of rgA/PR/8/34 were exposed to varying doses of UV-radiation (254nm) 
prior to attachment to separate series of GMK-Vero cell monolayers. Figure 2.2A shows 
the rate of inactivation of PFP that occurred as a function of UV dose (circles), which 
matches well the expected rate of inactivation (dashed line) where 1 lethal hit = 82.8 
ergs/mm2, a value previously reported [1,81,87]. These UV-irradiated virus samples with 
reduced infectious particle titers were then used to repeat the progeny-production 
experiment. As shown in Figure 2.2B, the rate of hemagglutinating-positive progeny 
formation decreases at a rate equivalent to that predicted by the decreased infectious 
particle (PFP) titers of the UV-irradiated virus stocks. The dashed lines are again 
theoretical and based upon a Poisson distribution of PFP amongst the cell monolayer 
over a range of mPFP, as described above. 
     The virus stock treated with the highest dose of UV-radiation (120 sec ≈ 7 lethal hits) 
was not able to maximize the progeny-producing potential of the cell monolayer and 
thus did not reach a plateau. This was due to the low PFP titer of the stock and the 
physical limitations of the attachment volume which was not allowed to exceed 300 µl in 
order to preserve virus attachment kinetics. Therefore, in order to calculate the fraction 
of hemagglutinating-positive progeny for the virus stock receiving 7 lethal UV hits, the 
maximum amount of hemagglutinating positive progeny produced by the virus stocks 
receiving 0 and 3.5 lethal hits (2048 HAU/100µl) was used and set equal to 1.0.  
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Fig. 2.2: The effect of UV-radiation on IAV infectious particle titers and on the rate 
of progeny formation. A/PR/8/34 was exposed to 0, 60, and 120 seconds of UV-
radiation prior to infecting monolayers of Vero cells. (A) The experimentally measured 
rate of inactivation of PFP is shown (squares). The dashed line is theoretical and is 
based on the prior observation that 82.8 ergs/mm2 delivers, on average, 1 lethal hit to 
the IAV genome. The error bars represent ±SD of three replicate plaque assay plates. 
(B) Demonstrates declining rates of production of hemagglutinating-positive progeny 
which occurs when the virus is pre-treated with varying amounts of UV-radiation (data 
points). The dashed lines are theoretical and represent the fraction of cells (≈1.0 × 106 
Vero/50mm dish) infected by one or more PFP (PFP titers: PR/8, 235 × 107 PFP/ml; 
PR/8 + 60s UV, 15.5 × 107 PFP/ml; PR/8 + 120s UV, 0.525 × 107 PFP/ml) and are 
based on a Poisson distribution of PFP amongst the cell monolayer given the average 
multiplicity of PFP at the corresponding volume of virus.  
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2.5 Discussion 
2.5.1 Infectious particles are the progenitors of all replication-deficient particle-
types 
          Figures 2.1 and 2.2B demonstrate that all of the hemagglutinating-positive 
progeny produced from Vero cells in response to infection by IAV may be attributed 
solely to the infectious particle subpopulation. The rate of hemagglutinating-positive 
progeny formation was observed to correlate well with the rate predicted by the 
infectious particle content of the three virus stocks tested. Given that only a small 
fraction of these progeny scored as infectious (data not shown), these experiments 
have for the first time directly demonstrated that IAV infectious particles are the 
progenitors of all other noninfectious particle types in this host cell system. 
These results are surprising given the widely accepted phenomenon of multiplicity 
reactivation which has long been associated with influenza viruses [6,51]. The early 
work documenting this phenomenon was performed on fragments and associated 
pieces of the chorioallantoic membrane of the egg. The results reported here may 
represent some difference in viral processing between the avian and mammalian 
systems. Hirst and Pons reported that virus aggregates increase IAV infectivity, 
suggesting that entering into the cell at a single locus increased the effect of 
complementation [53]. This spatial dependency might also be reflected here as the 
relative large size of Vero cells as compared to chicken embryo fibroblasts (10-2.5:1, 
based on the average surface area of a 50 mm petri dish (~20 cm2) and depending on 
cell density) might lower the probability of initializing and detecting multiplicity 
reactivation in the mammalian system. 
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In addition, a recent study showed that individual particles of IAV often failed to 
express all of the viral proteins necessary for propagation. It was demonstrated in vitro 
using MDCK cells, a mammalian cell line, that increased multiplicity of IAV resulted in 
complementation and restored the expression of those missing proteins [15]. The failure 
of complementation to restore propagation in vitro, as demonstrated here, is highlighting 
some unknown variable influencing the processes leading to IAV replication. 
 
2.5.2 On the nature of infectious particles and the probability of phenotype 
expression 
Type-A influenza virus (IAV) preparations are composed of a complex mixture of 
biologically-active particles which express a variety of measurable phenotypes 
[80,81,84,85,109,111]. Infectious particles are measured as plaque-forming particles 
(PFP) and are defined as those particles which establish a productive infection in the 
host cell, thereby facilitating the formation of viral progeny.  As noted, in order for a 
productive infection to occur, a particle of influenza virus must successfully express and 
achieve full function of each of the eight unique viral gene segments in the host cell.  
A comparison of the PFP titer to the total number of physical particles, measured 
as hemagglutinating particles (HAP), reveals that in the typical IAV preparation only a 
small fraction of the total number of physical virus particles register as infectious (< 5%). 
Given a preparation with typical titers of 5 × 108 PFP/ml, a titer of about 1.15 × 1010 
HAP/ml is predicted. Further, under the conditions of the plaque assay, which is 
typically performed under conditions of high dilution, typical multiplicity of infection is low 
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(mHAP ≤ 5 × 10-4, given a virus preparation of 1.15 × 1010 HAP/ml and a cell monolayer 
consisting of 107 cells). This is important for we can assume that any single plaque 
which develops over the course of the assay may be traced back to the infection of one 
cell by only a single virus particle.  
Recent studies have shown that packaging of gene segments in influenza 
viruses is an ordered process, producing virus particles with one copy of each of the 
eight gene segments [21,114]. Given these studies, and observations from electron 
microscopy where virus particles with eight gene segments dominate [115], it can no 
longer be assumed that the large discrepancy between hemagglutinating and infectious 
particles is the result of errant or inefficient packaging. Therefore, accepting that the 
majority of IAV particles are packaged with exactly one copy of each of the eight gene 
segments and yet so few particles score as infectious, it suggests that the disparity 
between hemagglutinating and infectious particle titers reflects an inefficiency with 
which gene products are successfully expressed and function within the host cell. We 
hypothesize that the probability of a single virus particle successfully expressing all the 
necessary functional gene products encoded for by the eight gene segments in the host 
cell is low, owing to any number of possible mechanisms (genetic mutation resulting in 
nonfunctional viral proteins; inefficiency in particle uncoating; nuclear transport failure; 
sequestering or degradation of gene segments through interactions with various host 
cell factors; etc.). 
In order to begin to address this hypothesis, consider the following mathematical 
approach: assume influenza virions are efficiently packaged and that the majority of 
particles include exactly one copy of each of the eight unique gene segments required 
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for infectivity. Based on the typical titers mentioned previously (5 × 108 PFP/ml and 1.15 
× 1010 HAP/ml), we deduce that there is only one infectious particle per twenty-three 
physical particles, on average. Recalling the conditions under which the plaque assay is 
performed and which were explained above, the probability that a single physical 
particle will express all eight gene segments and therefore produce a productive 
infection is approximately 4.4% (1/23). Defining x as the probability of expression of 
each individual gene segment and assuming that this individual probability is both equal 
to and independent of the other seven, then x8 = 1/23. Solving for x, the probability of an 
individual gene segment being successfully expressed within the host cell is 
approximately 67.6%.  Note that 67.6% is comparable to the rate that would be 
expected if virus gene expression were a truly random (rare) event (63%, as based on 
the Poisson distribution). 
The validity of this figure can begin to be assessed through comparisons to data 
recently reported by Brooke and colleagues [15]. They determined the rate of 
expression of 4 viral proteins by probing for viral proteins expressed in MDCK cells 
infected at low multiplicities of infection. Detection of any of the 4 viral proteins was 
considered sufficient to count a cell as infected and any cell expressing all 4 of the viral 
proteins was considered propagation-competent. The expression rates of each 
individual protein were calculated by taking the number of instances in which a specific 
protein was expressed and then dividing by the total number of cells to register as 
positive for any of the screened for viral proteins. Although this number varied 
depending on the specific gene segment, the average value is equal to 78.1% for the 
A/PR/8/34 stock tested. 
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They then sought to verify this number using another approach, utilizing another 
series of experiments and an analysis similar to the mathematical model explained 
previously. They infected MDCK cells with low multiplicities of IAV, probed for HA and 
NP, and searched for adjacent cells positive for expression of these viral proteins. Foci 
consisting of 3 or more positive cells were considered propagation-competent; foci 
consisting of 1 or 2 positive cells were considered the product of a single-cycle, abortive 
(i.e. noninfectious) infection. By these criteria and for the A/PR/8/34 stock, it was 
determined that 1 out of every 8 infectious events was propagation-competent. This 
gives the following mathematical relationship: x8 = 1/8, where x is the average 
probability of a single viral gene being expressed. Solving for x gives the probability of 
expressing any of the eight gene segments, or 77.1%. This value matches well the rate 
determined from the protein expression data. 
This approach was applied to two additional virus strains, A/Udorn/307/72 and 
A/California/07/09. They report that the ratio of propagation-competent to abortive, 
single-cycle infections vary by strain (viral genotype) and are equal to 1/3 and 1/20, 
respectively. Utilizing the same analysis, these ratios give gene expression rates equal 
to 87.2% and 68.8%, again respectively (our calculations). A virus preparation in which 
1 out of every 3 virus particles results in a productive infection would be extremely 
efficient and may be a byproduct of the methodology used by Brooke et. al. to tabulate 
the occurrence of infectious versus noninfectious events. By minimally considering 
noninfectious events as those cells expressing at least one virus protein, virus particles 
that infect the cell but otherwise fail to produce protein (i.e. failures in viral uncoating, 
genetic/functional integrity, nuclear transport, etc.) are not considered and noninfectious 
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events may be underrepresented. Using our approach in which the infectious particle 
titer is compared against the entire pool of physical particles, virus particles that fail to 
express for any reason are accounted for.  
Interferon induction-suppressing particles (ISP) have been demonstrated to 
require only the expression of a single gene segment, that of the NS gene [81]. Taking 
the physical particle titer (1.15×1010 HAP/ml) and multiplying by the probability of 
expression of a single gene (67.6%), we can calculate an expected ISP titer, in this 
case equal to 7×109 ISP/ml. Anecdotally, this number is within 2-fold of the ISP titers 
routinely produced by A/TK/OR/71 virus stocks. Although a more rigorous series of 
experimental tests would be required to fully assess the validity of this assertion, this 
line of reasoning begins to explain why the measurable/effective ISP titers are less than 
would be expected given the observation that every physical particle contains a copy of 
the NS gene. Further, this lesson applies to not only every biologically-active particle 
subpopulation identified to date, but also potentially explains why the majority of 
physical particles are noninfectious despite containing one copy of each of the eight 
gene segments. 
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CHAPTER 3 
 
 
 
 
 
CHARACTERIZATION OF INTERFERON-INDUCING PARTICLES OF IAV 
  
 44 
 
3.1 Abstract 
Type-A influenza viruses (IAV) have long been associated with the production of 
interferon (IFN). The magnitude of IFN produced by a host cell infected with IAV 
depends on the competing biological activities of both the IFN-inducing particle (IFP) 
and IFN induction-suppressing particle (ISP) subpopulations, both of which were only 
recently demonstrated as present within IAV preparations via the application of the 
appropriate biological assays [87]. In this chapter, the IFP subpopulation is the focus 
and the IFN-induction activity of IAV is analyzed separately from the biological activity of 
the ISP subpopulation, which is covered in more depth in Chapters 4 and 5. 
The viral mechanisms contributing to the IFN-induction activity displayed by the 
IFP subpopulation of IAV are characterized herein. IFN-induction is shown to be 
regulated by the NS1 protein primarily, but also through the expression of the viral 
polymerase subunit genes in the absence of functional NS1 in avian cells. Various 
methods of physical and chemical inactivation demonstrate that the minimum IFN-
induction moiety of IAV is likely the vRNA gene segments, and replication intermediates 
are not required. 
Differences in IFP recognition and regulation as occurs within avian and 
mammalian hosts also are documented. A single IFP suffices to induce IFN in avian 
cells, but 2 or more are required to induce IFN in Marc-145, a mammalian host cell 
system. Further, IFP are resistant to inactivation in avian hosts, but are inactivated at a 
rate consistent with the inactivation of the NS gene in mammalian hosts.  
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3.2 Introduction 
 Isaacs and Lindenmann first reported the discovery of interferon (IFN) in 1957 
through a series of seminal experiments in which fragments of chicken chorioallantoic 
membrane were exposed to heat-inactivated influenza virus [58]. Infection by heat-
inactivated virus produced an interfering activity that took upwards of 4 hours to be 
established. Residual interfering activity could be found in the virus-free supernatant 
used to bathe the chorioallantoic membrane during infection. When this supernatant 
was exposed to fresh membrane, antiviral activity was observed which limited the 
spread and replication of live influenza virus [57].  
  In 1965, Burke and Buchan observed that inactivation of influenza virus through 
exposure to ultraviolet (UV) radiation enhanced IFN-induction. Exposure of IAV to short 
wavelength (254 nm) UV radiation prior to attachment resulted in the production of even 
higher IFN yields by the cell than did infection with heat-inactivated virus [17,87]. Both 
heat and UV-irradiation are physical treatments that allow the IFN-induction activity of 
IAV to be perturbed, and the results observed and analyzed. 
Various strains of IAV are documented to differ as much as 100-fold in their 
potential to induce IFN [87]. These variations are interpreted to be manifestations of the 
balance that exists between the IFN-inducing particle (IFP) and IFN induction 
suppressing particle (ISP) subpopulations subsumed within every virus stock. This 
relationship is explored in more detail in Chapter 5. In this chapter, the interferon-
inducing particle (IFP) subpopulation of IAV is discussed and its behavior characterized 
independent of the IFN induction-suppression phenotype. The effects of physical and 
chemical inactivation treatments are more thoroughly characterized here and 
 46 
 
interpreted within the context of the IFP subpopulation. Differences between the 
recognition and regulation of IFP upon infecting avian and mammalian hosts are also 
highlighted. 
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3.3 Materials and Methods 
3.3.1 Cells and media 
 Cell suspensions of primary chicken embryo cells (CEC) were prepared from 9-
day old chicken embryos. Nutrient Colorado plus Inositol (NCI) medium (produced by 
Life Technologies, USA) plus 6% calf serum were used to maintain CEC and these cells 
were incubated at 38.5°C plus 6.5% CO2 so as to maintain pH 7.1. Marc-145 (Marc), an 
African green monkey kidney cell line, was maintained using minimal essential medium 
plus 5% fetal bovine serum. Marc cells were grown and maintained at 37.5°C plus 6.5% 
CO2. 
 
3.3.2 Viruses.  
Multiple strains based on A/TK/OR/71-SEPRL (Southeast Poultry Research 
Laboratory) differing in the composition of the NS gene were generated via reverse 
genetics techniques [161] and kindly provided by Chang-Won Lee (Ohio State 
University, Wooster, OH). rgA/TK/OR/71-NS1 (1-230)(H7N3) = [TK/OR-NS1] and its 
variant rgA/TK/OR/71-delNS1 (1-124) (H7N3) = [TK/OR-delNS1] were chosen for use 
specifically because they were created from identical plasmids and possess identical 
consensus sequences, save for the truncation of the NS gene. This virus pair provides a 
powerful tool for evaluating the genetic determinants of the IFP and ISP phenotypes as 
the consensus sequences of the other seven gene segments are in essence isogenic. 
This differs from previous research utilizing the naturally-occurring A/TK/OR/71 wild-
type and A/TK/OR/71-delNS1 (1-124) virus isolates [87], which demonstrate differences 
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at several additional amino acid residues amongst the HA, NP, and M1 proteins 
[19,149]. With the isogenic virus pair the observed phenotypic differences can be 
attributed with greater confidence to the alterations present in the NS gene segment. 
 
3.3.3 Generation of IFN samples and quantification.  
IFN-induction experiments were performed in both avian and mammalian cell-
types. Suspensions of primary chicken embryonic cells (CEC) are prepared from 9-day-
old embryonated eggs from specific-pathogen-free flocks. Cells are seeded at a density 
of 1.0 x 107 CEC per 50mm plate to produce confluent monolayers. CEC are 
maintained at 37.5°C in NCI medium plus 6% calf serum for 9-days without a medium 
change, allowing the cells to undergo the same programed development of the IFN 
system in vitro that they undergo in ovo [137]. This process is referred to as 
developmentally aging the cells and results in higher sensitivity to IFN and a more 
robust virally-induced IFN-induction response [140,141]. Copious amounts of IFN are 
induced/produced depending upon the nature of the inducer and when incubation is at 
40.5°C, the normothermic temperature of chickens. In developmentally aged CEC a 
single molecule of double-stranded RNA suffices to induce a full (quantum) yield of IFN 
[89].  
 IFN-induction was also assessed in a mammalian host cell system, using Marc-
145 cells. Marc cells were plated at a density of 0.5×106 cells/50mm plate and allowed 
to grow for 7 days at 37.5°C, reaching a density of 4.5×106 cells/plate, and maximizing 
the potential of these cells to induce IFN. Mammalian cell lines have previously been 
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demonstrated to benefit from the aging process [140]. IFN-induction for Marc cells was 
allowed to proceed for 24 hours at 37.5°C. 
The IFN yields peak at approximately 20 to 24 hours post-infection and the 
supernatant is then harvested and treated at a final concentration of 0.15M perchloric 
acid for 24hr in the presence of fetal bovine serum to precipitate and inactivate residual 
virus and other acid-insoluble/labile moieties. This acid treatment eliminates the activity 
of all but type-I IFN, which is acid-stable. The supernatants are titrated back to neutral 
pH via drop-wise addition of 4N KOH and then made slightly acidic (pH 6.5-6.8) via the 
addition of 0.15M PCA. Samples are assayed for their content of acid-stable, type-I IFN 
via a cytopathic effect-inhibition assay, described in detail previously [140]. The cell-type 
used for the IFN assay matched that used for IFN-induction, ensuring host-type 
compatibility. The increased sensitivity to IFN observed in aged cells provides the 
means for a very sensitive biological assay. 
 
3.3.4 Determination of IFP titer 
By utilizing increasing multiplicities of test virus in the sample-generation phase, 
IFN-induction dose-response curves were produced [87,92,141]. For IFN induction, the 
IFP titer of the preparation can be determined by assuming a random (Poisson) 
distribution of IFP within the cell monolayer.  The equation for the Poisson distribution 
follows: 
𝑃(𝑟) =
𝑒−𝑚𝑚𝑟
𝑟!
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P(r) is the fraction of cells receiving exactly r IFP when exposed to an average 
multiplicity of infection, m.  Given a type r ≥ 1 dose-response curve (see Chapter 5 for a 
complete explanation of the various types of IFN-induction dose-response curves 
produced by viruses), the dilution of virus that produces 63% of the quantum yield can 
be assumed to deliver, on average, 1 IFP per cell in the monolayer.  Based on the 
dilution of virus required to reach this point and the number of cells in the monolayer, 
the IFP titer can be calculated [80,87,92]. 
 
3.3.5 UV-irradiation (254 nm) 
IFN yields induced from infected cells increase when AIV is exposed to low 
doses of UV-radiation prior to attachment to the host cell [17,87]. The physical 
mechanism by which UV-radiation inactivates gene expression is primarily through the 
formation of dimers between adjacent uracil residues, a common genetic motif generally 
evenly distributed throughout the genome of AIV. This physical deformation of the RNA 
blocks the processivity of the viral polymerase, preventing both viral transcription and 
replication. Aliquots of virus are dispensed into a 50mm plate in a total volume of 1ml, 
providing an average depth of 1mm. These plates are kept on ice throughout the 
duration of treatment and are rocked at regular intervals to ensure even distribution of 
lethal UV hits. The experimentally observed rate of inactivation of infectivity has been 
reported previously as 1 lethal hit (D37) = 82.8 ergs/mm2 [87]. 
 
 
 51 
 
3.3.6 Aminomethyltrioxsalen (AMT) plus near-UV (350nm) treatment 
AMT-treatment is a two-stage process whose effectiveness may vary based on 
both the concentration of AMT and the dose of near-UV (nUV) light (350nm). To simplify 
analysis, the dose of AMT is kept constant (60 µg/mL) and the duration of near-UV light 
exposure is the variable by which viral inactivation is controlled. One lethal hit of AMT is 
defined as the dose of near-UV light necessary to reduce infectivity (PFP activity) by 
63% (i.e. 37% survival) at a given concentration of AMT. A plaque reduction assay was 
performed utilizing TK/OR-NS1 and one lethal hit of AMT (60 µg/mL) was delivered for 
every 6.95 seconds of nUV exposure. Exposure of AMT to UV results in the formation of 
covalent crosslinks between AMT and the vRNA. 
 
3.3.7 Thermal inactivation of IAV 
 Heat prevents initiation of primary viral transcription within the host cell by 
inactivating the extant viral polymerase complex associated with the panhandle of each 
gene segment, thereby preventing transcription and, ultimately, expression of the viral 
gene products. Furthermore, because each gene segment has only one polymerase 
complex associated with it [100], the rate of inactivation occurs in a gene-size 
independent manner. Virus stock are diluted 1:2 in NCI medium, pH = 8.0, in a glass 
test tube and submerged in a circulating water bath for the duration of the thermal 
inactivation procedure, mimicking previously reported conditions [87]. 
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3.4 Results 
3.4.1 Expression of IFP activity by TK/OR-NS1 and TK/OR-delNS1.  Figure 3.1 
shows the IFN-induction dose-response curves produced by both TK/OR-NS1 and 
TK/OR-delNS1, in which two series of plates of developmentally aged CEC monolayers 
were infected with increasing multiplicities of each respective virus preparation. 
Truncation of the NS gene segment (upper curve) has an obvious effect on the 
magnitude of IFN yielded from the virus dose-response experiments, resulting in an 
approximate fifteen-fold increase in biologically active type-I (acid-stable) IFN.  
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Fig. 3.1 IFN-induction dose-response curves of IAV. An IFN-induction dose-
response curve demonstrating the difference in IFN yield generated in CEC from 
TK/OR-NS1 and TK/OR-delNS1. Truncation of the NS1 protein results in an 
approximate 10-fold increase in induction. 
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3.4.2 IFN yields are enhanced by UV (254nm)-irradiation of IAV stocks.  IFN yields 
induced from infected CEC increase when IAV is exposed to low doses of UV-radiation 
prior to attachment to the host cell [17,87]. Figure 3.2 demonstrates the results of this 
treatment, and show an increase in IFN yield as a function of increasing doses of UV-
radiation. The quantum yield of IFN induced by both TK/OR-NS1 and TK/OR-delNS1 is 
observed to increase rapidly, even at relatively low doses of UV, although the rate of 
IFN yield enhancement differs between the two virus stains. 
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Fig. 3.2 UV target analysis. The dashed lines represent the expected rate of 
inactivation for: (A) PA + PB + PB2; (B) Any two of the polymerase genes; (C) PA or PB 
or PB2; (D) NS.  TK/OR-NS1 is less sensitive to UV than TK/OR-delNS1. 
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3.4.3 UV target analysis. A single lethal hit of UV to any of the eight gene segments 
suffices to inactivate infectivity. The dose of UV necessary to deliver a single hit to each 
virion is defined based on the Poisson distribution as equal to the dose of UV required 
to reduce infectivity by 63% (1 - 0.63 = 0.37 survival of IFN yield = D37). Experimental 
data that measured the inactivation of PFP as a function of UV has defined this dose 
(D37 = 82.8 ergs/mm2) [1,87]. Based on an observed equitable distribution of adjacent 
uridine residues throughout the genome, gene segments are inactivated at a rate 
proportional to their size. The expected rates of inactivation of specific gene segments 
can be calculated and these were compared to the rate of IFN-induction enhancement 
that occurs as a function of UV-dose. Figure 3.2 shows that the TK/OR-delNS1 virus is 
more sensitive to UV-treatment than is its parent strain. The rate at which the IFN yield 
increases is greater for the TK/OR-delNS1 virus, indicating a larger genetic target is 
being affected by the UV-irradiation. A previous study showed that the increase in IFN 
yield corresponded to the expected inactivation of one or two of the virus polymerase 
subunit genes (PA, PB1 and/or PB2), in the case of the TK/OR-delNS1 mutant [87]. 
This is in agreement with the current UV analysis demonstrated in Figure 3.2. In 
comparison, the TK/OR-NS1 virus shows a lesser rate of IFN yield enhancement, 
corresponding well with the expected inactivation of the NS gene segment. 
 
3.4.4 UV-irradiation enhances IFP efficiency, but not the number of IFP in avian 
cell systems 
In a separate experiment utilizing different stocks (passages) of IAV than used 
above, genetic truncation of the NS1 protein resulted in a 40-fold increase in the 
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magnitude of IFN yield produced by TK/OR-delNS1 as compared to that produced by 
TK/OR-NS1 in primary CEC (Fig. 3.3 – compare open circles to crossed circles). An 
egg-derived TK/OR/71-delNS1 stock was used to assess the effect of UV-radiation on 
IFN-induction by IFP since it lacks a detectable ISP subpopulation (Malinoski & Marcus, 
2012). Figure 3.3 (compare crossed circles to solid circles) shows that the IFN yield 
induced in aged CEC by TK/OR-delNS1 increases ~10-fold when the virus is UV-
irradiated at a dose which maximizes the yield of IFN (UV-dose ≈ 450 ergs/mm2) (cf. 
Fig. 6C in Marcus and others 2005). The IFP titer of the TK/OR-delNS1 subpopulation 
was calculated both before and after treatment with UV-radiation and was found to 
remain constant at a value of 20  108 IFP/ml. Based on the increase in IFN yield and 
the constancy of the IFP titer, we infer that the efficiency (the amount of IFN induced per 
IFP infected cell) of the extant IFP increased 9.5-fold as a result of UV-treatment. 
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Fig. 3.3 Enhancement of IFN Induction by IAV. Magnitude of IFN-induction by TK/OR-
NS1 (open circles) is increased ≈40-fold by genetic truncation of the NS1 protein 
(circles with cross). UV-irradiation of TK/OR-delNS1 (450 ergs/mm
2
; solid circles) further 
enhances IFN-induction ≈10-fold. Comparison of IFN-induction dose-response curves 
for TK/OR-delNS1 (circles with cross) and UV-TK/OR-delNS1 (solid circles) show that 
the dose of virus which induces 0.63 of the maximum IFN yield is equal for both 
preparations (dashed lines). Based on a Poisson distribution of IFP amongst the cell 
monolayer, both of these viruses have equal IFP titers (20×10
8
 IFP/ml), despite the 
increase in magnitude of IFN yield. (≈200 Units, TK/OR-NS1; ≈8000 Units, TK/OR-
delNS1; ≈ 75,000 Units, UV-TK/OR-delNS1). 
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3.4.5 Temporal differences in IFN-induction after UV-irradiation of IAV.  
Before and after UV-irradiation (720 ergs/mm2), the inducing virus TK/OR-
delNS1 was used to infect a series of monolayers of 9-day aged primary CEC. IFN-
induction was comparable at both 4 and 8 hours post-infection, but the UV-treated virus 
induced a greater amount of IFN between 8 and 12 hours post-infection than did the 
untreated virus. In both instances, the magnitude of IFN induced did not increase 
significantly between 12 and 24 hours, and after 24 hours biologically-active IFN 
suspended in the cell supernatant inactivated with an approximately equal half-life (T1/2 
≈ 25 hours).   
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Fig. 3.4 UV-radiation alters the IAV IFN-induction time course. TK/OR-delNS1 was 
used to induce IFN in primary CEC before and after exposure to a single dose of UV-
radiation (720 ergs/mm2). IFN-induction by before and after UV-treatment is comparable 
up to 8 hours post-infection. A large difference in IFN production is observed to occur 
between 8 and 12 hours post-infection, after which IFN degrades. Each data point is the 
average of three independently generated IFN-induction samples and the error bars 
represent the standard deviation between these replicates. 
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3.4.6 Aminomethyltrioxsalen (AMT)-treatment enhances IAV IFN-induction in 
avian cells. 
 TK/OR-NS1 and TK/OR-delNS1 were both treated with aminomethyltrioxsalen 
(60ug/ml), a chemical from the psoralen family, and then exposed to long wavelength 
(350nm) UV-radiation for increasing periods of time. This combination of treatments 
results in the inactivation of IAV through the formation of covalent crosslinks between 
AMT and the vRNA. In all AMT-experiments the dose of virus delivered to the cell 
monolayer was normalized such that the number of physical virus particles were 
comparable. 
As demonstrated in Figure 3.5A, AMT-treatment enhances IFN yields. Although 
the TK/OR-delNS1 virus induces a greater magnitude of IFN at peak yields (TK/OR-
delNS1: 14,000 Units; TK/OR-NS1: 8,000 Units), the TK/OR-NS1 virus displays a 
greater increase in IFN (TK/OR-delNS1: 4.8-fold increase; TK/OR-NS1: 9.8-fold 
increase). After 40 lethal hits, the theoretical dose required to inactivate all eight gene 
segments, the amount of IFN induced by each virus is equal.  
Figure 3.5B shows the IFN-induction dose response curves of both viruses 
(TK/OR-NS1 and TK/OR-delNS1) after receiving 120 lethal hits of AMT-treatment. This 
AMT-nUV dose is three-fold higher than the dose necessary to inactivate primary 
transcription of all eight gene segments. The extent of AMT-treatment was kept constant 
and IFN-induction was observed to vary as a function of virus dose, as expected. As 
before, the virus stocks were normalized to approximately equal physical particle titers. 
Note that both viruses now induce IFN with equal peak yields. Further, the kinetics of 
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the IFN-dose response curves are identical and the normalized, inactivated IAV strains 
demonstrate equal IFP titers (2×108 IFP/ml). 
Finally, the initial increase in IFN yield which occurs as a function of increasing 
AMT dose is compared to the expected rates of inactivation of IAV gene segments 
(Figure 3.5C). The upper, dashed line represents the inactivation of a gene target equal 
in size to one of the three viral polymerase subunit genes, based on its size relative to 
the rest of the genome. The enhancement of IFN yield by TK/OR-delNS1 matches well 
this expected rate of inactivation. The lower, solid line represents the inactivation of a 
target equal in size to the NS gene segment, and is in good agreement with those data 
generated by TK/OR-NS1. Similar to the results observed after UV-irradiation, the 
TK/OR-delNS1 virus is more sensitive to AMT-treatment than its parent strain. The rate 
at which the IFN yield increases is greater for the TK/OR-delNS1 virus, indicating a 
larger genetic target is being affected by the AMT-treatment. 
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Fig. 3.5 (Next page) Effect of AMT-treatment on IFN-induction. IFN-induction was 
performed using 9-day aged CEC. The virus stocks were normalized for HAP via 
dilution into attachment medium. (A) IFN-induction initially increases as a function of 
AMT-treatment. After peak IFN yield is reached, additional exposure decreases IFN 
yields. (B) Virus-dose response curves for TK/OR-NS1 and TK/OR-delNS1 were 
generated after both viruses were exposed to 120 lethal hits of AMT (AMT-dose equal to 
dashed box in (A)). (C) AMT-treatment target analysis. The solid line represents the 
expected rate of inactivation of the NS gene segment based on its size relative to the 
entire genome; the dashed line represents the rate of inactivation of one of the viral 
polymerase subunit genes.   
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Figure 3.5 Effect of AMT-treatment on IFN-induction. 
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3.4.7 Thermal inactivation of IAV in avian cells 
 Figure 3.6A shows the alteration of IFN-induction activity which occurs as a 
function of exposure of IAV to heat (50°C) prior to attachment to primary CEC. Three 
IAV strains are compared: TK/OR-NS1, TK/OR-delNS1, and PR/8. The viruses were 
normalized for HAP such that a constant dose of physical particles were delivered to the 
cells. The magnitude of IFN-induction by TK/OR-NS1 is observed to increase for the 
first hour of thermal inactivation treatment, but declines thereafter. In contrast, TK/OR-
delNS1 is observed to immediately decline at the first data point which represents a half 
hour of thermal inactivation treatment. IFN-induction by PR/8 initially increases, similar 
to TK/OR-NS1 which also produces a full length NS1 protein. After 1 hour of thermal 
inactivation treatment, the magnitude of IFN-induction is equivalent for all three viruses. 
 The same three viruses were again normalized by HAP titers, exposed to 6 hours 
of thermal inactivation treatment, and then used to generate full IFN-induction dose-
response curves. The thermally inactivated virus particles of all three strains produced 
dose-response curves of essentially identical kinetics, indicating equal IFP titers (1.7 × 
108 IFP/ml). 
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Fig. 3.6 The effect of thermal inactivation (50°C) on IAV IFN-induction. (A) 
Demonstrates the effect heat has on the magnitude of IFN-induction based on a single 
dose of three virus strains (TK/OR-NS1, TK/OR-delNS1, and PR/8). Each dose was 
normalized to deliver a constant number of physical particles to the CEC monolayer. As 
IAV is inactivated, the IFN yields converge. (B)  Each virus strain was diluted to equal 
HAP titers, exposed to heat (88 lethal thermal hits), and then used to generate IFN-
induction dose-response curves. After the initial treatment, each virus strain produces 
identical IFN-induction inactivation curves.  
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3.4.8 Comparison of IFN-induction by IAV in avian and mammalian cell types.  
The nature of the IFN-induction dose-response curve produced by primary 
chicken embryo cells in response to IAV (TK/OR-delNS1) is of the type r ≥ 1 (Fig. 3.7A 
– Upper dashed line, solid squares), indicating that infection by one or more IFP suffices 
to induce IFN in avian cells. In contrast, MARC-145 cells produced an r ≥ 2 type curve 
in which infection by 2 or more IFP were necessary for IFN-induction activity (Fig. 3.7A 
– Lower dashed line, open squares). These results demonstrate that avian and 
mammalian cells differ in sensitivity in regard to recognition of IFP. In avian cells, 2 out 
of every 7 HAP registered as an IFP; in mammalian cells, 1 out of every 7 HAP 
registered as an IFP. The IFP titers were calculated to be: CEC = 100 × 108; MARC = 
45 × 108 IFP/ml.  
 A follow-up experiment was performed to confirm these results. Monolayers of 
CEC were plated at three different densities: 6 × 106, 8 × 106, and 10 × 106. Similarly, 
Marc cells were plated at the following densities: 0.5 × 106, 1.5 ×106, and 3 ×106. All of 
these conditions, which are referred to as low, medium and high cell counts, were 
plated in quadruplicate. 
For both CEC and MARC, cells were plated in their respective growth media plus 
serum and allowed to settle, attach, and spread. After 20 hours the supernatants were 
aspirated, the monolayers washed 3x with serum-free medium, and 2 ml of serum-free 
media placed onto the cells. The cells were then incubated, or developmentally aged, 
for 5 days at their regular, respective incubation conditions. 
 After five days, one replicate of each the low, medium, and high cell count plates 
from each cell-type were trypsinized and the cells counted to confirm whether the initial 
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seeding densities were maintained. The other three replicates were infected with a 
constant volume of TK/OR-delNS1 virus. CEC monolayers were infected with 4.5 µl of 
virus, and Marc monolayers were infected with 2.25 µl of virus. Since the virus doses 
were held constant for each respective cell type, mIFP varied as a function of cell count. 
As the cell number is increased the probability that a single cell will be infected by two 
or more IFP decreased. As shown in Figure 3.7B, monolayers of CEC increased IFN 
yield as cell number increased, indicating that infection by only one IFP sufficed to 
induce IFN. In contrast, IFN yields decreased for Marc cells as the cell numbers 
increased, indicating that multiple IFP per cell are needed to induce IFN. 
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Fig. 3.7 IFN-induction activity of IFP differs between mammalian and avian hosts. 
(A) Demonstrates that IFN-induction by TK/OR-delNS1 on primary CEC (avian) cells 
produces a type r ≥ 1 IFN-induction dose-response curve. In response to the same 
virus, Marc cells generate a type r ≥ 2 dose-response curve. (B) IFN yields of CEC and 
MARC cells vary as a function of mIFP. Confluent monolayers were plated at varying cell 
densities, referred to as low, medium, and high (CEC = 6 × 106 (low), 8 × 106 (medium), 
and 10 × 106 (high); Marc = 0.5 × 106 (low), 1.5 ×106 (medium), and 3 ×106 (high)). 
These cells were infected by a constant dose of TK/OR-delNS1 so that mIFP varied as a 
function of cell count. Each cell density was induced in triplicate and the average of 
these repetitions is shown above. 
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3.4.9 UV-target analysis of various IAV stocks in avian and mammalian cell types.  
Figure 3.8A/B demonstrates that exposure of IAV to UV-radiation prior to viral 
attachment results in increased IFN production by the host cell. The dashed lines are 
theoretical and represent the expected rate of inactivation for: (A) PA + PB1 + PB2; (B) 
Any two of the polymerase genes; (C) PA or PB or PB2; (D) NS.  Comparison of the 
data points to the dashed lines allows for the identification of the primary genetic 
determinant of IFN-induction regulation in the cell. As these results demonstrate, the 
genetic target whose inactivation increases IFN production differed by virus strain and 
by host cell type. Figure 3.8A shows the genetic target for IFN-induction enhancement 
by TK/OR-NS1 is the NS gene in CEC, but shifts to one of the viral polymerase subunit 
genes in Marc cells. Figure 3.8B shows a similar shift in gene target: IFN-induction by 
TK/OR-delNS1 is enhanced through inactivation of one of the viral polymerase subunit 
genes in CEC, and has a gene target larger than all three polymerase genes combined 
in Marc cells.   
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Fig 3.8 Comparison of UV targets in avian and mammalian cell-types. The dashed 
lines represent the expected rate of inactivation for: (A) PA + PB + PB2; (B) Any two of 
the polymerase genes; (C) PA or PB or PB2; (D) NS.  Fig. 3.8A shows the UV target for 
TK/OR-NS1 is the NS gene in CEC, but is one of the viral polymerase subunit genes in 
Marc. Fig. 3.8B demonstrates that the UV target for TK/OR-delNS1 is one of the viral 
polymerase subunit genes in CEC, and is larger than all three polymerase genes 
combined in Marc cells. 
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3.4.10 UV-radiation inactivates IFP as recognized by mammalian hosts 
 The nature of the r ≥ 2 dose-response curve produced by IAV in Marc cells shifts 
to the right when the virus is inactivated via exposure to UV-radiation prior to 
attachment. UV-treatment resulted in decreased IFP titers as a function of UV dose, as 
demonstrated in Figure 3.9. The IFP titer equal to 100% of IFP activity was 13.3 × 108 
IFP/ml. The dashed lines are the expected rates of inactivation of the following: (Lower) 
plaque-forming particle activity (any gene segment); (Middle) any of the three 
polymerase subunit genes (PB1 + PB2 + PA); (Upper) the NS gene segment. The rate 
of IFP inactivation as measured in Marc cells was observed to equal the expected rate 
of inactivation of the NS gene segment. 
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Fig. 3.9 IFP are inactivated by UV-radiation as measured in Marc-145 cells. The 
inactivation of PFP is estimated based on the D37 dose for IAV (82.8 ergs/mm2). The 
slope of this line represents the accumulation of UV lethal hits anywhere in the IAV 
genome. The expected rate of inactivation of the polymerase subunit and NS genes are 
based on their size relative to the entire genome. The open squares are the 
experimentally determined IFP titers resulting from preparations of UV-irradiated 
TK/OR-delNS1. Each IFP titer was based on a full IFN-induction dose-response curve 
consisting of seven independently generated IFN yields and which were assayed in 
quadruplicate.  
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3.5 Discussion 
3.5.1 Characterization of IFN-inducing particles in avian cell systems 
Wide variation in IFN yield has been observed to exist amongst plasmid-derived 
recombinant IAV strains that are essentially isogenic with the exception of the 
sequence/length of their NS gene [84]. As demonstrated in Figure 3.1, truncation of the 
NS1 protein of the A/TK/OR/71 (H7N3) virus results in a 15-fold increase in IFN-
induction activity in primary CEC.  
These results seemingly place the IFN-induction regulatory emphasis on the NS 
gene product, NS1, which has been demonstrated to play an important role in regulating 
the IFN response produced by the host cell [19,45,69,125,161]. This postulate was 
tested by exposing TK/OR-NS1 and TK/OR-delNS1 to increasing doses of short 
wavelength UV-radiation (254 nm) prior to virus attachment. Burke and Buchan first 
observed that UV-radiation increased IFN yields of IAV in 1965 [17], although the 
mechanism was not elucidated at that time. UV target analysis is shown in Figure 3.2 
and demonstrates that TK/OR-NS1 and TK/OR-delNS1 possess UV-targets of differing 
size, one large and the other small, both of which effect the resultant yield of IFN 
produced by CEC in response to IAV.  
The wildtype virus, TK/OR-NS1, produces a full-size NS1 protein and the 
enhancement of IFN yield observed to occur as a function of exposure to UV-radiation 
matches well the expected rate of inactivation of the NS gene (compare squares to 
dashed line “D”). The expected rate of inactivation is based upon the probability of a 
lethal UV hit occurring within the NS gene segments and is dependent upon the size of 
the NS gene relative to the entire genome. Interestingly, in the absence of a full-size 
 75 
 
NS1 protein, it is observed that the TK/OR-delNS1 virus experiences an increase in IFN 
yield which corresponds to the expected rate of inactivation of one or two of the viral 
polymerase subunit genes (PA, PB1 or PB2) (compare circles to dashed lines “B” and 
“C”). The exact identity of this gene cannot be determined using this method as all three 
genes are approximately equal in size (nucleotides). This is in agreement with recent 
reports that have highlighted the contribution of viral polymerase to IFN-induction 
regulation based on the viral polymerase’s ability to inactivate host cell RNA polymerase 
II, thereby preventing host cell transcription including the production of IFN message 
[42,126,158]. These results suggest that the viral polymerase complex also modulates 
the IFN response. 
The observation that IFN yield has increased does not adequately address what 
effect such treatment has on the IFP and ISP subpopulations. An increase in IFN yield 
may occur due to any combination of the following: (i) an increase in numbers of IFP; (ii) 
an increase in IFP efficiency; (iii) a decrease in number of ISP; (iv) a decrease in ISP 
efficiency. The large ISP subpopulation of TK/OR-NS1 makes interpretations for the 
parent virus more complicated as increases in IFN yield could be attributable to 
changes in either IFP or ISP number and/or efficiency. The TK/OR-delNS1 virus 
consistently produces higher levels of IFP than the parent virus and its ISP titer is 
typically below the level of detection of our biological ISP assay (< 4 x 107/mL). These 
characteristics make the TK/OR-delNS1 virus ideal for interpreting IFN yield data in the 
context of the IFP subpopulation and will be the primary focus for the majority of this 
chapter. 
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With these parameters in mind, the effect of UV-radiation on the IFP 
subpopulation of IAV was investigated more thoroughly. Figure 3.3 shows a family of 
three full IFN-induction dose-response curves generated  by: (i) TK/OR-NS1, which 
expresses full-size NS1 and has a large subpopulation of ISP (bottom curve); (ii) 
TK/OR-delNS1, which expresses a truncated NS1 through a genetic defect, and 
displays an ~40-fold increase in IFN QY (middle curve); and (iii) UV-TK/OR-delNS1, 
which reveals an additional  ~10-fold  increase in the IFN QY following exposure to an 
optimal dose (450 ergs/mm2) of UV-radiation (upper curve) as determined from the UV-
dose response experiment (Fig. 3.2).     
Based on a Poisson distribution of IFP amongst the cell population in an r  1 
IFN dose-response curve of the types illustrated in Fig. 3.3 (middle and upper curves), 
there is an average of mIFP = 1 at the 0.63 level of the maximum (QY) of IFN produced 
[80].  Since the amount of virus that produces 0.63 of the QY yield of IFN is the same 
for TK/OR-delNS1 before and after UV-irradiation (Fig. 3.3, middle and upper curves), it 
follows that after a 10-fold increase in the IFN QY, the number of IFP responsible for 
IFN induction is the same,  20×108/ml. Since the number of IFP per cell and the 
composition of the cell population is the same, then the differences in the magnitude of 
the QY reflect a change in the average amount of IFN produced per IFP-infected cell –
not an increase in the number of IFP.  
What remained was to understand the mechanism by which UV-radiation 
enhanced the IFN-induction/production of IFP another order of magnitude.  Rodriguez 
and others [126,127], and Vreede and colleagues [157,158], showed that the 
polymerase complex of influenza virus degrades cellular RNA polymerase II (RNAP II). 
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From our view this effect represents a mechanism to elicit global shut-off of cellular 
mRNA in general, and IFN-mRNA in particular. Additional evidence implicates viral 
polymerase in the inhibition of IFN production [42,61].  Thus, low doses of UV-radiation 
preferentially inactivate expression of the viral polymerase subunit genes (large UV 
target), prevent the synthesis of nascent viral polymerase complex, and thereby thwart 
shut-off of cellular RNAP II.  This would prolong transcription of IFN-mRNA, and its 
subsequent translation and result in the elevated yields of IFN recorded in Fig. 3.3 (cf. 
the upper and middle curves). Additionally, by reducing the probability of producing 
nascent, functional viral polymerase, UV-radiation also would compromise the viral 
polymerase-dependent cap-snatching required for priming viral transcription [121]. This 
would also upregulate the amount of pre-IFN-mRNA being processed and its 
subsequent translation into IFN. 
This hypothesis was tested and the results shown in Figure 3.4. IFN-induction by 
primary CEC in response to IAV was tracked over time. Stocks of TK/OR-delNS1 were 
used to induce IFN, before and after UV-irradiation (720 ergs/mm2). The yields of IFN 
produced up to 8 hours post-infection are similar, but the UV-irradiated virus induces 
significantly more IFN between 8-12 hours post-infection than does the untreated stock. 
The observed results correspond to what would be expected if UV-radiation were 
enhancing IFN yields by inhibiting host RNAP II shut-off.  
Aside from the inactivation of the viral polymerase, a second theoretical 
mechanism exists that might also explain the observed UV-dependent increase in IFP 
efficiency. Due to the nature of the physical damage that occurs to the viral gene 
segment as a result of exposure to UV-radiation, multiple cycles of abortive transcription 
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may occur. This abortive transcription would result in the accumulation of short viral 
transcripts which may act as IFN-induction moieties within the cell. Due to the short 
length of these abortive transcripts, they possess a competitive advantage and 
accumulate in the cell to a greater degree than normal viral gene products. If these 
short viral transcripts were acting as IFN-induction moieties, their accumulation over 
time would also be consistent with the time course data (Figure 3.4). Experiments were 
thus devised that would allow for the distinction between the two proposed 
mechanisms.   
Aminomethyltrioxsalen (AMT) is a psoralen-related chemical which creates inter-
strand crosslinks between double-stranded nucleic acid molecules when exposed to 
near-UV light (350 nm). It also forms monoadducts between the chemical and single-
stranded pieces of nucleic acid. Importantly, it has been demonstrated that AMT + nUV 
treatment inactivates IAV in a manner that does not produce short viral transcripts [103]. 
Figure 3.5A shows the effect AMT+nUV-treatment has on IFN-induction by both TK/OR-
NS1 and TK/OR-delNS1. Similar to the UV treatment, IFN yields initially increase as a 
function of increasing AMT-treatment. Figure 3.5C again demonstrates that IFN-
induction by the two different viruses are regulated by genetic elements of differing size. 
IFN yields induced by TK/OR-NS1 increase as a function of inactivation of the NS gene 
(lower, solid line), and IFN yields induced by TK/OR-delNS1 increase as a function of 
inactivation of one of the viral polymerase subunit genes (upper, dashed line). Based on 
the AMT+nUV-treatment, IFP can be made more efficient through viral gene inactivation 
and enhanced IFN yields are not the result of short viral transcript accumulation.  
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3.5.2 The nature of the IAV IFN-induction moiety 
 Despite being integral to the discovery of IFN, the exact mechanism by which 
IAV induces IFN in the host cell has yet to be established definitively. For many years 
the prevailing theory was that low levels of dsRNA were produced as replication 
intermediates and that these molecules triggered the innate immune response via the 
appropriate cellular receptors, including toll-like receptor 3 (TLR-3), dsRNA-dependent 
protein kinase R (PKR), retinoic acid inducible gene I (RIG-I), or melanoma 
differentiation-associated protein 5 (MDA-5). However, Weber and colleagues failed to 
detect the production of dsRNA by IAV during the course of infection using 
immunofluorescence techniques [163]. Note that these results do not preclude the 
possibility of dsRNA being the IAV IFN-induction moiety. The levels of dsRNA produced 
by IAV may have been below the level of detection for the immunofluorescence 
technique utilized by Weber [163]. In primary CEC, the threshold dose of dsRNA 
needed to induce IFN has been demonstrated to be as low as a single molecule [89].  
It is clear that for the majority of infected cells, IFN-induction begins in the cytosol 
where the viral IFN-induction moiety must interact with the appropriate host cell factor. 
The cytosolic host cell factors most commonly associated with the induction of the IFN 
system are RIG-I, MDA-5, and PKR. However, recent reports have indicated that a 
homolog of the mammalian RIG-I protein is not present in chickens [5]. Since MDA-5 
recognizes only longer segments of dsRNA, this implicates PKR as the most likely 
cytosolic receptor leading to IFN-induction in response to infection by IAV in CEC.  
Infection by IAV has been shown to activate PKR [49,74,94] although IAV does 
not directly deliver dsRNA, the traditional PKR ligand, to the cell. However, it has been 
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reported that PKR can be activated by short double-stranded segments that contain 
single-stranded tails [104,172]. These tails may be structurally similar to the panhandle 
structure which forms at the end of every IAV gene segment. The vRNP of type B 
influenza viruses also have been reported to directly activate PKR [25]. 
Based on these observations, a model of IFN-induction by IAV was postulated. 
After uncoating, the viral gene segments of IAV are initially deposited into the cytosol 
but are then transported to the nucleus for transcription and replication. This nuclear 
transportation process occurs quickly after virus uncoating, as supported by the 
literature where viral transcription is shown to begin accumulating approximately 40 
minutes post-infection [9]. This is also consistent with reports where viral NS1 protein 
has been reported to appear in the cytoplasm of infected cells 1.5 to 2.5 hours post 
infection [143]. Once the vRNA segments are trafficked to the nucleus, they are no 
longer available to interact with the appropriate host cell factors (PKR) to induce IFN. 
This model suggests that every vRNA containing IAV particle has the potential to 
act as an IFP. If this is so, then the IFN-inducer moiety is pre-formed in the virion and 
viral transcription and translation is not necessary for the occurrence of IFN-induction. 
The virus inactivation experiments shown previously support this notion. As IAV is 
inactivated by low doses of UV-radiation (Fig. 3.2) or AMT-treatment (Fig.  3.5A), the 
first gene segments inactivated are probabilistically, based on UV-target size, the viral 
polymerase subunit genes. Viral replication (infectivity) and transcription is immediately 
impaired by these treatments and yet IFN-induction activity increases, indicating that 
neither process is necessary for IFN-induction. Indeed, at intermediate doses of these 
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inactivation treatments, doses at which viral infectivity can no longer be detected, IFN-
induction remains and is in fact enhanced by the limited metabolic activity of the virus. 
To further investigate this concept, thermal inactivation treatment was used. 
Thermal inactivation differs from both UV- and AMT-treatment in that the target of this 
treatment is not the nucleic acid, but rather the extant vRNA-associated viral 
polymerase complex which is responsible for primary transcription of the viral genome 
[16,81]. Three strains of IAV (TK/OR-NS1, TK/OR-delNS1, and PR/8) were normalized 
based on their HAP titers and exposed to heat (50°C). IFN-induction was measured as 
a function of duration of exposure and is displayed in Figure 3.6A. Note that as these 
three virus strains accumulate lethal hits of heath and approach levels of complete 
inactivation of primary transcription (40+ lethal hits), IFN-induction by each virus strain 
converges. Note that this trend in activity is also observed under similar circumstances 
using AMT-treatment (Fig. 3.5A) 
The convergence of IFN-induction potential is again demonstrated by the IFN-
induction dose-response curves shown in Figure 3.6B. Stocks of TK/OR-NS1, TK/OR-
delNS1, and PR/8, again normalized based on their HAP titers, were exposed to a total 
of 88 lethal thermal hits. Biological activities reliant on the expression of only a single 
gene, namely the development of hemadsorption (not shown) and IFN-induction 
suppression activity (Chapter 4), can no longer be detected at these doses of thermal 
inactivation. IFN-induction activity is demonstrated to not only be extremely resistant to 
heat treatment, but the nature of the IFN-induction dose-response curves for all three 
strains are identical. Given that these stocks were normalized based on their physical 
particle titers, this experiment demonstrates that when IAV is fully-inactivated no 
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difference exists in the IFN-induction potential of these three virus strains. Similar 
results were observed using IAV inactivated by 120 lethal AMT hits (Fig. 3.5B). 
Combined, these data strongly suggest that the IFN-induction moiety of IAV is 
preformed within the virion and is not generated as a replication intermediate. 
 
3.5.3 Differences in IFP activity between mammalian and avian hosts 
 The biological activity of IFP as described in this chapter is based upon 
observations from experiments performed in an avian host cell system, developmentally 
aged primary chicken embryonic cells. Due to the need to better understand the 
interaction between viral and host cell components, the question of whether the lessons 
learned from the avian system would be directly applicable to mammalian host systems 
was considered. This inquiry was based partially on a recent report which demonstrated 
that IFN-induction efficiency was observed to reverse when induction in avian cells was 
compared to induction in mammalian cell lines [110].  
 Figure 3.7A shows that the nature of the IFN-induction dose-response curve 
produced by TK/OR-delNS1 is altered depending upon the host cell system. Primary 
CEC produce IFN in a manner matching a type r ≥ 1 curve, indicating that infection by 
one or more IFP sufficed to induce IFN. In the mammalian cell system, Marc-145 cells, 
the IFN-induction dose-response curve takes the form of a type r ≥ 2 curve. This type of 
curve indicates that IFN-induction occurs only if the cell is infected by 2 or more IFP. 
An experiment was devised to confirm the above results. Primary CEC and Marc-
145 cells were plated initially at three different densities, and allowed to form confluent 
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monolayers (CEC = 6 × 106 (low), 8 × 106 (medium), and 10 × 106 (high); Marc = 0.5 × 
106 (low), 1.5 ×106 (medium), and 3 ×106 (high)). The monolayer with the lowest cell 
count for each cell type was infected by a virus dose that ensured the majority of cells 
were multiply infected by IFP (mIFP = 3). As the virus dose was kept constant for each 
cell type, an inverse relationship between mIFP and cell count was established; as the 
cell count increased, the multiplicity of IFP decreased. 
 As shown in Figure 3.7B, the IFN yield produced by primary CEC increased 
along with the cell number. This occurs because as cell count increases, so does the 
total number of cells infected by one or more IFP. Conversely, IFN yield as produced by 
Marc-145 cells decreases. Thus, in the mammalian system, the total number of cells 
receiving 2 or more IFP decreases as the cell count is increased and IFN is not induced. 
Combined, these two experiments demonstrate that there is a significant difference in 
the manner in which avian and mammalian cells register virus particles as IFP. The IFP 
titer of the TK/OR-delNS1 stock decreases 2-fold when comparing avian to mammalian 
systems (100 × 108 IFP/ml in CEC, as compared to 45 × 108 IFP/ml in Marc-145). 
If the manner in which IFP register differs between avian and mammalian hosts 
so too might the mechanisms of regulation of IFP activity. A UV-dose response 
experiment was performed tracking the rate of enhancement of IFN yield observed to 
occur when TK/OR-NS1 or TK/OR-delNS1 was used to infect either CEC or Marc-145 
(Fig. 3.8A/B). For both viruses, the rate of IFN yield enhancement is observed to 
change depending on the host cell used for the induction, indicating a change in the 
genetic target of UV-inactivation. IFN-induction by TK/OR-NS1 is shown to depend 
upon the activity of the NS gene in CEC, but this dependency switches to one of the 
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viral polymerase subunit genes in Marc-145 (Fig. 3.8A). Similarly, regulation of IFN-
induction by TK/OR-delNS1 depends on one other viral polymerase subunit genes in 
CEC, but is dependent upon a target considerably larger than all of the viral polymerase 
subunit genes combined in Marc-145 cells (Fig. 3.8B). This latter results indicates that a 
lethal hit anywhere in the genome suffices to enhance IFN-induction by TK/OR-delNS1 
in mammalian cells, but note that the magnitude of IFN-induction decreases quickly as 
lethal UV hits accumulate.  
Finally, a series of IFN-induction dose-response curves were performed using 
aliquots of TK/OR-delNS1 exposed to varying doses of UV-radiation. In contrast to the 
result in avian cells where IFP were resistant to inactivation (Fig. 3.3), UV-radiation 
does inactivate IFP as recognized by Marc-145 cells. A consistent shift to the right was 
observed to occur in the IFN-dose response curve, indicating a decrease in IFP was 
occurring as a function of UV. The inactivation of IFP titer observed to occur as a 
function of UV-dose is displayed in Figure 3.9. A UV-target analysis is also shown, and 
the rate of inactivation of IFP is observed to occur at a rate consistent with the 
inactivation of the NS gene segment. This is a particularly interesting result as this virus 
strain produces a nonfunctional NS1 protein in terms of IFN induction-suppressing 
activity, suggesting that some other activity encoded for by the NS gene may be playing 
a role in the regulation and recognition of IFP by mammalian cells. Although the 
mechanisms may not be known at this time, it is clear that significant differences in IFN-
induction and IFP recognition exist between avian and mammalian hosts.  
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CHAPTER 4 
 
 
 
 
 
CHARACTERIZATION OF  
INTERFERON INDUCTION-SUPPRESSING PARTICLES OF IAV 
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4.1 Abstract 
 Influenza virus populations contain several subpopulations of noninfectious 
biologically-active particles that are measured by the unique phenotypes they express.  
Two of these subpopulations were studied: (i) interferon (IFN)-inducing particles (IFP) 
and, (ii) IFN induction-suppressing particles (ISP).  The activity of IFP is characterized in 
depth in Chapter 3 of this thesis. Here, ISP are shown to be dominant in cells coinfected 
with one or more IFP; ISP completely suppress IFN-production in cells otherwise 
programmed to induce it. Influenza virus ISP are shown to act in host cells in a 
nonspecific manner, suppressing IFN-induction independent of the family of viruses 
serving as IFN inducers. Further, the inhibition of IFN-induction caused by ISP cannot 
be outcompeted through exposure of the cell to excess viral IFN-induction moieties 
suggesting a global mechanism of action. It is shown that ISP must be present within 
the first 3 hours of coinfection with IFP to be maximally effective; by 7 hpi IFN-
induction/production is refractory to the action of superinfecting ISP.  UV-target and 
thermal inactivation analyses reveal that ISP activity is dependent solely on the 
expression of the NS gene in avian cell systems.  
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4.2 Introduction 
Influenza A viruses (IAV) are major worldwide contributors to morbidity and 
mortality in human, animal, and avian populations [38]. Based on the facile with which 
IAV undergo antigenic drift [33] and genetic reassortment [119], the emergence of new 
pandemic strains remains a continued threat [166]. To date, vaccination continues to be 
the most effective means of preventing and containing outbreaks of pandemic and 
seasonal strains of influenza virus. Two types of vaccines have been approved for use 
in humans: (i) inactivated virus and, (ii) live-attenuated influenza virus vaccines (LAIVs) 
[171]. The use of LAIVs is becoming more prevalent due to the ease with which these 
types of vaccines are administered, and to the enhanced protection LAIVs confer by 
inducing innate and adaptive immune responses [12,41,99,106].  
Influenza viruses are intrinsically highly sensitive to the action of IFN, albeit with 
some fractions of the virus population transiently resistant to IFN action [19,108,138]. 
The success of candidate LAIVs depends in large part upon the interferon (IFN)-
inducing capacity of the virus: in particular, the magnitude and efficiency of the IFN-
inducing particle subpopulation in a given host cell [84,109,125]. Indeed, recent in vitro 
experiments have demonstrated that the efficiency with which candidate LAIVs induce 
IFN in chicken cells may be used to predict their efficacy as LAIV in chickens [84], and 
in mammals [109].  
Given the dominate role of IFN in the activity of effective LAIV, and its role as a 
natural adjuvant [13,19,45,102], it is important to characterize the dynamic interplay of 
subpopulations of influenza virus particles known to: (i) induce IFN, and (ii) down-
regulate IFN induction/production. This chapter addresses the genetic integrity of the 
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IFN induction-suppressing particle (ISP) subpopulation and identifies the viral gene 
products required to suppress IFN-induction/production in cells co-infected with IFN-
inducing particles (IFP). Further, the behavior of the ISP subpopulation is characterized 
in a biologically-relevant context. This information may contribute to a better 
understanding of the role of regulation of IFN induction/production by ISP during 
infection, pathogenesis, and the course of the disease.  
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4.3 Materials and Methods 
4.3.1 Cells and media 
Cell suspensions of primary chicken embryo cells (CEC) prepared from 9-day old 
chicken embryos were obtained from Charles River SPAFAS, Inc. (Storrs and 
Willimantic, CT).  CEC are maintained in NCI medium plus 6% calf serum (AS = 
attachment solution) and incubated at 38.5°C in an air-CO2 mixture to maintain a pH  
7.1.  Cells were incubated for 9-days without a medium change to developmentally 
mature the IFN system. These “aged” CEC produce copious amounts of acid-stable, 
type-I IFN when suitably induced [136,137,141].  
 
4.3.2 Viruses 
Seed stocks of rgA/TK/OR/71-NS1 (1-230) (H7N3) = [TK/OR-NS1] and its variant 
rgA/TK/OR/71-delNS1 (1-124) (H7N3) = [TK/OR-delNS1] were generated via reverse 
genetics and kindly provided by Chang-Won Lee (Ohio State University, Wooster, OH). 
These two virus strains were chosen because they were created from identical plasmids 
and share the same virus background, A/TK/OR/71-SEPRL (Southeast Poultry 
Research Laboratory), except for the truncation of the NS gene. Virus stocks were 
generated in 10-day old embryonated chicken eggs from specific-pathogen-free flocks 
and stored at -80°C. The TK/OR-NS1 and TK/OR-delNS1 viruses naturally produced 
stocks with high titers of ISP and IFP, respectively [80,87]. 
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4.3.3 IFN-induction and IFN induction-suppression assays 
These assays have been described [80].  Briefly, for IFP assays, 
developmentally aged cells were infected with increasing multiplicities of virus and the 
amount of IFN produced in 24 h was measured as acid-stable, type-I IFN. Full IFN 
induction dose-response curves generated in this manner reveal the maximum 
(quantum) yield (QY) of IFN produced, and allow for the calculation of the number of 
IFP in the subpopulation of particles that induced the IFN (Chapter 3).  For an ISP 
assay, all of the cells of the monolayer are infected with an IFP at mIFP = 5, to insure that 
virtually all cells produce IFN, and then coinfected with increasing amounts of the ISP-
containing virus. The exponential decrease in the amount of IFN produced as a function 
of ISP permits the calculation of the ISP titer. 
 
4.3.4 Quantification of IFN samples 
IFN samples were quantified via the cytopathic effect (CPE)-inhibition assay in 
96-well trays using VSV-HR as the challenge virus [140]. Cells were vitally stained with 
neutral red, allowing for the photometric determination of the 50% endpoint for CPE-
inhibition. Based on this endpoint and the dilution of IFN applied to the cells, the titer of 
IFN for the sample was calculated. All samples were run in quadruplicate and the titers 
averaged. Two different standards were applied to normalize the IFN yields from 
samples generated and assayed on different batches of primary CEC. Aliquots of a 
rChIFN-α standard [139] were used to calibrate the sensitivity of the cells to IFN action, 
and UV-irradiated avian reovirus was used to determine the responsiveness of a given 
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batch of cells to an inducer of IFN. In combination, these two controls were used as a 
standard for cell sensitivity to IFN, and for the cells’ capacity to produce IFN when 
induced.  All IFN assays were normalized to the average of over 30 batches of CEC.  
 
4.3.5 IFP and ISP titer determination 
By utilizing increasing multiplicities of test virus in the sample-generation phase, 
IFN-induction, or IFN induction-suppression, dose-response curves were produced 
[87,92,141]. For IFN induction, the IFP titer of the preparation can be determined by 
assuming a random (Poisson) distribution of IFP within the cell monolayer.  The Poisson 
distribution dictates that 𝑃(𝑟) =
𝑒−𝑚𝑚𝑟
𝑟!
 where P(r) is the fraction of cells receiving exactly 
r IFP when exposed to an average multiplicity of infection, m.  Given an r ≥ 1 dose-
response curve, the dilution of virus that produces 63% of the quantum yield can be 
assumed to deliver, on average, 1 IFP per cell in the monolayer.  Based on the dilution 
of virus required to reach this point and the number of cells in the monolayer, the IFP 
titer can be calculated [80,87,92]. 
A similar approach is taken to determine the ISP titer from the IFN induction-
suppression dose-response curves. Cells were infected by UV-ARV at mIFP = 5, where 
virtually all cells will contribute to the quantum yield. A Poisson distribution of ISP within 
the cell monolayer is assumed and cells coinfected by one or more ISP (r ≥ 1) will have 
their IFN-induction activity suppressed. The dilution of ISP at which the IFN yield is 
reduced by 63% is defined to deliver, on average, 1 ISP per cell [90].  
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4.3.6 UV-irradiation and UV-target analysis 
The protocol by which UV-irradiation (254nm) was performed has been 
described [87]. Lethal UV hits occur as the result of dimer formation at adjacent uridine 
residues in the RNA gene segments and are delivered as a random (Poisson) 
distribution. The experimentally observed rate of inactivation of infectivity has been 
reported previously as 1 lethal hit (D37) = 82.8 ergs/mm2 [87]. 
 
4.3.7 Thermal inactivation of IAV ISP 
The rate of inactivation of infectivity was determined by plaque reduction as a 
function of the duration of exposure of TK/OR-NS1 to 50°C. The virus was diluted 1:2 in 
NCI medium, pH = 8.0, for the heat treatment procedure, mimicking previously reported 
conditions [87].  The line of best fit through these data corresponds to the equation: y = 
e-0.243x . The slope of this line (slope = -0.243) is assumed to represent the inactivation 
of the extant viral polymerase complex associated with any one of the eight gene 
segments in the virion. The slope of the line representing the rate of inactivation of one 
specific gene (Fig. 4.2 – dashed line) is calculated as equal to -0.030375 (-0.243/8).  
 
4.3.8 IAV gene segment sequences (sizes) and accession numbers 
 The sizes of the gene segments used in the UV-target analysis reported here are 
based on the following entries in the GenBank database, and were first described in the 
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indicated references: DQ870885-DQ870890 (Gene segments PB2, PB1, PA, HA, NP, 
NA; [19]); AF073197 (M segment; [148]); and U96740 (NS gene segment; [149]). 
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4.4 Results 
4.4.1 UV-irradiation inactivates ISP: UV-target analysis 
Figure 4.1 demonstrates that UV-irradiation of TK/OR/71-NS1 results in the 
inactivation of infectivity at an exponential rate (lower dashed line). This theoretical 
curve was based on an earlier report where 1 lethal UV hit = 82.8 ergs/mm2 [87].  The 
solid circles represent experimental data following the loss of infectivity (PFP) as a 
function of UV dose and are in good agreement with the expected rate of inactivation 
represented by the lower line. 
The upper dashed line (Fig. 4.1) is also theoretical, representing the expected 
rate of inactivation of the NS gene based on its size (865 nts) [149] relative to the entire 
genome (13,228 nts) [19,148,149]. Based on size, the NS gene, and any biological 
activities dependent on its expression, are expected to be ~1/15th as sensitive to UV 
treatment as is infectivity. The open circles in Fig. 4.1 represent experimental data and 
demonstrate the loss of ISP which occurs as a function of UV dose.  ISP titers were 
calculated as described. The good fit of the data to the theoretical curve lend credence 
to the conclusion that expression of the ISP phenotype requires expression of the NS 
gene.  
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Fig. 4.1 UV-radiation inactivates ISP. The dashed lines are theoretical: the lower line 
is based on the expected rate of inactivation of PFP if a single UV hit occurs anywhere 
in the genome (D37 = 82.8 ergs/mm2) (Marcus and others 2005); the upper dashed line 
represents the expected rate of inactivation of the NS gene based on its size relative to 
the entire genome (865 out of 13,228 nts total) [19,148,149]. Solid circles represent 
infectious particle titers measured as PFP. Open circles represent ISP titers calculated 
from a series of ISP dose-response assays, performed on multiple batches of primary 
CEC. Each data point represents an assay comprised of eight independently generated 
IFN yields and was carried out in quadruplicate.  
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4.4.2 Thermal inactivation of ISP 
Figure 4.2 (solid line and circles) shows the experimentally determined rate of 
inactivation of TK/OR71-NS1 infectious particles (PFP) following exposure to 50.0°C as 
a function of time. Heat prevents viral transcription within the host cell by inactivating the 
extant viral polymerase complex associated with each gene segment [16]. Unlike UV-
treatment, thermal inactivation allows for the inactivation of expression of gene 
segments in a gene-size independent manner. The dashed line (Fig. 4.2) represents the 
expected rate of inactivation of expression of a single gene segment relative to the 
inactivation of infectivity (described in detail in the Materials and Methods). The good 
match of ISP-inactivation (open circles) with the dashed, theoretical line indicates that 
ISP activity is dependent on the expression of a single gene segment. 
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Fig. 4.2. Thermal inactivation of PFP and ISP. Infectious particles of TK/OR-NS1 
measured as PFP are inactivated at an exponential rate as a function of time at 50°C 
(solid circles). The rate of PFP inactivation (solid line) is assumed to represent the 
inactivation of expression of any one of the 8 viral gene segments required for 
infectivity.  The dashed line represents the expected rate of inactivation of a single gene 
segment, i.e., 1/8th the slope of the solid line. The rate of inactivation of ISP is 
consistent with this biological activity depending on the expression of a single gene 
segment –the NS gene. The open circles represent the average of two ISP titers 
calculated from ISP-dose response curve assays comprised of 8 independently 
generated IFN yield assays in quadruplicate.  Exposure of the virus to the highest dose 
of heat had no effect on the hemagglutinin titer.  
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4.4.3 ISP activity of IAV is nonspecific in action 
Figure 4.3 shows a series of IFN induction-suppression curves in which the ISP 
activity of TK/OR/71-NS1 is measured against viral IFN-inducers belonging to four 
different virus families: (i) influenza virus TK/OR/71-delNS1 (Orthomyxoviridae); (ii) UV-
irradiated avian reovirus (Reoviridae); (iii) Newcastle disease virus (Paramyxoviridae); 
and (iv) vesicular stomatitis virus (Rhabdoviridae).  In each series the IFN yield is 
presented as a fraction of the maximum potential IFN yield of the inducing virus (dashed 
line) as determined by a control in which a cell monolayer received only the IFN-
inducing virus. The rate of IFN induction-suppression is similar for each of the IFN-
inducing viruses from the four different families, demonstrating that the ISP activity acts 
independent of the nature of the IFN-induction moiety delivered to the host cell.  
We have observed that for most ISP assays, the efficiency of activity decreases 
with increasing values of mISP. Consequently, calculations of ISP titers are derived from 
low mISP portions of the curves which are exponential over the range of doses where 
only 1 or a few ISP infect cells. This phenomenon is under study. Our working 
hypothesis is that at high multiplicity of infection the finely honed regulation of virus 
replication is perturbed because of the large excess of viral gene segments being 
transcribed and replicated [87]. 
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Fig. 4.3 Nonspecific action of ISP. A series of CEC monolayers were co-infected with 
a constant dose (mIFP = 5.0) of an IFN-inducing virus and increasing doses of TK/OR-
NS1 as ISP. The inducing viruses are indicated in the legend. The nature of the IFN 
induction-suppression curve generated by TK/OR-NS1 is shown to be independent of 
the source or type (family) of viral inducer. The absolute number of IFN units produced 
by 107 CEC as represented by the fraction of IFN yield equal to 1.0 (dashed line) varies 
for each inducing virus as follows: UV-ARV ≈ NDV-AV ≈ 38,000 units; VSV T1026R1 ≈ 
12,000 units; and TK/OR-delNS1 ≈ 8,000 units. The ISP titer of the TK/OR-NS1 stock 
was equal to 50×108 ISP/ml.  
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4.4.4 Global ISP activity and assessment of high IFP-multiplicity interference   
Varying multiplicities of a heterologous IFN-inducing virus (UV-ARV) were used 
to assess the mechanism by which TK/OR NS1 suppresses IFN-induction. The input 
multiplicities of UV-ARV were as follows: mIFP = 5.0; mIFP = 10.0; and mIFP = 20.0.  The 
doses of ISP (TK/OR NS1) were kept constant relative to each experimental series. 
Figure 4.4 shows that the IFN yield induced in CEC by infection with UV-ARV was 
suppressed by the ISP at a rate independent of the amount of inducing virus delivered. 
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Fig. 4.4 Global action of ISP and assessment of high-multiplicity interference. 
Three experimental series are shown, in which the ISP activity of TK/OR-NS1 is 
demonstrated to act in a constant, uniform manner independent of the dose (mIFP = 
5.0; 10.0; or 20.0) of inducing virus (UV-ARV) received by the host cell.  The high 
multiplicities of UV-ARV do not alter the shape or nature of the IFN induction-
suppression curve generated by TK/OR-NS1. The fraction of IFN yield equal to 1.0 and 
represented by the dashed line equals approximately 30,000 units of IFN per 107 CEC. 
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4.4.5 Temporal dependency of ISP activity 
During the course of natural infection not all cells may become simultaneously 
infected with IFP and ISP. To gain insight into how effective ISP coinfection of IFN-
inducing cells would be after IFN-induction had been initiated, monolayers of aged CEC 
were exposed to the IFN-inducing virus UV-ARV (mIFP = 5.0) at time = 0, and allowed to 
develop IFN-induction for various periods of time before superinfection with ISP.  Figure 
4.5 demonstrates that if cells infected with IFP are coinfected with ISP for up to about 3 
h post-initiation of IFN induction, little or no IFN is produced.  If superinfection of cells 
programmed to induce IFN is delayed beyond about 3 h the ISP lose their effectiveness 
as suppressors. By 7 h post initiation of IFN-induction any added ISP is essentially 
ineffective. 
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Fig. 4.5. ISP activity is time-dependent. 9-day developmentally-aged CEC were 
infected with UV-ARV (mIFP = 5.0) at T = 0. IFN-induction was allowed to progress at 
40.5°C and coinfection with the suppressing virus TK/OR-NS1 (mISP = 5.0) occurred at 
the times indicated. Cells infected with UV-ARV and mock-infected with suppressing 
virus were used to determine the maximum IFN yield at each time point after a total 
incubation period of 20 h, and as a control for the physical manipulations. Data points 
represent the average of three independently generated IFN yields, each of which was 
assayed in quadruplicate and averaged. The error bars represent ±SD of the three 
trials. Note: scale on ordinate is logarithmic.  
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4.5 Discussion 
4.5.1 Characterization of ISP subpopulation of IAV 
UV (254 nm) irradiation of influenza A virus (IAV) not only rapidly inactivates 
infectivity, it also markedly enhances IFN production in CEC [17] relative to the levels 
reported for heat-inactivated virus [58]. More recently, influenza virus variants 
expressing truncated NS1 proteins, already potent inducers of IFN [125], were shown to 
induce even higher yields of IFN when exposed to relatively low doses of UV-radiation 
[87]. For viruses expressing truncated NS1, the observed increase in IFN yield was 
shown to correspond to the inactivation of a large UV-target, the equivalent of one or 
two of the polymerase genes (Chapter 3: Fig. 3.2). Furthermore, the IFN yields induced 
by IAV that expressed full length NS1 also were enhanced by UV-radiation [87], 
although a UV-target was not identified at that time.  
Since IAV populations often contain IFN induction suppressing-particles (ISP) 
[80] it was not clear from this earlier work whether the enhanced yields of IFN observed 
after UV-irradiation were due to an increase in IFP activity, a decrease in ISP activity, or 
both. In Chapter 3, experiments were reported that confirm that the IFP subpopulation 
as measured in primary CEC is not inactivated, but IFP efficiency is enhanced by UV-
radiation (Fig. 3.3). Here, the effect of UV-radiation on the ISP subpopulation of TK/OR-
NS1 as measured in an avian cell system, primary CEC, is investigated.  
Figure 4.1 (lower dashed line) shows the expected fraction of surviving infectivity 
(PFP) as a function of UV-dose based on the value that 1 lethal UV-hit (D37) = 82.8 
ergs/mm2 [87]. It is assumed that 1 lethal UV hit to any one of the 8 genes (≈ 13,228 
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nts) will inactivate infectivity. The data points (solid circles) for PFP inactivation reveal a 
good fit based on this model. The upper dashed line in Fig. 4.1 represents a UV-target 
size of 865 nts, and is equivalent to the expected rate of inactivation of the NS gene.  
The open circles represent the experimentally determined rate of ISP inactivation. 
These data fit well a model in which the integrity of the NS gene is required to express 
the ISP phenotype.  Thus, a virus which expressed a full-sized NS1 protein gained IFN-
inducing capacity as the suppressive action of NS1 on IFN induction was ablated, either 
genetically [84,125], or physically through UV-irradiation.  
Based on a Poisson (random) distribution of UV hits to the virus genome and 
taking into account the differences in size between the eight gene segments, only 2 
lethal hits to the entire genome are required to probabilistically ensure that at least one 
of the three polymerase subunit genes has received, on average, one lethal hit. In 
contrast, only a single lethal hit will be delivered to the NS gene for every 15 lethal hits 
delivered to the virion, a dose that would certainly inactivate all expression of functional 
viral polymerase. Since UV-inactivation of ISP activity follows the expected rate of 
inactivation of the NS gene, it follows that synthesis of nascent viral polymerase 
complex and therefore further amplification of the NS gene is not required. Thus, we 
conclude that the basal level of NS1 expressed during primary transcription from the 
extant gene-associated polymerase complex suffices for full expression of ISP activity. 
That primary transcription of NS alone suffices to express ISP activity was 
verified using an independent method of physical inactivation, i.e., heat.  Figure 4.2 
illustrates the rate of inactivation of infectivity (PFP) (solid line) as a function of time 
exposed to heat (50oC), and compares it to the rate of inactivation of ISP (dashed line).  
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We assume that thermal inactivation of influenza virus, unlike that of UV-radiation, is not 
dependent on the size of the viral gene segments, but instead, reflects the thermal 
lability of the heterotrimeric RNA-dependent RNA-polymerase complex associated with 
the complementary RNA at the 3’-5’ panhandle of each gene segment.  Temperatures 
of 45°C and higher have been shown to inactivate the transcription function of the viral 
polymerase-RNA complex [16].  Notably, only one polymerase-RNA complex appears 
to be associated with each gene segment [100].  Based on this stoichiometry, the 
probability of thermal inactivation should be the same for each of the 8 polymerase-
gene complexes. Thus, the rate of inactivation for infectivity (Fig. 4.2, solid line) is 
assumed to correspond to the inactivation of expression of any one of the 8 gene 
segments since all are required for plaque formation. The expected ratio for the rate of 
thermal inactivation of a particular gene associated with the expression of the ISP 
phenotype should be a line with a slope 1/8th of that relative to infectivity.  That 
theoretical rate of inactivation of ISP is shown in Fig. 4.2 (dashed line). The data points 
(open circles) fit well the rate of inactivation expected for expression of a single gene 
segment. Based on the UV-target data, we reasonably assume this to be the NS gene. 
Since TK/OR-NS1 encodes functional viral polymerase [126,127,157,158], it 
should also degrade cellular RNAP II. However, UV-irradiated TK/OR-NS1 still 
expresses ISP activity, even at relatively high UV doses (>450 ergs/mm2; cf. Figure 
4.1). Such doses would inhibit degradation of host RNAP II by inactivating synthesis of 
nascent viral polymerase, yet leave ISP activity largely intact because of its small UV-
target. This suggests that only the activity of NS1 is required for the expression of ISP 
activity. The mechanism(s) whereby NS1 regulates the QY and/or nature of the IFN-
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induction dose-response curve requires further study.  Suffice it to say that the species 
of the host cell plays a significant role in that regulation [109]. 
The phenotypic expression of influenza virus ISP was shown earlier to be 
dominant in cells coinfected with influenza virus IFP [87].  As documented in Fig. 4.3, 
the same can now be concluded for IFP from three very different virus families. We infer 
that the action of ISP is nonspecific, and that down-regulation of IFN production is 
independent of the specific form of the IFN-induction moiety produced by each family of 
IFN-inducing viruses.  This is in keeping with the generally accepted concept that 
influenza viruses, like many RNA viruses, act globally in their capacity to inhibit the 
expression of cellular genes [156].  
Can increasing the number of IFP per cell overcome the dominant suppressing 
activity of a single co-infecting ISP?  Cells infected with the UV-ARV at mIFP = 20 
demonstrated that a single ISP per cell still sufficed to block totally the 
induction/production of IFN (Fig. 4.4). This result is also consistent with a model in 
which the shut-off of IFN-induction is global and a single ISP suffices to initiate maximal 
turnoff of the cells’ capacity to induce IFN. Vesicular stomatitis virus appears to share 
this attribute as an ISP [88], albeit via a different molecular pathway, and may represent 
a feature common to other RNA viruses [77]. 
Lastly, we asked to what extent the delayed addition of ISP to a cell already 
programmed to induce IFN could still suppress its production, mimicking in effect one 
element of the dynamics of virus-cell interaction expected during infection of a host. 
Figure 4.5 shows that in cells infected with UV-ARV as the IFP, the addition of ISP up to 
about 3 h later still sufficed to suppress the yield of IFN virtually totally. Any delay of co-
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infecting IFP-infected cells with ISP beyond 3 h revealed an increasing degree of 
escape of IFN induction from suppression by ISP.  Thus, by 7 hpi the cell produced a 
full yield of IFN, implying that transcription of IFN-mRNA had escaped suppression and 
was translated into a QY of IFN when tested 20 h later. Based on the time-course of 
transcription of IFN-mRNA in chicken cells induced by UV-ARV, most IFN-mRNA has 
been transcribed by about 7 h and is subsequently translated [139].  These data 
indicate that once transcription of IFN-mRNA is completed ISP will no longer be 
effective and that that message will be translated to produce IFN.       
In the context of a rational approach to the design of live attenuated influenza 
vaccines (LAIV), the magnitude of IFN induction/production, its role as an 
immunoadjuvant, along with the nature of the IFN induction dose-response curve, have 
been shown to play a significant role in the efficacy of the vaccine 
[19,45,84,102,109,161]. The total elimination of ISP subpopulations may not result in 
the attributes of a LAIV that are most effective as evidenced by a report contrasting two 
effective and two ineffective LAIVs [84]. The effective LAIVs were shown to produce 
type r = 1 or r = 2 type IFN induction dose-response curves, indicating that some degree 
of regulation of IFN induction by ISP may be advantageous in producing more highly 
effective vaccines.  Thus, analyses of subpopulations of replication-deficient biologically 
active particles of influenza virus [84,109] may provide insight into the design and 
production of more effective LAIVs.    
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CHAPTER 5 
 
 
 
 
 
IFN-INDUCING AND IFN INDUCTION-SUPPRESSING PARTICLES:  
A PARTICLE MODEL OF INTERFERON REGULATION 
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5.1 Abstract 
IFN is induced by a subpopulation of noninfectious biologically active particles 
(niBAP) that can be defined and quantified as IFN-inducing particles (IFP).  When 
chicken embryonic cells are infected with increasing multiplicities of IFP (mIFP), the 
amount of IFN produced was that expected from a Poisson distribution of cells infected 
with ≥ 1 IFP (Chapter 3).  Some isolates of influenza virus induce less IFN than 
expected at higher mIFP. These stocks were shown to contain another subpopulation of 
niBAP, IFN induction-suppressing particles (ISP). A single ISP was assumed capable of 
preventing IFN production completely in cells coinfected with IFP (Chapter 4). A 
mathematical model based upon the Poisson distribution of both IFP and ISP was 
formulated which described the host:virus particle interactions occurring within the cell 
monolayer: it accounted for the observed IFN yields. The model predicts that the 
fraction of IFP-infected cells expected to become coinfected with ISP, and hence not 
yield IFN, increases as the ratio IFP:ISP decreases. Virus mixtures were reconstructed 
to contain a wide range of ratios of IFP:ISP and used experimentally to generate IFN-
induction dose-response curves. The deviation of the observed yields of IFN from those 
expected if the virus stock consisted only of IFP fit well the results expected from that 
mathematical model. The IFP:ISP particle analysis also allows for a method by which 
the IFP particle titers from type r = 1 dose-response curves can be calculated. 
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5.2 Introduction 
The pathogenesis of influenza virus and the course of the disease is considered 
the resultant expression of each of the 11 proteins encoded for by the 8 gene segments 
required for infectivity and their interaction with host cells [119]. Initially, influenza virus 
populations were defined and quantified only in terms of infectious virus, often scored 
as plaque-forming-particles, or egg-infectious dose-50%, and physical particles, scored 
by electron microscopy or as hemagglutinating particles calculated from conversion 
factors applied to hemagglutination titers [26,31].  Defective-interfering particles, usually 
generated as a result of high multiplicity passages constituted another, albeit highly 
variable, component of the virus population [11,78,105].  Do these three subpopulations 
solely account for the wide range in virulence observed in different influenza virus 
isolates [131]? Recently, the interferon-inducing capacity of an influenza virus 
population has emerged as an important parameter in the virulence of the virus and the 
design of effective candidate live attenuated influenza vaccines (LAIV) 
[19,84,125,145,161] . Deletions in the NS gene that result in the production of truncated 
NS1 proteins were shown to play a role in the expression of virulence, based in large 
part on the enhanced capacity of the virus to induce interferon (IFN) [19,45,69,125,161] 
and the action of that IFN as both an antiviral agent [119] and adjuvant [45,82]. 
Because of the emerging role of the IFN system in influenza virus pathogenesis 
and the development of live attenuated influenza vaccines (LAIV), this study focuses on 
the IFN-inducing capacity of influenza virus populations.  Analysis of IFN-induction dose 
(multiplicity)-response (IFN yield) curves [84,87,92] generated by the IFP subpopulation 
in influenza virus populations allows: (i) determination of the maximum (quantum) yield 
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that IFP can induce in a given cell system; (ii) quantification of the number of IFP in the 
virus population; and (iii)  calculation of the efficiency of the IFP in terms of inducing IFN 
[84,87].  The most commonly observed IFN-induction dose-response curve fits well a 
theoretical curve based on a Poisson distribution of IFP amongst the cell population in 
which every cell that receives  1 IFP produces a full yield of IFN.  The maximum 
plateau (quantum) yield of IFN is reached when all of the cells have received 1 or more 
IFP. 
In the course of determining the capacity of influenza virus populations to induce 
IFN, some stocks of influenza virus consistently generated IFN dose-response curves 
that produced less IFN than expected at higher mIFP.  Observations of this anomaly 
provided the impetus for the development of a special application of the Poisson 
distribution, to design and test the hypothesis that a distinct subpopulation of ISP extant 
in some preparations of influenza virus function as a dominant phenotype to block 
completely the IFN-inducing activity of IFP in cells coinfected with one or more ISP. 
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5.3 Materials and Methods 
5.3.1 Viruses 
Both rgA/TK/OR/71-NS1 (1-230) (H7N3) = [TK/OR-NS1]  and its variant 
rgA/TK/OR/71-delNS1 (1-124) (H7N3) = [TK/OR-delNS1] were generated via a reverse 
genetics system [161] and kindly provided by Chang-won Lee (Ohio State University, 
Wooster, OH). A deletion of ten nucleotides in the NS gene of the TK/OR-delNS1 virus 
produces a truncated NS1 product lacking part of the C-terminal effector domain [161]. 
The two viruses are otherwise isogenic for the remaining seven gene segments. The 
TK/OR-delNS1 virus displays a propensity to produce IFP, while the virus with the intact 
NS gene produced high titers of ISP.   
Virus stocks were prepared in 10-day old embryonated chicken eggs from 
specific-pathogen-free flocks (Charles River SPAFAS, Storrs, CT) by infecting with seed 
virus at near end-point dilution and incubating for 48 hours at 34°C. Allantoic fluid 
containing virus was harvested from the eggs and stored at -80°C. The TK/OR-NS1 
virus contained a plaque-forming particle titer of 3.2 x 108/ml and an ISP titer of 40 x 
108/ml. Due to the high ISP content, the IFP titer of this preparation could not be 
measured and was presumed negligible. The TK/OR-delNS1 virus possessed a plaque-
forming particle titer of 2.0 x 108/ml and an IFP titer equal to 43 x 108/ml. The ISP titer of 
the TK/OR-delNS1 virus is below the limits of detection of the in vitro biological ISP 
assay (≤ 0.33 x 108/ml). 
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5.3.2 Cells 
Monolayers of primary chicken embryo cells (CEC) were prepared from cell 
suspensions and plated at a final density of 1.0 x 107 CEC per 50 mm culture dish. Cell 
suspensions were prepared from 9-day-old embryos. The cell monolayers were 
maintained in NCI medium plus 6% calf serum and incubated undisturbed at 38.5°C 
plus 6.5% CO2.  
 
5.3.3 IFN-induction and induction-suppression assays 
Monolayers of CEC were incubated for 9-days without a medium change 
(developmentally aged) for IFN inductions, and when infected with IFP they produced 
copious amounts of IFN [140].  Briefly, a series of cell monolayers was infected with 
increasing numbers of virus particles, and the amount of IFN produced was collected at 
peak yields (24 hours post-infection) [87,140]. Biologically active, acid-stable IFN was 
quantified via a cytopathic effect-inhibition assay [140]. IFP were calculated from the 
resulting dose-response curves as described in the text.  
ISP are measured via a similar assay in which monolayers of 9-day “aged” CEC 
are simultaneously exposed to a known IFN-inducing virus, UV-irradiated avian reovirus 
(7,500 ergs/mm2) [168] and increasing amounts of the suspected IFN induction-
suppressing virus. This procedure has been described previously [87,90]. A control trial 
in which every cell in a CEC monolayer is infected by only the inducing virus (mIFP = 5.0) 
is used to establish a maximum IFN yield. Simultaneous exposure to increasing 
multiplicities of the ISP-containing preparation results in an exponential decline in IFN 
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yield from that maximum. According to the Poisson distribution, the volume of ISP-
containing virus that reduces the maximum IFN yield by 37% contains on average mISP 
= 1.    
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5.4 Results 
5.4.1 Theoretical IFN induction dose (multiplicity) –response (IFN yield) curves 
Figure 5.1 displays families of theoretical dose-response curves that IFP might 
generate in cell populations.  They fall into two general types, termed: (A) r 1, r 2, r 
3, …; and (B) r =1, r =2,  r = 3, …, where the class of cells that produce IFN is 
equivalent to the fraction of cells infected with r IFP at a given mIFP based on a Poisson 
distribution of particles where: 
𝑃(𝑟) =
𝑒−𝑚(𝐼𝐹𝑃)𝑚(𝐼𝐹𝑃)
𝑟
𝑟!
 
P(r) is the probability of the cells in a given population attaching r IFP when the average 
multiplicity of infection is mIFP; e is the base of the natural logarithm and; ! = factorial.  
The most commonly observed IFN-induction curve is type r 1. It is generated by 
plotting the yield of IFN as a function of mIFP. As mIFP increases, so does the yield of 
IFN, reflecting an increase in the fraction of cells that are infected with 1 or more IFP.  
The plateau, or quantum yield, of IFN is reached when virtually all of the cells have 
received at least 1 IFP: when mIFP = 4.6 then P(r  1) = 0.99.  The plateau of maximum 
IFN yield at high values of mIFP represents a quantum yield of IFN, indicating that the 
addition of 2 or more IFP does not increase, nor decrease, IFN production (Fig. 5.1A, r 
 1 curve). The titer of IFP is calculated from a type r  1 based on a Poisson 
distribution where the dilution of virus that reduces the plateau of IFN by 37% contains 
on average mIFP = 1.  Along with knowing the number of cells in the monolayer, using 
virus attachment conditions where virtually all virus is bound, it is possible to calculate 
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the IFP titer [87].  Curves of type r  2, r   3, or greater, have not been observed with 
influenza virus to date.  
Fig. 5.1B shows a family of theoretical IFN-induction curves represented by types 
r = 1, r = 2, and r = 3.  These curves are characterized by a rapid decrease in the yield 
of IFN after the quantum yield is reached at mIFP = 1, 2, and 3, respectively.   A type r 
=1 curve fits best a situation in which the class of cells that produce IFN are those 
infected with 1, and only 1, IFP [89]. Thus, the presence of 2 or more IFP appears 
functionally to suppress IFN-induction.  Similarly, type r = 2 curves describe a class of 
virus-cell interactions whereby infection with 2, and only 2, IFP produce IFN: these have 
been reported for influenza virus [84].  To date, type r = 3 curves have not been 
observed. 
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Fig. 5.1 Theoretical IFN-induction dose-response curves. (A) Theoretical type r ≥ 1, 
r ≥ 2, and r ≥ 3 and (B) type r = 1, r = 2, and r = 3 induction curves are shown.  (A) 
Based on a Poisson (random) distribution of virus particles in the cell monolayer, the 
type r ≥ 1family of IFN-induction curves describes the fraction of cells that induce IFN 
when infected by one-or-more, two-or-more, or three-or-more IFN inducing particles, 
respectively, as a function of multiplicity.  (B) The type r = 1 family of IFN-induction 
curves describes the fraction of cells that induce IFN when infected by exactly one, two, 
or three IFN inducing particles, respectively, as a function of multiplicity. 
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5.4.2 Observed vs. theoretical IFN-induction dose-response curves: an anomaly 
Influenza virus stocks commonly generate IFN-induction curves that closely 
approximate type r  1 [84] when developmentally-aged primary chicken embryonic 
cells are hosts [81,87]. Problematically, some stocks consistently display a decrease in 
IFN yield of varying magnitudes once an apparent plateau is reached, and therefore do 
not conform precisely to any of the theoretical curves described in Figure 5.1.  For 
example, in Figure 5.2, a stock of TK/OR-delNS1 virus does not maintain a plateau yield 
of IFN at higher mIFP as predicted from a type r 1 dose-response curve (Fig. 5.1A), nor 
does it match the sharp decrease predicted by a type r = 1 dose-response curve (Fig. 
5.1B). 
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Fig. 5.2 IFN-induction dose-response curves: Theoretical vs. Experimental.  Data 
points represent an average of three IFN-induction experiments using TK/OR-delNS1 
virus.  Cell monolayers of developmentally aged primary chicken embryonic cells were 
infected with increasing doses of virus, incubated for 24hr at 40.5°C, and the 
supernatant was harvested and assayed for IFN.  The IFN-induction dose-response 
curve as shown (dotted line) is not adequately described by the traditional theoretical 
type r ≥ 1 dose-response curve (solid line) because of the marked decline in IFN yield 
after the maximum (plateau) is reached. Error bars represent the mean ± SD. 
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5.4.3 IFN induction-suppressing particles are responsible for the less than 
expected yields of IFN observed at high mIFP 
Insight into the discrepancy between expected and observed yields of IFN noted 
in Figure 5.2 was gained by considering the presence of an ISP subpopulation in stocks 
of influenza with otherwise high titers of IFP.  In this context, the suppressing activity of 
influenza virus ISP is dominant to IFN-induction by IFP in coinfected cells [87], as is the 
case for ISP found and quantified in several families of viruses [90]. We postulated that 
the observed decline in IFN yield at high mIFP was due to a small subpopulation of ISP 
which becomes detectable as the multiplicity of virus is increased.  The magnitude of 
this suppression would reflect the relative ratio of IFP:ISP in a given stock.   
The veracity of this postulate was tested based on three assumptions: (i) the 
virus population consisted of a mixture of discrete particles, IFP and ISP; (ii) infection of 
a cell by 1 or more IFP resulted in the production of a full yield of IFN, and; (iii) 
coinfection of cells by 1 or more ISP suppressed IFN-induction completely in a cell 
otherwise programmed to produce it.  A series of theoretical curves based on these 
assumptions were derived from the following equation:    
𝑃(𝐼𝐹𝑃) = (1 −
𝑒−𝑚(𝐼𝐹𝑃)𝑚(𝐼𝐹𝑃)
𝑟(𝐼𝐹𝑃)
𝑟(𝐼𝐹𝑃)!
) (
𝑒−𝑚(𝐼𝑆𝑃)𝑚(𝐼𝑆𝑃)
𝑟(𝐼𝑆𝑃)
𝑟(𝐼𝑆𝑃)!
) 
Where r (IFP) and r (ISP) are both set equal to zero, and P (IFP) represents the fraction of 
cells that are infected only with IFP and hence would induce IFN.  This calculation is 
different from the previous which assumed that only IFP were present. This model 
proposes that influenza virus stocks may contain two discrete subpopulations of 
particles: one that induces IFN and one that suppresses its induction, and that the 
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phenotype of the latter is dominant over the former [87,90]. It is important to note that 
the probability of a cell receiving 1 or more IFP and no ISP is dependent upon the 
relative proportion of IFP to ISP in the preparation. The equation as written does not 
assume that the relative ratios of IFP and ISP are equal, but varies with the values of 
mIFP and mISP.  Figure 5.3 (dotted lines) illustrates the changes expected in the shape of 
the IFN-induction dose-response curves generated with increasing amounts of virus if 
the ratio IFP:ISP varied over the wide range illustrated.   
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Fig. 5.3 Experimental reconstruction of hybrid IFP:ISP dose-response curves.  
The solid line is theoretical and represents the yield of IFN expected from a pure 
subpopulation of IFP, producing a true type r  1 curve.  The dotted lines describe 
theoretical curves with IFP:ISP ratios as shown.  Data points are from an average of two 
complete reconstruction experiments using independently mixed stocks containing the 
following IFP:ISP ratios: (   ) 100 IFP: 1 ISP; (   ) 10 IFP: 1 ISP; and (    ) 1 IFP: 1 ISP.  
Error bars represent the mean ± SD. 
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5.4.4 Comparison of expected and observed results in the IFN-induction dose-
response curve with changes in the ratio IFP:ISP 
To test the validity of this model a series of IFN-induction dose-response curves 
were generated experimentally from virus preparations reconstructed with known ratios 
of IFP:ISP.  This was accomplished by appropriately mixing a stock of TK/OR-delNS1 
that naturally contained a high titer of IFP (4.3  109/ml) with a stock of TK/OR-NS1 
which contained a high titer of ISP (4.0  109/ml).  The IFP:ISP ratio was adjusted by 
adding an appropriate volume of ISP to the IFP stock.  The doses of the viruses used in 
the reconstruction experiments were corrected to account for these dilutions so that the 
number of IFP delivered to the monolayer were normalized. The data points shown in 
Figure 5.3 represent the average of two experiments. Considering the complexity of the 
protocol and the biological system, the relatively good fit of the experimental curves 
over a large range of IFP:ISP ratios appears to validate the proposed model and 
supports the postulate that influenza virus populations contain IFP and ISP as two 
distinct subpopulations. 
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5.5 Discussion 
5.5.1 A particle model of IFN regulation 
The identification and quantification of niBAP of influenza viruses revealed large 
subpopulations of novel particles that expressed phenotypes with the potential to 
influence the pathogenesis of influenza virus and the course of the disease 
[19,84,85,87,111], and to modulate the efficacy of LAIV [45,69,125,145,161].  Foremost 
among them are subpopulations of IFP because of the IFN they induce [87].  
Furthermore, influenza viruses are quite sensitive to the action of IFN, albeit, a small 
fraction of the infectious virus may be transiently resistant [138]. IFN also can function 
as a natural adjuvant [13,14,45,82,102,153,169], providing a link between the innate 
and adaptive immune systems [84,153].  Many delNS1 mutants expressing truncated 
NS1 proteins have proved to be effective as LAIV in several species [125,145,161,169] 
with the IFN-inducing capacity of the virus closely associated with its attenuation in the 
host [45,69,84,125,145].  
Given a theoretical preparation of influenza virus consisting of a mixture of 
interferon-inducing particles and ISP, there are three possible outcomes to an 
attempted IFN-induction experiment at the cellular level: (i) if a cell is infected by one or 
more IFN-inducing particles, a yield of IFN will be produced; (ii) if a cell is infected by 
one or more ISP, little to no IFN will be produced; and (iii) if a cell is infected by one or 
more IFN-inducing particles and one or more ISP, the ISP phenotype is dominant and 
little to no IFN is produced by that cell. It is the combination of these three conditions 
occurring across the entire cell monolayer which produces the IFN yield measured by 
the in vitro biological assay. These three conditions may well pertain to natural infection 
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mimicking the spread of virus in the host.  It follows that the absolute value of the yield 
of IFN, and even the nature of the IFN-induction dose-response curve, is dependent on 
the ratio of IFP to ISP within a given influenza virus population. 
Figure 5.3 shows a type r ≥ 1 IFN-induction dose-response curve generated by a 
pure population of IFP (solid line) and the deviations expected based on the presence of 
heretofore undetected small subpopulations of ISP (dotted lines), with the two kinds of 
distinct particles acting independently of each other as expected from a Poisson 
distribution.  The good fit of the expected and observed IFN-induction dose-response 
curves generated from populations of virus reconstructed to contain different known 
ratios of IFP:ISP supports a model in which an IFP-infected cell otherwise programmed 
to produce IFN fails to do so when coinfected with 1 or more ISP (Fig. 5.3).  Notably, 
both the magnitude and shape of the IFN induction dose-response curves were shown 
to be dependent on the content of ISP in the reconstructed mixtures of IFP and ISP.  
These results may account for the anomalously lower than expected yields of IFN 
sometimes observed at high mIFP. 
This represents the second example in which niBAP that express different 
phenotypes constitute distinct subpopulations relative to each other. Thus, defective-
interfering particles do not interfere with the expression of noninfectious cell-killing 
(apoptosis-inducing) particles and vice versa [85]. This means that populations of 
influenza virus contain at least four subpopulations of niBAP (defective-interfering 
particles, noninfectious cell-killing particles, IFP, and ISP) that express distinct 
phenotypes each of which can be quantified in the presence of the others [85,87,111].   
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Based on the important role that the IFN system plays in the generation of 
effective LAIV [84,125,161], it would seem advantageous to design vaccines in which 
the generation of IFP is maximized and that of ISP minimized.  However, in contrast to 
two ineffective LAIV that generated type r  1 with relatively low yields of IFN, two 
candidate LAIV that were effective as vaccines consistently generated type r = 2 IFN-
induction curves that produced high peak yields of IFN, but a steep down-regulation of 
IFN production at high mIFP, suggesting that fine-tuning the production of IFN may be an 
important parameter for optimizing the efficacy of LAIV [84]. The in vitro analysis of 
niBAP subpopulations in candidate LAIV permits such screening, and may lead to the 
design of more effective LAIV.  The suppressing effect of ISP on the expression of IFP 
brings in to question the role of the dominant ISP phenotype in the virulence of the 
influenza virus and the course of the disease.  Studies in hosts infected with 
reconstructed IFP:ISP populations of influenza virus may provide insight into our 
understanding of influenza virus-host cell interactions.   
 
5.5.2 Determination of IFP titers from IAV stocks producing type r = 1 IFN-
induction dose-response curves 
Implications from the IFP:ISP IFN-induction dose-response curve analysis 
complicates the determination of IFP titers from IAV stocks producing type r = 1 curves. 
Recall that in type r = 1 curves, IFN yields increase as a function of virus multiplicity until 
the peak (quantum) yield of IFN is reached, after which IFN yields decrease (Fig. 5.1A). 
The classical interpretation of these curves is that IFN-induction occurs when a cell is 
infected by one and only one IFP. Although this interpretation may remain valid for other 
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viruses that induce IFN through a different mechanism [89], for IAV the IFP:ISP IFN-
induction dose-response curve analysis suggests that the production of a curve of this 
nature is due to the action of coinfecting ISP. 
Using the classical interpretation of type r =1 dose-response curves, the dose of 
virus that produces the peak (quantum) IFN yield has delivered, on average, one IFP 
per cell amongst the monolayer. This allows for a straight forward calculation to 
determine the IFP titer of the virus stock, as follows: 
𝐼𝐹𝑃
𝑚𝑙
= (𝑚𝐼𝐹𝑃)(𝐷𝑖𝑙.  𝐹𝑎𝑐𝑡𝑜𝑟)(𝑁𝑜. 𝑐𝑒𝑙𝑙𝑠),  
where mIFP = 1.0, Dil. Factor = virus dilution factor = (1000/Vol. of virus required to 
reach peak IFN yield in µL), and No. cells = the total number of cells in the monolayer. 
In contrast, the IFP:ISP dose-response curve analysis of type r = 1 curves 
dictates that the peak IFN yield occurs when some unknown percentage of the cells 
amongst the monolayer have received one or more IFP and no ISP. The exact number 
of cells that have received 1 or more IFP and no ISP at the peak IFN yield depends 
upon the ratio of IFP:ISP, and this fraction of cells cannot be deduced based on the 
data from the IFN-induction experiment alone. 
This complication can be resolved and the IFP titer of the IAV stock calculated as 
follows: Alongside the IFN-induction dose-response experiment, an IFN induction-
suppression dose-response experiment (ISP assay) should be performed. For primary 
cell culture is may be important for consistency to perform these two experiments on the 
same batch of cells. From the ISP assay, the ISP titer can be determined as previously 
discussed (Chapter 4). Once the ISP titer is known, the exact number of ISP delivered 
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to the cell monolayer at the volume of virus required to reach the peak IFN yield of the 
type r = 1 IFN=induction dose-response curve can be calculated. Since the total number 
of cells in the monolayer is known, the multiplicity of ISP at the peak IFN yield follows. 
Utilizing a simplified form of the Poisson distribution (where r ISP has been set 
equal to 0) and the mISP, determined as described above, the percentage of cells 
receiving no ISP at the peak IFN yield can be calculated:  
𝑃(𝐼𝑆𝑃=0) =  𝑒
−𝑚𝐼𝑆𝑃, 
where P(ISP = 0) = the probability of a cell receiving no ISP = the fraction of the total 
number of cells that have received no ISP, e = the base of the natural logarithm, and 
mISP = the multiplicity of ISP. 
 Notably, this fraction of cells also is equal to that fraction of cells eligible to 
induce IFN by having received one or more IFP and no ISP (P(ISP = 0) = P(IFP ≥ 1)). The 
mIFP at the peak IFN yield can then be calculated using a rearrangement of the Poisson 
distribution: 
𝑚𝐼𝐹𝑃 = −𝑙𝑛(1 − 𝑃(𝐼𝐹𝑃 ≥ 1)), 
 After the mIFP at the peak IFN yield is known, the IFP titer can be determined as 
follows: 
𝐼𝐹𝑃
𝑚𝑙
=
(𝑚𝐼𝐹𝑃)(𝑁𝑜. 𝑐𝑒𝑙𝑙𝑠)
(𝑉𝑜𝑙. 𝑣𝑖𝑟𝑢𝑠)
, 
where (No. cells) = the total number of cells in the monolayer, and (Vol. virus) = the 
volume of virus, in milliliters, required to reach the peak IFN yield. 
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 Note that this method is based on the assumption that IFP are present in excess 
in the virus stock and that all of the cells in the monolayer that did not receive one or 
more ISP did, in fact, receive one or more IFP. This assumption may not be true, given 
the example of a theoretical virus stock in which the IFP:ISP significantly favors ISP. If 
this is so, then the fraction of cells contributing to the peak IFN yield may be lower than 
the value determined via this method. As such, the IFP titer calculated here represents 
a maximum probable number, although the actual IFP titer may be lower.  
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CHAPTER 6 
 
 
 
 
 
INHIBITION OF TYPE-I VIRAL-MEDIATED IFN-INDUCTION BY LIPOPOLYSACCHARIDE 
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6.1 Abstract 
 During the course of codifying low pathogenicity influenza, viruses were tested 
for their capacity to induce type-I interferon (IFN) and to measure their content of IFN 
induction-suppressing particles (ISP). One isolate caused a >10-fold reduction in the 
yield of IFN from chicken embryonic cells co-infected with a virus that normally induces 
high yields of IFN. The apparent content of ISP was calculated to be  100-fold higher 
than the number of physical particles of virus measured as hemagglutinating particles. 
This unrealistic interpretation prompted us to test for a soluble IFN induction-
suppressing activity in the allantoic fluid freed of the virus by centrifugation, and the IFN 
induction-suppressing activity remained in the virus-free supernatant. The original virus 
stock subsequently was found to be contaminated with a Gram-negative bacterium, 
leading us to test lipopolysaccharide (LPS) as the putative IFN-induction suppressor. 
Pure LPS mimicked in a similar dose-dependent manner the IFN induction-suppressing 
activity of the original allantoic fluid-derived virus, and the allantoic fluid freed of all virus 
and bacteria. The inhibition of viral-mediated type-I IFN-induction by LPS was observed 
for viruses from three different families. These observations indicate that exposure of a 
host to endotoxin may compromise the IFN induction response of the innate immune 
system and thus exacerbate virus infection.  
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6.2 Introduction 
 Type-A influenza viruses (IAV) induce IFN in primary cultures of developmentally 
aged primary chicken embryonic cells [87], and are sensitive to its antiviral action 
[19,138].  The maximal amount of IFN induced in the host cell is determined by the ratio 
of two virus particle subpopulations expressing antagonistic phenotypes: IFN-inducing 
particles (IFP) and IFN induction-suppressing particles (ISP) [90,91].  Both phenotypes 
may be expressed to varying degrees in any given population of IAV, but the ISP 
phenotype is dominant [90].   
In an ongoing study, multiple IAV strains were screened for IFN-inducing 
potential by generating IFN-induction dose (multiplicity of virus)-response (IFN yield) 
curves [92].  The expectation was that virus stocks producing low quantum yields of IFN 
would subsequently be shown to possess high titers of ISPs via the appropriate 
biological assay. When an IFN induction-suppression assay was performed, one IAV 
strain paradoxically demonstrated a content of ISP well in excess of the preparation’s 
physical (hemagglutinating) particle count. 
A series of experiments, presented herein, demonstrate that the IFN induction-
suppression activity of this IAV stock was due to the activity of lipopolysaccharide 
(LPS), present in the IAV stock because of a bacterial contaminant. LPS is a major 
molecular component of the outer membrane of most gram-negative bacteria and is 
shed into the environment as bacteria grow, replicate, and lyse [123]. Recognition of 
LPS by the cell occurs at the cell surface and first requires LPS to bind to the soluble 
LPS-binding protein (LBP). The LPS-LBP complex then interacts with CD14, which 
allows for interaction with Toll-like receptor-4 (TLR-4). The accessory protein MD-2 
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must also be present to interact with TLR-4, and signal transduction occurs through a 
variety of pathways including those of the IKK, ERK, JNK, and p38 systems. This 
ultimately results in the activation of various transcription factors and the production of 
numerous inflammatory cytokines, including IL-1, IL-6, IL-8, TNF-α, IFN-α, IFN-β, and 
IFN-γ [43,44]. Overstimulation of the innate immune system in this manner can lead to 
endotoxemia, or sepsis, which can be fatal. This is equivalent to the concept of a 
cytokine storm, which has been implicated as a main contributor to mortality by infection 
with highly pathogenic H1N1 and H5N1 IAV strains [22,76,130,160]. 
Viral-mediated IFN-induction by primary chicken embryo cells in response to 
three different virus families is shown to be inhibited by exposure of the inducing cells to 
LPS. This work demonstrates suppression of viral-mediated IFN induction as a relatively 
unappreciated activity of LPS, and underscores the potential implications for the 
outcome of pathogenesis under conditions where viral and bacterial coinfection exists.   
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6.3 Materials and Methods 
6.3.1 Cells and media 
Primary chicken embryonic cells (CEC) were prepared from 9-day old 
embryonated eggs. Suspensions of CEC were plated at confluency (10 × 106 
CEC/50mm plate) and developmentally aged by incubating in Nutrient Colorado plus 
Inositol medium plus 6 % calf serum for 9 days without a change of medium [140].  
These developmentally-aged cells were used for IFN-induction and the generation of 
IFN samples. All cell cultures were grown and maintained in certified, nonpyrogenic 
plasticware. 
 
6.3.2 Viruses 
 Several strains of IAV were delivered to our laboratory as part of an ongoing 
study in conjunction with Dr. Suarez of the Southeast Poultry Research Laboratory: 
A/Laughing Gull/MD/470/00 (H6N4), A/BlueWingTeal/LA/b156/88 (H4N6), 
A/CK/NJ/12220/97 (H9N2), and A/Red Knot/744/03 (H9N2). These viruses were tested 
directly for IFN-inducting capacity. Seeds of A/TK/OR/71-NS1 (1-230) (H7N3) and 
A/TK/OR/71-delNS1 (1-124) (H7N3) were provided by D. Suarez of the Southeast 
Poultry Research Laboratory and stocks were generated through passage in the 
amniotic/allantoic membranes of day-9 embryonated chicken eggs. A stock of bacterial-
free A/RedKnot/744/03 was produced after the original stock was filtered twice through 
0.22 µM Millipore filters and then passaged in day-9 embryonated chicken eggs from 
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specific-pathogen-free flocks from Charles River SPAFAS, Inc. (Storrs, CT). All virus 
stocks were stored at -80°C. 
 
6.3.3 Lipopolysaccharide 
 A pure stock of powdered lipopolysaccharide (LPS) was obtained from Sigma-
Aldrich (# L2654). This particular LPS was prepared from Escherichia coli serotype 
026:B6. The powdered LPS was reconstituted in 1ml of sterile NCI media, giving a stock 
solution of 106 ng/ml ≈ 6.0 × 105 endotoxin units (EU)/ml. This stock was further diluted 
in cell culture medium as appropriate for use in the described experiments. Aliquots of 
LPS were stored at -20°C. 
 
6.3.4 IFN-induction and sample quantification 
Briefly, IFN was induced in day-9 developmentally-aged CEC monolayers 
following attachment of virus for 1 hr and a 24 hr period of incubation at 40.5° C.  The 
medium was then collected and infectious virus removed via the addition of fetal bovine 
serum in the presence of perchloric acid. The resulting samples therefore only contain 
acid-stable, type-I IFN and were assayed via a cytopathic-effect inhibition assay, as 
previously described [140]. 
 
6.3.5 ISP titer determination 
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 Based on a Poisson distribution of virus particles amongst the CEC of the 
monolayer, the amount of ISP added to cells that results in 0.37 of the maximal yield of 
IFN is assumed to contain an average of 1 ISP/cell [90]. Based on the dilution of virus 
necessary to reach this point on the suppression curve and the total number of cells in 
the monolayer, the ISP titer is calculated as described in Chapter 4. 
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6.4 Results 
6.4.1 IFN-induction by IAV 
The maximum (quantum) yields of acid-stable, type-I IFN were determined for six 
different IAV isolates through IFN-induction dose-response assays. The peak IFN yield 
produced by primary CEC in response to each virus is shown in descending order 
(Figure 6.1). The peak IFN yields of these strains of IAV are shown to vary over a 100-
fold range. The A/RedKnot/744/03 virus produced approximately 100 Units per 107 
CEC, significantly lower than any other virus strain tested. 
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Fig. 6.1 The maximum yield of IFN induced by each of six influenza virus strains 
in developmentally aged CEC.  IFN induction dose-response curves were generated 
for each strain and analyzed for the maximal yield of IFN induced [92,140].  The peak 
IFN yields, from left to right, are as follows (in Units per 107 CEC): A/TK/OR/71-delNS1 
(1-124) (H7N3) = 27,000; A/Laughing Gull/MD/470/00 (H6N4) = 15,500; 
A/BlueWingTeal/LA/b156/88 (H4N6) = 13,500; A/CK/NJ/12220/97 (H9N2) = 11,000; 
A/TK/OR/71-NS1 (1-230) (H7N3) = 5,000; and A/Red Knot/744/03 (H9N2) = 100. 
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6.4.2 IFN induction-suppression by A/Red Knot/744/03 (H9N2) 
The ISP subpopulation of A/Red Knot/744/03 was assessed utilizing the standard 
IFN induction-suppression assay (Chapter 4). Briefly, primary CEC were coinfected at 
mIFP = 5 with a good inducer of IFN (A/TK/OR/71-delNS1 (1-124) [H7N3]) along with 
increasing multiplicities of the potential ISP (A/Red Knot/744/03), and incubated for 24 
hr at 40.5° C. Quantification of these samples generated the IFN induction-suppression 
curve shown in Figure 6.2.  About 90% of the yield of IFN initially was lost at an 
exponential rate. About 10% of the IFN yield appeared refractory to suppression at 
higher amounts of Red Knot virus.   
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Fig. 6.2 The IFN induction-suppressing activity of A/Red Knot/744/03.  Control 
monolayers of aged CEC were infected with an excellent inducer of IFN, TK/OR/71-
delNS1 (1-124) (see Fig. 1), at mIFP = 5 so as to produce a maximal yield of IFN from 
each cell (dashed line) [90].  The test monolayers of cells were simultaneously infected 
with increasing amounts (multiplicities) of Red Knot virus to determine its capacity to 
suppress the yield of IFN shown as the dashed line, presumably functioning as IFN 
induction-suppressing particles (“ISP”). The “ISP” titer of the preparation shown here is 
calculated to be 2.5 × 1010 ISP/ml. 
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6.4.3 IFN induction-suppression activity before and after high-speed 
centrifugation 
 Figure 6.3 demonstrates the IFN induction-suppressing activity of the 
A/RedKnot/744/03 virus stock before and after high speed centrifugation. The virus 
stock was centrifuged for 4hr at 40,000 ×g and the hemagglutinating activity of the virus 
was found to reside in the pellet after reconstitution. The virus-free supernatant was 
then tested for IFN induction-suppression activity. As shown, the IFN-induction 
suppression activity was found to reside in the supernatant, as evidenced by the similar 
kinetics of suppression observed to occur before and after high-speed centrifugation.  
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Fig. 6.3 The IFN induction-suppressing activity of the Red Knot virus stock before 
and after centrifugation. An aliquot of the original allantoic fluid from Red Knot-
infected eggs was tested before and after centrifugation at 40,000 x g for 4 hr.  . The 
data indicate that the degree of IFN induction-suppression by the supernatant material 
was virtually unchanged following centrifugation.  A single curve accommodates, within 
experimental error, the variations of both data sets. 
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6.4.4 IFN induction-suppressing activity of lipopolysaccharide 
The IFN induction-suppression dose-response curve generated by infecting CEC 
with a known good IFN inducer and increasing doses of lipopolysaccharide is shown in 
Figure 6.4. There was an initial exponential rate of loss of about 90% of the quantum 
yield of acid-stable type-I IFN, up to a dose of about 50 endotoxin units (EU)/ml.  Higher 
doses of LPS revealed that about 10% of the IFN yield was refractory to the action of 
LPS.  Thus, when a good inducer of IFN (A/TK/OR/71-delNS1 (1-124)) was attached to 
107 CEC for 1 hr in the presence of   50 endotoxin units (1 EU = 1.67 ng)/ml of LPS, 
there was a 90% reduction in IFN yield measured 24 hr later.  A 50% reduction in IFN 
yield was obtained with 2.5 EU(4.2 ng)/ml LPS. 
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Fig. 6.4 Assay for IFN induction-suppression by LPS.   Monolayers of aged CEC 
were exposed to A/TK/OR/71-delNS1 (1-124) to induce maximal levels of IFN in all 
control cells.  Other monolayers of cells infected with this virus were exposed to varying 
amounts of LPS during the 1 hr virus attachment period.  The monolayers then were 
washed, fresh medium added, incubated at 40.5oC for 24 hr, and the supernatants 
assayed for acid-stable IFN [140]. The amount of LPS is noted in both endotoxin units 
(EU) and the amount (ng) per 107 cells. 
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6.4.5 Lipopolysaccharide inhibits IFN-induction by multiple virus families 
A new, bacteria-free stock of A/Red Knot/744/03 was generated by passage in 9-
day old embryonated chicken eggs. Figure 6.5A shows that the bacterial-free virus 
induced over 2,000 IFN U/107 CEC, and that the IFN induction-suppressing activity was 
restored by mixing the contaminate-free A/RedKnot/744/03 preparation with either the 
supernatant from the centrifuged, bacterial-contaminated stock of Red Knot, or with 
pure LPS. 
The IFN induction-suppression activity of LPS also was tested against the IFP 
activity of viruses from different families; vesicular stomatitis virus, and Newcastle 
disease virus, and included a different strain of IAV (A/TK/OR/71-delNS1 (1-124)),  (Fig. 
6.5B). On average, the IFN yield produced by each virus was reduced by 95% through 
the action of LPS. 
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Fig. 6.5 LPS-mediated suppression of IFN. From left to right the histobars show the 
IFN-inducing capacity of (A) Red Knot stocks in the presence of the supernatant from a 
high speed centrifugation of allantoic fluid contaminated with a Gram-negative 
bacterium; virus grown free of the bacterium; and virus in the presence of chemically 
pure LPS.  (B) From left to right the histobar sets of two demonstrate that pure LPS is 
effective in suppressing IFN-induction from aged CEC infected separately with three 
different families of virus: (A/TK/OR/71-NS1 (1-124)); Newcastle disease virus; and 
vesicular stomatitis virus. Note the change in scale between figures A and B.  
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6.5 Discussion 
6.5.1 Lipopolysaccharide is a potent inhibitor of viral-mediated IFN-induction 
Figure 6.1 shows the maximum yield of acid-stable, type-I IFN induced by six 
different isolates of chicken egg allantoic fluid-derived virus arranged in the order of 
decreasing capacity to induce IFN.  The virtual absence of IFN-inducing capacity of the 
A/Red Knot/744/03 (H9N2) isolate flagged it as a virus population that potentially 
contained high levels of the ISP subpopulation [87,90].   
The A/RedKnot/744/03 virus stock was initially found to suppress IFN induction 
at such a high dilution of virus as to suggest that there were about 100-times more ISP 
present than could be accounted for by the physical particles of IAV measured as 
hemagglutinating particles (HAP) [85]. The kinetics of this IFN induction-suppression 
dose-response curve are displayed in Figure 6.2. Note that this preparation is calculated 
to contain 2.5 × 1010 ISP/ml and yet consists of only 5.9 × 108 HAP/ml (data not shown). 
This initial experiment presented a quandary, as a virus preparation cannot 
contain more particles of any subpopulation than exists as total physical 
(hemagglutinating) particles. This improbable interpretation of the data prompted a 
reevaluation of the interpretation of the calculated ISP titer, and highlights the need to 
appreciate the biology of the viral system when utilizing statistical methods for 
quantifying particle subpopulations through the measurement of their phenotypes. If the 
apparent ISP content of the preparation was in excess of the physical virus particles, 
perhaps the activity being measured did not reside within the particulate portion of the 
 149 
 
virus stock. With this hypothesis in mind, a soluble moiety that possessed IFN induction-
suppressing activity similar to that of ISP was sought. 
Consequently, the original chicken egg, allantoic fluid-derived A/RedKnot/744/03 
stock was freed of virus and any other particulate matter by centrifuging it at 40,000 x g 
for 4 hr. In addition, the virus particle-free supernatant was filtered twice through 0.22m 
Millipore filters prior to being tested for ISP activity. This supernatant was found to have 
lost little or no IFN induction-suppressing activity (Fig. 6.3). This confirmed that the 
observed IFN induction-suppressing activity of A/Red Knot/744/03 resided in some 
soluble component in the allantoic fluid of the virus stock. It was not clear at this time 
whether or not this soluble moiety was of viral origin. 
Fortuitously, a plaque-assay of the original Red Knot stock, incubated for one 
day longer than the usual 3-days, revealed a low level of contamination with a rod-
shaped Gram-negative bacterium (105 Colony Forming Units/ml). This prompted a test 
of lipopolysaccharide (LPS), a major molecular component of the membranes of Gram-
negative bacteria, as the putative IFN-induction suppressor. Figure 6.4 demonstrates 
that pure LPS prepared from Escherichia coli 026:B6 (Sigma-Aldrich #L2654) mimicked 
in a similar dose-dependent manner, the observed IFN-induction suppressing activity of 
the virus- and bacteria-free allantoic fluid (cf. Fig. 6.3). Similar results were obtained if 
the IFN-inducing virus was allowed to attach and enter the cell prior to the addition of 
the LPS, indicating that LPS was not blocking uptake or entry of virus into the cell (data 
not shown). Serum was present in the medium at all times thereby eliminating the LPS 
binding protein as a rate limiting step in the action of LPS on CD14/TLR-4 receptors 
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[154]. These results were surprising due to the reputation of LPS as a known inducer of 
IFN and other inflammatory cytokines [44]. 
Monolayers of 2-day old cells were exposed to a single high dose of LPS (300 
EU/ml) which remained in the medium for the duration of the 9-day aging process.  
These cells were found to induce IFN at yields comparable to non-treated cells.  Thus, 
the continuous presence of LPS did not perturb the maturation of the interferon system 
during developmental aging of embryonated chicken cells.  As only a single dose was 
administered on day 2 of the aging process, we interpret that the signaling effects of the 
LPS have been alleviated during that time due to the half-life of LPS under these 
conditions, which was not determined. Also, the cell signaling events that result in the 
suppression of viral-mediated IFN-induction occur rapidly following exposure to LPS.  
When administered prior to viral infection, a dose of LPS equal to 50 EU [83.3 
ng]/ml/107 cells demonstrated maximal suppression of IFN yield within a 15 minute pre-
incubation period (data not shown). 
Following double filtration through 0.22m Millipore units to remove any bacteria, 
a new stock of A/Red Knot/744/03 was generated by passage in 9-day old embryonated 
chicken eggs. Removal of the contaminating bacterium resulted in the restoration of the 
IFN-induction activity of the A/RedKnot/744/03 virus (Fig. 6.5A). Addition of either pure 
LPS or the virus-free supernatant from the centrifuged, bacterial-LPS contaminated 
stock of Red Knot sufficed to inhibit IFN-induction by the new virus stock. The relatively 
comparable levels of IFN-induction indicate that the poor IFN-induction activity of 
A/RedKnot/744/03 was due to the presence of LPS.  
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Further, the IFN induction-suppression activity of LPS is not unique to IFN-
induction by the A/RedKnot/744/03 virus. Figure 6.5B shows that IFN-induction by 
A/TK/OR/71-delNS1 (1-124), vesicular stomatitis virus (VSV), and Newcastle disease 
virus (NDV) was also suppressed by LPS in a similar fashion, indicating a global action 
of LPS on the cells. On average, IFN yields were reduced 95%, indicating that about 5% 
of the yield of IFN appeared to be refractory to the action of LPS (Fig. 6.5B). We 
postulate that from 5% -10% of the cells in a preparation of primary chicken embryo 
cells may be intrinsically refractory to the action of LPS as a suppressor of IFN 
induction, possibly because these cells lack the appropriate receptors [154].   
The suppression of viral-mediated IFN-induction by LPS has been reported 
previously using RAW cells, a line of mouse macrophages, and NDV as an IFN inducer, 
to demonstrate lowered levels of type-I IFN mRNA transcription [63]. This study showed 
that LPS inhibited the phosphorylation and nuclear transport of two important virus-
activated IFN-regulatory factors, IRF-3 and IRF-7. Our results indicate that the lower 
levels of  type-I IFN mRNA reported after LPS treatment [63] also are reflected in lower 
yields of biologically-active IFN protein.    
A second study investigated the cytokine expression profiles in mice following 
exposure to NDV [44].  A heat-inactivated NDV stock was unexpectedly found to induce 
elevated levels of IL-10, M-CSF, and type-II IFN, suggesting a possible LPS 
contamination which was later confirmed via a Limulus lysate assay.  This study makes 
clear that given the relatively high thermal stability of LPS [79], even heat-inactivated 
virus stocks are still at risk for containing functional LPS.  
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Finally, the presence of variable amounts of LPS in calf serum used in the days 
of cell culture before animal sera were tested for endotoxin offers a plausible 
explanation for the wide variation in the yields of IFN from chicken embryo cell cultures 
observed from batch-to-batch of sera (See table in Sekellick and Marcus 1986), and 
why the highest yields of IFN were obtained from cells without serum in the medium 
[79]. In 1984, a study screened 111 lots of fetal bovine serum and found endotoxin 
levels ranged from 0.006ng/ml to 800ng/ml [18]. At the high extreme, the levels of 
endotoxin would certainly be high enough to have a significant effect on type-I IFN-
induction activity. 
The capacity of LPS to modulate and suppress the normal innate immune 
response to viral exposure has been demonstrated in embryonic chicken cells which, in 
developmental terms for the IFN system, mimic acquisition of IFN-inducing capacity in 
the incubating egg [138]. Collectively, these data suggest the vulnerability in a clinical 
setting of the IFN-induction element of the innate immune system to a co-infecting 
bacterium which produces endotoxin. Thus, LPS-producing bacteria may enhance the 
establishment and severity of viral infections [144]. Indeed, some deaths in the 1918-
1919 influenza pandemic were attributed to coinfection with Hemophilus influenzae 
[56,96], and more recently, the copurification of LPS with plasmid DNA prepared from E. 
coli further points out the caution that should be exercised in using reagents derived 
from endotoxin producing bacteria [79,167].  Our data and the reports cited here seem 
especially relevant in a clinical setting.  Since type-I IFN also has been shown to play a 
role in innate immunity during bacterial and protozoan infections [159], abrogation of 
IFN induction by LPS may have even broader implications in clinical situations. 
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CHAPTER 7 
 
 
 
 
 
QUASISPECIES MARKERS OF INFLUENZA VIRUS: 
INTERFERON-INDUCTION AND INTERFERON INDUCTION-SUPPRESSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experiments and the data presented in this chapter are the result of a collaboration 
between myself, Christopher Malinoski, and Drs. Philip I. Marcus, Margaret J. Sekellick 
and John M. Ngunjiri. Data presented herein is to be included in a manuscript that is in 
preparation.  
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7.1 Abstract 
 Influenza A viruses (IAV) are known to exist as a quasispecies, that is, as a 
closely related mutant spectra or cloud. IAV regularly accumulate nucleotide point 
mutations during the course of the normal replication cycle due to the error-prone 
activity of the viral RNA-dependent RNA-polymerase. Based on reported mutation rates, 
every single virus particle in an influenza virus population is closely related yet 
genetically distinct from every other particle within that population. The extent to which 
this inherent genetic plasticity effects the quantifiable biological activities associated 
with IAV is explored herein. 
 In this chapter, variation within a single strain of influenza A virus (IAV), 
A/TK/OR/71 (H7N3), is assessed through the quantification of the IFN-inducing and IFN 
induction-suppressing phenotypes as manifest by plaque-derived isolates. Plaque-
derived isolates are used as such stocks demonstrate less variance than the parent 
stock, likely because the origins of a plaque lay in the replication of only a single 
infectious particle. Both the IFN-inducing and the IFN induction-suppressing capacities 
of 117 plaque-derived isolates are observed to vary over an approximate 1000-fold 
range. Variations within these phenotypes are shown to be consistent with a log-normal 
distribution. 
 The log-normal distribution of phenotypes is consistent with the expected 
incremental variation of genotype that occurs within a quasispecies population like IAV. 
Select virus isolates manifesting specific phenotypes were selected for NS gene 
sequencing. The NS gene was chosen for this analysis due to the dominant role it plays 
in regulating IFN-induction and IFN induction-suppression in the A/TK/OR/71 (H7N3) 
 155 
 
virus strain (Chapters 3, 4, and 5). Mutations resulting in alterations to the NS1 protein 
sequence are highlighted, and the effects of these mutations are considered in the 
context of the observed biological activities. 
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7.2 Introduction 
 The error-prone activity of the viral RNA-dependent RNA-polymerase complex, 
which lacks a proof-reading mechanism, is one source of genetic variation amongst 
influenza A viruses (IAV)  [33,119,171]. Nucleotide point mutations have been 
demonstrated to accumulate at a high frequency during the course of replication [7] in a 
process commonly referred to as antigenic drift. RNA viruses in general are considered 
the most genetically variable organisms in the entire known biosphere [55], with error 
rates as high as 10-4 per nucleotide copied [132]. These polymorphisms are responsible 
for the subtle shifts in antigenicity that occur from season to season and contribute, in 
part, to the need to reformulate the trivalent inactivated influenza vaccine each season. 
A second form of genetic variation occurs through the mechanism of 
reassortment, also referred to as antigenic shift [119,171]. When a suitable host is 
multiply infected by differing strains of IAV, novel progeny are produced as gene 
segments from both strains mix during packaging. Although this mechanism of genetic 
variation is a major contributor to the generation of new pandemic strains of IAV, it is of 
lesser consideration here. Although reassortment produces novel IAV strains, it does 
not directly contribute to the ongoing accumulation of genetic variance within a single 
virus strain.  
 The high frequency with which mutations accumulate via antigenic drift [7,33] 
ensures that IAV populations exist as a spectra of closely related yet genetically distinct 
particles. This mutant spectra, or cloud, of related particles, is also commonly referred 
to as a quasispecies [30,86,124,132]. Based on the most recent estimations of mutation 
frequency [7], every individual IAV particle within the population varies from the 
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consensus sequence of the population. Many of these nucleotide changes also result in 
alterations to the amino acid sequence of viral proteins, potentially also altering their 
functionality. 
It is important to remember that the consensus sequence as determined by 
traditional Sanger sequencing methods represents the average of all the genotypes in 
the population. It is thus difficult to determine whether a specific biological activity can 
be attributed to a change in the consensus sequence. It is possible that a distinct 
subpopulation with a unique genotype exists, but that the determination of this genotype 
is obfuscated by the subpopulation’s low percent composition as compared to the entire 
population. 
Theoretically, differences in functionality seem assured based upon the high 
frequency with which variations in genetic sequence are known to occur. Recent 
estimates utilizing the 2009 pandemic IAV (H1N1) show that these nucleotide mutations 
can translate to non-synonymous amino acid substitutions at a frequency ranging from 
0.35 to 1.00, depending on the specific gene segment. Still, non-synonymous mutations 
of individual amino acid residues within the virus proteins may not necessarily effect 
functionality to a significant, or even measurable, extent. Do these mutations result in 
quantifiable alterations to measurable phenotypes? If so, certain groupings of 
mutations, occurring spontaneously during replication via the mechanism of antigenic 
drift, may be partly responsible for the existence of replication-deficient biologically 
active particles in IAV populations. 
The work presented in this chapter provides a systematic characterization of the 
biological activities of a series of plaque isolates originating from a single IAV strain. 
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Variations in interferon (IFN)-induction, and IFN induction-suppression are measured. 
Further, differences in IFN-induction activity have been observed to occur between 
individual passages of the same virus strain, but the extent to which this variance is 
functionally expressed within a single preparation has yet to be quantified. Finally, the 
NS genes of plaque isolates expressing extreme IFN-induction phenotypes are 
sequenced in order to examine the genotypic basis for the observed differences in 
biological activity.  
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7.3 Materials and Methods 
7.3.1 Cells and media 
 Marc-145 cells are a mammalian green monkey kidney cell line, maintained in 
minimum essential medium (MEM) plus 5% fetal bovine serum and incubated at 37.5°C 
plus 6.5% CO2 so as to maintain pH 7.1. Chicken kidney embryo cells (CEK) were 
prepared from 18-day-old chicken embryos. CEK were obtained from Charles River 
SPAFAS, Inc. (Storrs and Willimantic, CT). CEK are maintained in Nutrient Colorado 
plus Inositol (NCI) medium plus 6% calf serum and incubated at the same conditions 
outlined for Marc-145 cells above. 
 
7.3.2 Viruses 
 Seed stocks of low-pathogenicity rgA/TK/OR/71-NS1 (1-230) (H7N3) = [Wt], 
based on the wildtype strain A/TK/OR/71-SEPRL (Southeast Poultry Research 
Laboratory), were generated via reverse genetics techniques [161] and were kindly 
provided by Dr. Change-Won Lee (Ohio State University, Wooster, OH). This virus 
produces a full-length, functional NS1 protein (amino acids 1 to 230). Multiple plaque 
isolates of this virus were generated, as outlined below. A reconstituted A/TK/OR/71 
virus, termed RcWt, was created by mixing together a constant number of physical 
particles of each of the 117 plaque isolates (2.17 × 109 HAP) in a total volume of 5ml.  
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7.3.3 Generation of plaque isolate stocks 
 A plaque assay using the seed stock of rgA/TK/OR/71 was performed on CEK 
following the protocol described earlier (Chapter 2). After 48 hours, the resulting 
plaques were counted. Well-isolated plaques, clearly whole and separate from all 
surrounding plaques, were identified and diameters measured and recorded. Next, the 
agar above the plaque was aspirated using a disposable transfer pipette. The agar plug 
was submerged into 1ml of Dulbecco’s minimum essential medium (DMEM) and placed 
at 4°C overnight to facilitate elution of the virus. The plaque-forming titers of these 
plaque isolates were measured via the standard plaque assay protocol (Chapter 2), 
again using CEK. A total of 117 of these plaque-derived isolates are used in the 
following work. 
 In order to have enough viral material to perform the biological assays needed to 
measure IFN-induction and IFN induction-suppression activity, each plaque isolate was 
passaged in day-9 or day-10 specific-pathogen-free embryonated chicken eggs, 
(obtained from Charles River SPAFAS, Inc., Storrs, CT). Each egg was infected with 
100 PFP of the given plaque isolate, in a total volume of 0.2ml DMEM. Each plaque 
isolate was passaged in a total of 5 or 6 eggs. Inoculated eggs were incubated at 
34.5°C for 72hr and rocked at regular intervals. After incubation, allantoic fluid is 
harvested and viral content assessed via hemagglutination assay. For each plaque 
isolate, eggs containing detectable amounts of HAU were pooled together into a single 
virus stock. The variability between these individual eggs in terms of IFN-inducing 
capacity were assessed for 2 plaque isolates (Isolates #26 & 88: See Table 7.1). All 
virus stocks were centrifuged at 2000rpm for 10 minutes to remove membrane and 
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other large precipitates, and the virus-containing supernatants decanted and stored at -
80°C. 
 
7.3.4 Generation of IFN samples 
 The biological assay for IFN-induction was performed using the Marc-145 cell 
line. Marc-145 demonstrate greater consistency and reproducibility on a week-to-week 
basis, as opposed to primary chicken embryo cells that are prepared from new batches 
of embryos on a weekly basis. 50mm plates are seeded with 0.5 × 106 Marc-145 cells 
per plate and are incubated for 8 days without a media change at 37.5°C plus 6.5% 
CO2. Cell density at the time of viral attachment is ~4.5 × 106 cells/plate. IFN-induction 
was allowed to proceed for 24 hours at 37.5°C.  
After 24 hours, the IFN-containing supernatant is harvested and treated at a final 
concentration of 0.15M perchloric acid in the presence of fetal bovine serum. The acid-
treated samples are refrigerated overnight at 4°C to inactivate residual virus and acid 
labile proteins. The IFN samples are then titrated back to slightly acidic (pH 6.5-6.8) via 
the drop-wise addition of 4N KOH and 0.15M PCA, as needed. IFN samples are 
centrifuged at 1000 rpm. Salts and other precipitates are then removed via decanting. 
Finally, IFN samples are stored at -20°C. The IFN samples were quantified via 
cytopathic effect-inhibition assay, described previously [140]. 
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7.3.5 NS gene sequencing 
 Viral RNA was extracted from select plaque isolates using the QiaAMP Viral RNA 
Mini Kit (QIAGEN, Cat. No. 52904), following the manufacturer’s protocol. Reverse 
transcription (RT)-PCR was carried out using the QIAGEN OneStep RT-PCR Kit (Cat. 
No. 210210) in a total reaction volume of 50 µl. Each PCR reaction contained the 
following: QIAGEN OneStep RT-PCR Buffer (final concentration (1x) contains 2.5mM 
MgCl2); dNTP Mix (final concentration of each dNTP = 400 µM); forward and reverse 
primers (final concentration = 0.4 µM); QIAGEN OneStep RT-PCR Enzyme Mix (2 µl); 
RNase-free water; and RNase inhibitor (final concentration = 0.25 U/µl).  
 The forward and reverse primers (termed BSM-NS-F1 and BMS-NS-R890, 
respectively) used for amplification were specific for the NS gene segment and were as 
follows: 
 
Forward, 5’-TATTCGTCTCAGGGAGCAAAAGCAGGGTG-3' 
Reverse, 5’-ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3' 
  
The RT-PCR was carried out as previously described [72]. Briefly, the RT step is 
performed at 50°C for 30 min. The hot-start taq in the Qiagen kit (HotStarTaq DNA 
polymerase) is activated by being placed at 95°C for 15 min. The PCR incubation steps 
involved 35 cycles of the following: 94°C for 45s (melting); 53°C for 15s (annealing); 
72°C for 150s (elongation). The final extension step (72°C) was held for 10 min. The 
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PCR products were purified and confirmed by size via agarose gel electrophoresis. The 
QIAquick Gel Extraction Kit (QIAGEN, Cat. No. 28704) was used to extract the PCR 
products from the agarose gel. The concentration of the gel-purified PCR products was 
determined at 260nm using the Nanodrop 2000 spectrophotometer. The products were 
sequenced via traditional Sanger sequencing methods via the ABI 3130XL Genetic 
Analyzer. 
 
7.3.6 Statistical software 
For the Shapiro-Wilk Normality test, all data were analyzed using the statistical software 
package R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria). 
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7.4 Results 
7.4.1 IFN-induction as a quasispecies marker of IAV populations 
 Marc-145 cells were used to assess the IFN-inducing capacity of 117 plaque 
isolates of A/TK/OR/71. Full IFN-induction dose response curves were generated for 
117 plaque isolate stocks, as well as the parent A/TK/OR/71 and reconstituted 
A/TK/OR/71 virus stocks. Each dose-response curve was comprised of 8 
independently-generated data points. The peak (quantum) yield of IFN for each plaque 
isolate was determined based on these curves and appear in ascending order as the 
upper series of black histobars in Figure 7.1. The hatch-marked histobars represent the 
parent and reconstituted virus stocks and are thus highlighted for ease of comparison. 
The range of IFN yield induced by these plaque isolates is observed to vary over a 
1000-fold range. 
 
7.4.2 IFN induction-suppression activity of A/TK/OR/71 plaque isolates 
 IFN inducting-suppression activity was assessed for the 117 plaque-derived 
isolates utilizing day-8 developmentally aged Marc-145 cells. The inducing virus used 
was A/TK/OR/71-delNS1 (1-124) and the yield of IFN produced by 10µl of this virus was 
set equal to 1.0, determined as an average of 6 independently-generated IFN yields 
(730 units of IFN per 106 Marc cells). A series of monolayers of Marc-145 cells were 
coinfected with 10µl of the inducing virus and a single dose of one of the plaque isolate 
stocks. The inoculum for each plaque isolate was normalized such that a constant 
number of physical particles (1.27 × 109 HAP) were delivered to each cell monolayer. 
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The IFN induction-suppression activity of each plaque isolate is presented as the 
surviving fraction of the control IFN yield produced by the inducing virus under the 
coinfection conditions described above. IFN induction-suppression activity is 
demonstrated to vary over a wide range (~1000-fold) and appears as the lower set of 
grey histobars in Figure 7.1. 
  
 
1
6
6 
 
 
Fig. 7.1 IFN-induction and IFN induction-suppression as markers of IAV quasispecies. The IFN-inducing capacities 
of the 117 plaque isolates are demonstrated via the series of ascending, black histobars (above) which display the peak 
IFN yield produced by a monolayer of Marc-145 cells in response to infection by each virus stock. Below, the gray 
histobars represent the IFN induction-suppressing activity of each plaque isolate, represented as the fraction of IFN yield 
produced by a monolayer of Marc-145 cells infected by a known IFN-inducing virus (A/TK/OR/71-delNS1 (1-124) ≈ 730 
Units of IFN) and the corresponding plaque isolate. The original recombinant A/TK/OR/71 (Wt) and the reconstituted 
A/TK/OR/71 (RcWt) stocks are highlighted and appear as the hatch-marked histobars (    ). Data presented here is to be 
included in a manuscript that is in preparation.
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7.4.3 The IFN-induction and IFN induction-suppression activities of the plaque 
isolates correspond to a log-normal distribution 
 Figure 7.2 demonstrates a good-fit to a log-normal distribution of (A) the peak 
IFN yields and (B) the degree of IFN induction-suppression (as measured as the 
fraction of a maximum IFN yield produced by a known inducer) as produced by the 
collection of plaque-derived virus isolates. The data shown is taken directly from Figure 
7.1, although replicate data points have been reduced to single points on the figure 
shown. The logarithm of the IFN-induction and IFN induction-suppression data shown a 
good fit to a Gaussian distribution (also called a log-normal, or Dalton, distribution). The 
arithmetic data values showed a poor fit the Gaussian distribution (data not shown) and 
so the log-transformation of the data was performed to offset the effect of the broad 
range of values observed. 
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Fig. 7.2 Lognormal distribution of IFN-induction and IFN induction-suppression 
activities. (A) The logarithm of the peak IFN yields produced by the plaque isolates of 
A/TK/OR/71 are shown to conform to a Gaussian distribution. (B) The logarithm of the 
IFN induction-suppression activity (measured as the fraction of the IFN yield produced 
by a known inducing virus, A/TK/OR/71-delNS1 (1-124), when the cell is coninfected by 
a suppressing virus) conforms to a normal distribution. For both (A) and (B) some of the 
data points represent replicated (duplicate, triplicate, or quadruplicate) values and are 
not represented as separate points on the figure. These separate replicates are 
included in the following calculations: (A) Mean, 1.62; standard deviation, 0.36; (B) 
Mean, -1.297; standard deviation, 0.70. Data presented here is to be included in a 
manuscript that is in preparation.  
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7.4.4 IFN-induction phenotype is consistent between individual passages of 
plaque isolates 
 Two plaque isolates (#26 and #88) were passed at end-point dilution, such that 
the probability of a productive infection being established in the egg was ≈ 10% (Egg 
Infectious Dose = 0.2). Each individual egg that successfully produced virus progeny 
was harvested and stored separately. Each of these replicate virus stocks were then 
used to generate full IFN-induction dose-response curves. The IFN yields produced in 
Marc-145 cells by a various volumes of these isolates were compared to the IFN yield 
produced by equal volumes of the pooled isolates of #26 and #88. The variations in 
these data are dispersed in a manner consistent with a Gaussian distribution, as 
evidenced by the results of the Shapiro-Wilk normality test. Pertinent data from the 
Shapiro-Wilk test appears in Table 7.1. Note that all p-values are above the level of 
statistical significance (0.05). 
 
Table 7.1 Shapiro-Wilk Normality Test: IAV plaque isolates are consistent in IFN-
induction phenotype amongst individual passages in chicken eggs 
 
n = number of observations/virus stocks 
W = Shapiro-Wilk test result 
  
Virus Dose n Mean (IFN Units) STDev W p -value
Isolate #26 5 µl 8 25.88 12.82 0.9357 0.5365
Isolate #26 10 µl 8 32.20 4.60 0.9827 0.9733
Isolate #26 50 µl 8 18.40 6.62 0.8733 0.2103
Isolate #88 5 µl 11 682.37 193.82 0.9652 0.8055
Isolate #88 50 µl 11 821.31 251.23 0.9349 0.4678
Isolate #88 150 µl 11 829.73 222.98 0.9496 0.6163
 170 
 
7.4.5 IFN-induction and IFN induction-suppression activity of select plaque-
derived isolates 
 Seven plaque-derived isolates were selected for NS gene sequencing based on 
these stocks demonstrating specific IFN-induction and IFN induction-suppression 
phenotypes of interest. The phenotypes of the selected isolates are demonstrated in 
Figure 7.3. The following is a brief description of these phenotypes: the Wt (parent 
A/TK/OR/71) and RcWt (reconstituted A/TK/OR/71) stocks induce low levels of IFN and 
are good suppressors of IFN-induction; isolate #26 is a randomly selected plaque-
derived isolate that acts similarly to the parent virus; isolate #32 induces very low levels 
of IFN, much lower than the parents virus, and acts as an excellent IFN induction-
suppressor; isolates #88 and #110 induce 10-fold higher IFN yields than does the wild-
type parent virus and are poor IFN induction-suppressors, similar to the A/TK/OR/71-
delNS1 (1-124) virus; and isolate #40 induces intermediate levels of IFN (like the parent 
virus), but also does not demonstrably suppress IFN-induction, a previously 
undocumented combination of phenotypes. 
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Fig. 7.3 Summary of IFN-induction and IFN induction-suppression activity of 
select virus stocks for NS sequencing. The peak IFN yield induced by each virus 
stock in Marc-145 cells is shown (black histobars). The IFN induction-suppression 
activity of each virus stock is presented as a reduction (fraction) of a control IFN yield 
induced by A/TK/OR-delNS1 (1-124). Data presented here is to be included in a 
manuscript that is in preparation. 
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7.4.6 NS gene sequences of select isolates 
 The large differences in IFN-inducing capacity prompted a comparison of the NS 
gene sequences of select plaque isolates with varying biological activities. The NS gene 
segments of seven virus stocks were sequenced, and the amino acid sequences of the 
NS1 proteins are shown in Figure 7.4. The viruses shown are: the original recombinant 
A/TK/OR/7-NS1 (1-230) = [Wt] after a single passage in eggs; a reconstituted 
A/TK/OR/71 = [RcWt], in which a constant number of physical particles (2.17 × 109 
HAP) from each of the 120 plaque isolates were mixed to a total volume of 5ml. No 
nucleotide or amino acid alterations were detected in the regions encoding for the NS2 
protein of any of the seven plaque isolates sequenced. Mutations in the regions 
encoding for the NS1 proteins were observed in 3 isolates: D74G in isolate #40; L185F 
in isolate #32; and an internal deletion in isolate #88 resulting in the production of a 
truncated NS1 (1-121).   
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Wt           1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
RcWt         1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
#26          1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
#32          1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
#40          1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
#88          1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
#110         1 MDSNTITSFQVDCYLWHIRKLLSMRDMCDAPFDDRLRRDQKALKGRGSTLGLDLRVATME 
 
 
Wt          61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
RcWt        61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
#26         61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
#32         61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
#40         61 GKKIIEDILKSETGENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
#88         61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVWTR 
#110        61 GKKIIEDILKSETDENLKIAIASSPAPRYITDMSIEEISREWYMLMPRQKITGGLMVKMD 
 
 
Wt         121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
RcWt       121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
#26        121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
#32        121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
#40        121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
#88        121 G----------------------------------------------------------- 
#110       121 QAIMDKRITLKANFSVLFDKLETLVSLRAFTDDGAIVAEISPIPSMPGHSTEDVKNAIGI 
 
 
Wt         181 LIGGLEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
RcWt       181 LIGGLEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
#26        181 LIGGLEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
#32        181 LIGGFEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
#40        181 LIGGLEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
#88            -------------------------------------------------- 
#110       181 LIGGLEWNDNSIRASENIQRFAWGIRDENGGPPLPPKQKRYMARRVESEV 
 
 
 
Fig. 7.4 Sequences of NS1 proteins of select IAV plaque isolates. The complete 
sequences of the NS1 proteins produced by select plaque isolates are shown. The 
observed differences in amino acid identity are: D74G in isolate #40; L185F in isolate 
#32; a truncation in isolate #88 resulting in NS1 (1-121), where the last 4 amino acids 
before the truncation differ as shown above. Data presented here is to be included in a 
manuscript that is in preparation. 
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7.5 Discussion 
Different strains of IAV have been reported to vary broadly in their capacity to 
induce IFN [87]. The yield of IFN produced by the cell in response to viral infection has 
been shown to primarily depend on the ratio of IFP and ISP present in the virus stock 
[80]. Anecdotally, IFN-induction by a single strain of IAV was seen to vary between 
individual passages, presumably due to differences in the activities in the IFP and ISP 
subpopulations, although the extent of these variations was not well characterized. 
Here, 117 plaque-derived isolates of A/TK/OR/71 (1-230) (H7N3) were used to assess 
the range of IFN-induction and IFN induction-suppression activity of the A/TK/OR/71 
virus, as measured in the mammalian green monkey kidney cell line Marc-145.  
IFN-related phenotypes are typically measured in primary chicken embryo cells 
due to the highly sensitive nature of that system to IFN-induction by viruses [89,137]. 
However, due to the large number of isolates using in this quasispecies study, the IFN-
induction experiments could not all be performed on a single batch of primary chicken 
embryo cells. As IFN-induction by primary cell preparations may vary substantially from 
batch to batch, the Marc-145 cell line was chosen for use instead in the interest of lower 
variance and higher reproducibility. Further, by limiting the variance as contributed by 
the cell system, we have greater confidence that observed differences can be attributed 
to the virus population. 
As shown in Figure 7.1, the IFN-inducing capacity of these 117 IAV plaque 
isolates varies over a 1000-fold range (black histobars), ranging from below the level of 
detection of the biological assay (<2 Unit/106 cells – Isolate #32) to 917 U/106 cells 
(Isolate #88). The majority of the plaque-derived isolates demonstrated IFN-induction 
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phenotypes which were characterized as low-IFN inducers; 95 out of the 117 isolates 
induced less than 100 Units of IFN/106 cells. This is consistent with the typical IFN-
inducing phenotype of individual passages of the parent A/TK/OR/71-NS1 (1-230) virus 
strain on Marc-145 cells. Both the parent A/TK/OR/71 virus stock and the reconstituted 
A/TK/OR/71 virus stock (hatch-marked histobars, Figure 7.1) are also shown to produce 
less than 100 Units of IFN/106 cells. 
The IFN induction-suppressing capacity of these 117 plaque-derived isolates is 
also summarized in Figure 7.1 (grey histobars). A total of 22 isolates were able to 
reduce the control yield of IFN (induced by A/TK/OR/71-delNS1 (1-124), ~730 U/106 
cells) by over 99%. Each of these 22 isolates with high ISP activity were subsumed in 
those isolates also characterized as low IFN inducers. None of the 22 isolates which 
produced over 100 Units of IFN/106 cells were able to suppress IFN-induction to this 
extreme. These data suggest a correlation between low IFN-induction capacity and high 
IFN induction-suppression activity, as would be predicted by the IFP:ISP dose-response 
model presented in Chapter 5.  
The broad range of IFN-inducing and IFN induction-suppressing capacities 
demonstrated by the plaque-derived isolates are distributed in such a way as to be 
consistent with a log-normal (Dalton) distribution (Fig. 7.2A/B, respectively). Restated, 
the logarithm (log10) of both data sets is dispersed in a manner consistent with a normal 
(Gaussian) distribution. A visual inspection of the distribution of these data is presented 
as the quantile-quantile (QQ) plot depicted in figure 7.2. The majority of the data fit well 
the linear trendlines (dashed lines) representative of the normal distribution. The 
Shapiro-Wilk test indicated that, overall, these log-transformed data sets were 
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consistent with a normal distribution (IFN-induction: W = 0.9894, p-value = 0.8323; IFN 
induction-suppression: W = 0.9731, p-value = 0.2150). These analyses suggest that the 
genotypes of the plaque-derived isolates differ from that of the parent in a manner 
consistent with the concept of a quasispecies. This behavior is also consistent with the 
idea that the observed alterations in both phenotypes may be attributed to slight 
changes within each isolate’s genetic sequence, a concept previously reported in 
reference to the IFN-inducing capacity of isolates of vesicular stomatitis virus, another 
RNA virus whose populations exist as a closely-related mutant spectra [86]. 
Collectively, these data demonstrate for the first time the extent of phenotypic variance 
that exists within a single strain of IAV. 
Of particular interest are the phenotypes associated with the parent A/TK/OR/71 
virus stock (termed “Wt” in Figure 7.1, left hatch-marked histobar) and the reconstituted 
A/TK/OR/71 virus stock (termed “RcWt” in Figure 7.1, right hatch-marked histobar). The 
parent stock is a low IFN-inducer (<100 Units/106 cells) and is a good IFN induction-
suppressor (Control IFN yield reduced by 99%). The plaque-derived isolates are 
amplified virus stocks, but are representative of single infectious particles within the 
parent population. The broad range of IFN-inducing and IFN induction-suppressing 
phenotypes reported in Figure 7.1 are all subsumed within the parent population; the 
phenotypes associated with the parent virus population are an aggregate of the 
individual isolate phenotypes on display. The reconstituted virus stock is a direct 
representation of this concept. A constant number of physical particles (2.17 × 109 HAP) 
from each of the 117 plaque-derived isolate stocks were mixed together to create the 
reconstituted stock. As can be seen in figure 7.1, the reconstituted virus stock (termed 
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“RcWt”, right hatch-marked histobar), a literal aggregate of the plaque isolate 
phenotypes, resembles closely the behavior of the parent virus. This serves as an 
important reminder that IAV strains and even individual virus stocks are not uniform in 
regards to both genotype and phenotype. 
As mentioned in the Materials and Methods section, due to the need to generate 
enough virus material to perform all of the requisite biological assays, each plaque-
derived isolate was passaged in eggs. Therefore, depending on the specific isolate, the 
plaque-derived virus stocks used in the studies discussed in this chapter represent a 
pool of the material harvested from a minimum of at least 3, up to a maximum of 6, 
chicken eggs. Unlike the parent strain, from which a broad range of differing phenotypes 
was recovered (Fig. 7.1), it was postulated that variance arising from passaging of these 
plaque-derived isolates would be minimal.  
Recall that every plaque can be traced back to the establishment of a productive 
infection by a single infectious (plaque-forming) particle. All of the virus particles within 
the plaque should be closely-related as they originated from the same infectious particle 
and have only undergone a limited number of replication cycles (~4 cycles in 48 hours). 
The plaque-derived isolation step therefore introduces a genetic bottleneck, the benefits 
from which are carried over to passage in the egg and should result in IAV populations 
with less phenotypic variance. This is in contrast with passage of the parent virus, in 
which infectious events within the egg may originate from particles capable of 
expressing any of a broad range of phenotypes.  
To test this, individual eggs were inoculated with plaque-derived virus material at 
end-point dilution. At high dilution, eggs that produce virus progeny have likely been 
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infected by only a single infectious virus particle. Such a passaging protocol should 
increase the likelihood of generating virus stocks expressing varying phenotypes, if they 
are present within the plaque-derived virus material. Two plaque-derived isolates were 
passaged in this manner, isolates #26 and #88. Eggs that successfully produced virus 
progeny were subsequently harvested and kept as individual stocks.  
Monolayers of Marc-145 cells were then infected with varying doses of these 
individual stocks and the resulting IFN yields measured. A QQ plot of the IFN yields 
produced by each dose of the two virus isolates visually showed a good fit to a normal 
distribution (not shown). Table 7.1 shows the results of the subsequent Shapiro-Wilk 
tests, confirming that the variations in the IFN yields observed were consistent with a 
Gaussian distribution. The arithmetic values of the IFN yields were used in these 
analyses as the range of IFN yields produced in response to infection by these stocks 
was less than that observed within the parent virus population (Fig. 7.1), and the use of 
log-transformed data was not necessary. In terms of the IFN-inducing phenotype, these 
data support the notion that use of plaque-derived virus material as inoculum can be 
effective in limiting variance amongst egg-passaged progeny. 
The use of plaque-derived isolates in this study was to provide a form of 
selection which would allow for the enrichment of a specific genotype amongst the 
swarm of varying genotypes found within the parent population. The IFN-inducing 
capacity of the plaque-derived isolates was used as a quasispecies marker, as the 
primary determinant of IFN-induction by the wild type A/TK/OR/71 virus has been 
shown to be dependent on the successful expression of the NS gene segment [81]. 
Based on these reports, it was assumed that the NS gene sequences of the plaque-
 179 
 
derived virus preparations displaying extreme phenotypes (low or high IFN-inducing 
capacity) would differ from the parent population in some measurable manner, and so 
specific isolates were chosen for sequencing based upon the displayed phenotypes. 
Seven select plaque-derived isolates were selected for NS gene sequencing 
based on their IFN-inducing and IFN induction-suppressing phenotypes which are 
summarized in Figure 7.3. The parent A/TK/OR/71-NS1 (1-230) (termed “Wt” in Figure 
7.3) and the reconstituted A/TK/OR/71 (termed “RcWt”) stocks induce intermediate 
levels of IFN and are good suppressors of IFN-induction. Isolate #26 is a randomly 
selected plaque-derived isolate that acts similarly to the parent virus. Isolate #32 
induces very low levels of IFN, much lower than the parent virus, and acts as a 
prototypical IFN induction-suppressor. Both isolates #88 and #110 induce 10-fold higher 
IFN yields than does the wild-type parent virus, and are poor IFN induction-suppressors. 
Finally, isolate #40 induces low levels of IFN, like the parent virus, but also does not 
demonstrably suppress IFN-induction, a previously undocumented combination of 
phenotypes. 
The NS gene sequences of these seven isolates were determined via RT-PCR 
and traditional Sanger sequencing methods. No differences were detected in the coding 
regions of the NS2 protein for any of the seven isolates, nor amongst the 3’ or 5’ 
conserved regions. The amino acid sequences of the NS1 proteins produced by these 
seven plaque isolates appears in Figure 7.4. The NS1 protein of the parent A/TK/OR/71 
virus was sequenced and is displayed as a control. Differences in the NS1 protein 
sequence as compared to the consensus sequence of the parent (Wt) virus were 
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detected in three of the isolates (#32, #40, and #88). The remaining isolates (#26, #110, 
and RcWt) possessed NS1 sequences identical to that found in the parent virus. 
Isolate #32 is a low IFN-inducer and an excellent suppressor of IFN-induction. 
The NS1 protein sequence has a single mutation at position number 185, substituting a 
leucine residue for phenylalanine. The large 6-carbon side chain of the substituted 
phenylalanine has the potential to result in increased steric hindrance. The L185F 
mutation occurs in the cleavage and polyadenylation specificity factor (CPSF)-binding 
domain. Amino acids 184 to 188 are involved in the direct binding of NS1 to a zinc 
finger motif in a 30kDa subunit of CPSF (CPSF30). Normally, CPSF assists in the 3’-
end processing of cellular pre-mRNA and its inhibition through interaction with NS1 is 
thought to be responsible for the downregulation of type-I IFN production [107]. Krug 
and colleagues showed that mutating all five amino acids of the CPSF-binding domain 
(residues 184-188) of A/Udorn/71 (H3N2) could abolish the interaction between CPSF 
and NS1, and enhanced IFN-induction [112]. A more recent study has shown that 
mutation of the glycine in position 184, the residue just prior to the substitution here, can 
alter the virulence of IAV without affect the host interferon response [147]. Here, it is 
clear that the L185F mutation present in isolate #32 does not prevent this virus from 
acting as an excellent suppressor of IFN-induction in our biological assay, and indeed 
may serve to enhance this biological activity. 
A different mutation was found in the coding region for the NS1 protein produced 
by isolate #40. This virus stock demonstrated a low IFN-inducing capacity, but did not 
measurably suppress IFN-induction by A/TK/OR/71-delNS1 (1-124). Typically, low IFN-
induction by IAV is a byproduct of IFN induction-suppression activity [80]. At amino acid 
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residue number 74, an aspartic acid residue is replaced by glycine. This region has 
been shown to interact with and inhibit components of the cellular mRNA nuclear export 
machinery, specifically E1B-AP5 [46,133]. Disruption of these interactions could result 
in the repression of IFN induction-suppression activity by allowing cellular IFN-mRNA to 
escape the nucleus and be translated. 
An internal deletion of nineteen nucleotides from positions 378-396 results in a 
frame-shift mutation and produces the truncated NS1 (1-121) of IAV isolate #88. This 
truncation of the NS1 protein eliminates the majority of the C-terminal effector domain, 
which interacts with a variety of host cell factors. Similar truncations have been 
observed, a prime example being the A/TK/OR/71-delNS1 (1-124) virus strain used as 
the IFN-inducing control in the IFN induction-suppression assay. The A/TK/OR/71-
delNS1 (1-124) produced truncated NS1 is the result of a ten nucleotide internal 
deletion and is the result of an unknown passage history. The recovery of isolate #88 
demonstrates that the wildtype A/TK/OR/71 virus spontaneously produces NS1-
truncated variants.  
IAV strains expressing truncated NS1 proteins have been shown to be good 
inducers of IFN [87,161], and is consistent with the phenotypes demonstrated by isolate 
#88. As evidenced by the spectra of phenotypes produced by the various plaque-
derived isolates (Fig. 7.1), the production of even a single virion expressing truncated 
NS1 would seemingly be a rare event. The establishment of a stock of virus expressing 
a truncated NS1 would be unlikely without the exploitation of a genetic bottleneck, like 
the plaque isolation step performed here. Under normal passage conditions, numerous 
infectious particles produce and contribute progeny to the progeny population, and the 
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majority of these progeny would be genetically similar to the parent virus. Virus strains 
expressing truncated NS1 also tend to replicate poorly in vivo in hosts with competent 
IFN-induction systems [161], further placing such variants at a competitive disadvantage 
when passaged in chicken eggs. 
 The remaining virus stocks, #26, #110, and the reconstituted wild type, all 
produced NS1 proteins identical to the parent virus’ protein sequence. This was a 
surprisingly result for isolate #110, which is a good inducer of IFN compared to the 
parent virus, producing ~700 Units per 106 cells. This result seems to contradict the 
findings reported in Chapter 4, specifically that expression of NS1 alone suffices for ISP 
activity by the A/TK/OR/71 virus strain. This contradiction may be reconciled by 
considering that NS1 can only be effective as a suppressor if it is adequately expressed.  
In the parent virus, the extant, virion-associated viral polymerase complex associated 
with the NS gene segment must be sufficiently functional so as to express the minimum 
levels of NS1 needed for ISP activity. This may not be the case in isolate #110.  
We postulate that although the NS1 protein of isolate #110 is of the same 
sequence as the parent virus, there may be some difference in expression levels which 
results in the increased IFN-inducing capacity demonstrated by isolate #110. The 
current data suggest that this may be occurring. Isolate #110 was observed to suppress 
IFN-induction as induced by A/TK/OR/71-delNS1 (1-124) by ~60%. In this coinfection 
scenario, viral polymerase complex is produced by both the inducing and the 
suppressing viruses. The nascent, functional viral polymerase produced by the inducing 
virus may then increase expression of the NS gene of isolate #110, explaining the 
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relatively low levels of IFN induction-suppression observed. Additional studies are 
needed to clarify this situation. 
 Finally, it is interesting to note that the reconstituted virus produces an NS1 
protein identical to that of the parent virus. These series of experiments have shown 
that a broad range of IFN-inducing and IFN induction-suppressing phenotypes may be 
produced by the parent virus, and that these phenotypes are the result of varying 
genotypes. The reconstituted virus shows this same principal, but in reverse. A series of 
virus isolates with varying phenotypes and genotypes, when mixed together into a 
single stock, manifest a phenotype that is the aggregate of all of the various 
subpopulations. Note that although the reconstituted virus contains a mixture of viruses, 
some with gene sequences confirmed to be different from the parent (isolates #32, #40, 
and #88), the gene sequence as determined by traditional Sanger sequencing averages 
out to appear identical to that of the parent virus. This is the first time that this concept 
has been demonstrated experimentally in the context of IAV quasispecies, and has 
consequences for the interpretations of gene sequence data. Biological activities of 
virus strains, particularly those measured at low multiplicities of infection, may be 
attributable to subpopulations within a virus population and that particles expressing the 
consensus sequence may not be involved in the observed activity. 
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CHAPTER 8 
 
 
 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
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Both infectious and noninfectious (replication-deficient) biologically-active 
particles of influenza A virus (IAV) contribute to the outcome of viral infection. It is the 
sum total of all biological activities, acting in concert, which ultimately determine 
virulence and/or pathogenicity. The relatively small genome of IAV (<14,000 
nucleotides) belies the complex array of possible biologically-relevant effects that the 
virus can manifest within the host, given that some specific amalgamation of viral 
expression is achieved. The work presented within this dissertation focuses on the 
characterization of some of these emergent biological activities of IAV, but is cognizant 
that other, currently undefined biological activities may also be involved in some 
significant manner. The development of additional assays allowing for the quantification 
of other biological activities will progress over time. 
 Recent studies have shown that the majority of IAV particles are packaged with a 
complete set of genes; each virion contains one of each of the eight unique gene 
segments [21,114,115]. Despite possessing the minimum required components, the 
majority of IAV particles do not express the infectious particle phenotype [26,31,84,85]. 
These findings support the idea that even infectivity is an emergent biological activity, 
dependent not only on genetic sequence but also on the proper (functional) expression 
of all of the required viral proteins. Although some recent reports suggest that IAV 
particles may establish productive infections through multiplicity-related 
complementation [15], the studies reported in Chapter 2 do not support this as a wide-
spread phenomenon (Fig. 2.1 & 2.2). Multiplicity-dependent complementation 
(multiplicity-reactivation) is seemingly a poorly efficient process and is not a major 
contributor to the replication/virulence of IAV populations. The kinetics at which nascent 
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physical particles (progeny) are formed fits well the expected rate of formation based on 
the infectious particle titer of the virus stock being passaged (Chapter 2). The evidence 
provided here supports the idea that the establishment of a productive infection seems 
to require a specific type of particle, namely an infectious particle.  
 Also in Chapter 2, a mathematical treatment is presented which addresses the 
disparity in number (titer) observed to exist between physical and infectious particles of 
IAV. This mathematical treatment is based on typical physical and infectious titers as 
expressed by the A/TK/OR/71 (H7N3) virus strain. It is important to note that this 
mathematical approach accounts for all physical particles, and thus differs from an 
experimental report which does not account for physical particles that fail to express at 
least one viral protein [15]. The model suggests that the frequency with which any given 
viral protein is expressed may be random based on a Poisson distribution, or 
approximately 63% given a gene copy number equal to 1. It is an attractive explanation 
given the complexity of the system and the numerous opportunities where failure might 
occur, comprised in the least as follows: genetic mutation resulting in nonfunctional viral 
proteins; inefficiency in particle uncoating; nuclear transport failure; sequestering or 
degradation of gene segments through interactions with various host cell factors. 
A broad, systematic study enumerating physical and infectious particle titers 
across multiple preparations of multiple stains of IAV would be needed to determine the 
veracity of this mathematical model. It is possible that differences between individual 
virus strains could affect the frequency with which viral gene segments are successfully 
expressed. It is conceivable that some virus strains could successfully express gene 
segments at a frequency inconsistent with that predicted by a random event. For 
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example, a mutation in any one of the four known nuclear localization signals 
associated with the IAV nucleoprotein could reduce the expression levels of all of the 
gene segments [24,75,162]. Although the same random chance would exist for the viral 
gene to interact with the correct host cell receptor (karyopherin-α), such a mutation 
would prohibit the occurrence of nuclear transport and therefore gene expression and 
infectivity. 
Such a study examining the disparity between physical and infectious particle 
numbers would need to test infectious particle titers across multiple host cell systems. 
The problem is complex, as infectivity may vary not only based upon features 
associated with the virus itself, but also with the specific host system in question. 
Different host cell systems may vary in the presence or concentration of certain 
cytosolic receptors, and it is possible that such variations could substantially alter the 
proportion of physical particles that register as infectious. Recognition and binding of the 
viral gene segments by any of the cytosolic receptors associated with the activation of 
the innate immune system (PKR-R, RIG-I, MDA-5, etc.) would result in the 
sequestration of that gene segment [70]. Such binding would prevent the transport of 
the gene segment into the nucleus, and would ultimately prevent the establishment of a 
productive infection.  
 Infectivity requires the functional expression of all eight unique gene segments. 
The failure of any one of these genes products to express results in a noninfectious 
particle. From there, the biological activity that is expressed is dependent on the 
expression of specific subsets of viral genes: IFN induction-suppression must 
successfully express the NS gene segment (Chapter 4); defective-interfering particles 
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must successfully express the defective-interfering RNA; cell-killing particles must 
express one of the viral polymerase subunit genes. An exception to this rule is IFN-
induction (Chapter 3), as measured in the primary chicken embryo cell system. Primary 
transcription of viral gene segments was not required for IFN-induction activity in avian 
hosts, as evidenced by three different methods of inactivation: UV-radiation (254nm), 
aminomethyltrioxsalen + UV-radiation (350nm), and exposure to heat (50°C). This is the 
strongest evidence presented to date that the IFN-induction moiety is preformed within 
the virion. 
 As with the discussion regarding infectivity, this result regarding the minimum 
requirements for IFN-induction may vary for other virus strains or host cell systems. 
Although the viral gene segments seem to be sufficient for IFN-induction in avian 
systems, evidence is provided in Chapter 3 that this may not be the case in mammalian 
systems. The results from IFN-induction in Marc-145 cells showed that the IFN-inducing 
particle (IFP) subpopulation was inactivated by exposure to UV-radiation, with a gene 
target consistent with the size of the NS gene segment (Fig. 3.9). This may be 
interpreted to mean that the NS gene product itself is necessary for IFN-induction in 
Marc-145 cells, however another interpretation is also valid. As the NS gene segment is 
the smallest gene segment, it is probabilistically the last gene segment to be 
inactivated. All of the other gene segments, based on size, will be inactivated prior to 
the NS gene segment. The alternative interpretation of this result is that primary 
transcription of any of the eight viral gene segments, not necessarily the NS gene 
specifically, may be required for IFN-induction activity in Marc-145 cells. 
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 The contrasting requirements for IFN-induction by IAV in avian and mammalian 
host cell systems is a subject that would benefit from further study. The behavior of 
Marc-145 cells alone may not be sufficient to generalize about mammalian cell systems, 
and so these experiments should be repeated in other mammalian host cell systems. 
Further, increased understanding of the differences that exist in regards to the effects 
IAV have on varying host cell systems will assist in screening candidate live attenuated 
influenza vaccine (LAIV) virus strains. Good LAIV candidate viruses tend to induce high 
levels of IFN [109], but it is clear from the work presented here that the relative 
efficiency of IFN-induction is not constant across different host cell species. This is 
especially relevant given that differences in IFN-induction between host cell types has 
already been shown to effect the efficiency with which IAV strains act as a LAIV [84].  
 Further, differences in the activity of the IFN induction-suppressing particle (ISP) 
subpopulation as expressed within avian and mammalian host cell systems have not yet 
been fully assessed. The work presented in Chapters 4 and 5 which characterize ISP 
and which define the IFP:ISP particle interactions resulting in IFN-induction are specific 
to the avian cell system. Expression of the NS gene product NS1 is shown to be the 
dominant regulator of IFN-induction within primary chicken embryo cells, suppressing 
IFN in cells otherwise programmed to induce IFN (i.e. cells coinfected by both ISP and 
IFP). However, the UV-inactivation data from Marc-145 cells presented in Chapter 3 
suggests that the viral polymerase may be the primary regulatory factor of IFN-induction 
in mammalian cells. It may be that nascent viral polymerase is needed to express NS1 
at high enough levels so as to suppress IFN, or it may be that some activity associated 
with the viral polymerase itself is controlling IFN-induction by the virus. This would need 
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to be directly tested in a series of experiments specifically investigating the ISP 
subpopulation. 
 The quasispecies study (Chapter 7) assessed the variability of the IFN-induction 
and IFN induction-suppression activities expressed by a single strain of IAV, 
A/TK/OR/71 (H7N3). Both activities were observed to vary over a 1000-fold range. 
Some of the isolates expressing extreme phenotypes were observed to express 
mutated NS1 proteins (Isolate #32, #40, #88), but others were not (Isolate #110). This 
study should be extended, beginning with sequencing additional gene segments. Isolate 
#110 demonstrated a NS1 sequence identical to that produced by the wild type virus, 
and yet induced high (>100 Unit/106 cells) amounts of IFN. Given that the NS1 protein 
of isolate #110 should be capable of restricting IFN-induction based on its sequence, 
the problem may lay in the extent to which the NS1 protein is expressed. For this 
reason, differences in the viral polymerase subunit gene segments should be assessed 
first. Mutations amongst the gene segments encoding for the viral polymerase complex 
could ultimately effect the extent to which NS1 is expressed. 
 The library of plaque-derived isolate stocks already generated could also be used 
to assess variability amongst the other known biological activities associated with IAV. 
The activities of the cell-killing particle and defective-interfering particle subpopulations 
could be measured for all the plaque isolates utilizing the appropriate biological assay. 
Once these biological activities have been measured, patterns of expression amongst 
them may be analyzed. This may gain insight into the biology of the virus; perhaps 
some of these biological activities are interdependent.  
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 Ultimately, the goal of the work presented in this dissertation is to better 
understand the biology and lifecycle of the IAV so as to provide insight into those 
processes that modulate virulence and pathogenesis.  Much of the research presented 
here focuses on the IFN-induction and IFN induction-suppression phenotypes, due to 
the role that IFN plays as an adjuvant [13,19,45,102] and its association with effective 
LAIV preparations [19,45,84,102,109,161]. Further studies could focus on exploiting the 
biology of the virus to develop better LAIV candidate virus preparations. In the 
quasispecies study, IFN-induction activity was observed to vary over a 1000-fold range; 
this same variability may also result in varying effectiveness as LAIV candidates. The 
quasispecies study might be extrapolated further. Antibody titration experiments utilizing 
mice and/or chickens could be used to assess the effectiveness of various plaque 
isolates as LAIV candidates and patterns in the corresponding expression of biological 
activities analyzed. It may be that IAV strains demonstrating ineffective vaccine 
phenotypes may contain subsets of particles that act as effective vaccines, and that 
these subpopulations may be revealed through the use of plaque isolation techniques.  
In the context of effective LAIV design, although it may seem obvious to target 
those virus preparations which induce the highest levels of IFN, a role may yet be 
defined for the regulation of IFN-induction as manifest by the ISP subpopulation. A 
recent report contrasting two effective and two ineffective LAIV candidate viruses [84] 
demonstrated that the effective LAIVs produced type r = 1 or r = 2 IFN induction dose-
response curves. Type r =1 and r = 2 IFN-induction dose-response curves are 
inherently indicative of some balance existing between the IFP and ISP subpopulations 
(Chapter 5). This indicates that some degree of regulation of IFN induction by ISP may 
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be advantageous in producing more highly effective vaccines; the total elimination of the 
ISP subpopulation may not result in the attributes of a LAIV that are most effective. The 
interdependence of these subpopulations may prove to be equally as important as the 
activities of either subpopulation alone. 
IAV is a highly variable biological system, manifesting a wide array of biological 
activities which emerge dependent upon the occurrence of specific combinations of 
virus:host interactions. This phenotypic variability and its potential consequences are 
not widely recognized or appreciated. The biological activities expressed by IAV vary 
based on properties of both the virus and the host cell, and are important when 
considering the full extent to which the virus may exert influence over the host. The 
identification of these biological activities and the quantification of the associated 
noninfectious (replication-deficient) biologically-active particle subpopulations has 
resulted in a clearer understanding of the biology of influenza virus. The quantification of 
these biological activities as particle subpopulations provides a useful and practical 
method for measuring and comparing these biological activities across different strains 
of IAV. Further, this allows for a more granular characterization of individual 
preparations of different IAV strains. The work presented in this dissertation represents 
some of the first steps towards identifying those specific characteristics which contribute 
to virulence and pathogenicity. Further studies may ultimately assist in developing more 
effective vaccines for use in both poultry and humans.  
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